

## STATISTICAL ANALYSIS PLAN

### SEP361-308

**AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856  
IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS**

**PHASE: PHASE III**

**AUTHOR:** PPD [REDACTED]

**VERSION NUMBER AND DATE: FINAL VERSION 1.0, 06MAY20244**

---







Document:	PPD [REDACTED]		
Author:	PPD [REDACTED]	Version Number:	1.0
		Version Date:	06MAY2024

## STATISTICAL ANALYSIS PLAN SIGNATURE PAGE

Statistical Analysis Plan Version 1.0 (Date 07MAY2024) for Protocol SEP361-308.

	Name	Signature	Date
Author:	PPD	 DocuSigned by PPD	May 8, 2024
Position:	PPD Biostatistics	 PPD	I approve this document May 8, 2024   7:23:21 AM PDT
Company:	Sumitomo Pharma America, Inc.	 A8A9348CD9B74E6EBF126E878D21636D	

Upon review of this document, the undersigned approves this version of the Statistical Analysis Plan, authorizing that the content is acceptable for the reporting of this study.

	Name	Signature	Date
Approved By:	PPD	 DocuSigned by PPD	May 8, 2024
Position:	PPD Biostatistics	 PPD	I approve this document May 8, 2024   7:46:40 AM PDT
Company:	Sumitomo Pharma America, Inc.	 EC9C165A28E5496FB1D33D0D3A1991B3	
Approved By:	PPD	 DocuSigned by PPD	May 8, 2024
Position:	PPD PVRM Lead	 PPD	I approve this document May 8, 2024   7:21:49 AM PDT
Company:	Sumitomo Pharma America, Inc.	 326629BB7F3E4244BC8D468744AAF1D2	

Document: PPD

Author: PPD

Version Number: 1.0

Version Date: 06MAY2024

Approved By:	PPD [REDACTED], MD	May 8, 2024
Position:	PPD [REDACTED] of Global Clinical Research Psychiatry	DocuSigned by PPD [REDACTED]
Company:	Sumitomo Pharma America, Inc.	PPD [REDACTED]   I approve this document May 8, 2024   10:18:11 AM PDT
		166B614E082542F2BBB9EF5F6F059938
Approved By:	PPD [REDACTED]	DocuSigned by PPD [REDACTED] May 8, 2024
Position:	PPD [REDACTED] Clinical Trials Management	PPD [REDACTED]   I approve this document May 8, 2024   8:37:31 AM PDT
Company:	Sumitomo Pharma America, Inc.	7F578718D1A9474E99044E0EA32819F1
Approved By:	PPD [REDACTED]	DocuSigned by PPD [REDACTED] May 8, 2024
Position:	PPD [REDACTED]	PPD [REDACTED]   I approve this document May 8, 2024   11:32:18 PM JST
Company:	IQVIA	15B689A559B14B98A4BDC5B2D561D369

Document: PPD [REDACTED]

Author: PPD [REDACTED] Version Number: 1.0  
Version Date: 06MAY2024

## MODIFICATION HISTORY

Unique Identifier for this Version	Date of the Document Version	Author	Significant Changes from Previous Authorized Version
Stable Draft	30MAY2023	PPD [REDACTED]	Not applicable – First Version
Version 1.0	07MAY2024	PPD [REDACTED]	<p>Change in the enrolled subjects definition.</p> <p>Change in sample size.</p> <p>Addition of AEs leading to dose increase and decrease analyses.</p> <p>Addition of Treatment-related AEs by PT analysis.</p> <p>Addition of haloperidol equivalent doses for lumateperone.</p>

Document: PPD [REDACTED]

Author: PPD [REDACTED] Version Number: 1.0

Version Date: 06MAY2024



## TABLE OF CONTENTS

<b>1. Introduction</b>	<b>12</b>
<b>2. Study Objectives and Endpoints</b>	<b>12</b>
<b>2.1. Study Objectives</b>	<b>12</b>
2.1.1. Primary Objective	12
2.1.2. Secondary Objective	12
2.1.3. Other Objectives	13
<b>2.2. Study Endpoints</b>	<b>14</b>
2.2.1. Primary Endpoint	14
2.2.2. Secondary Endpoint	14
2.2.3. Other Endpoints	14
<b>3. Study Design</b>	<b>15</b>
<b>3.1. General Description</b>	<b>15</b>
<b>3.2. Method of Assigning Subjects to Treatment Groups</b>	<b>16</b>
<b>3.3. Blinding</b>	<b>16</b>
<b>3.4. Determination of Sample Size</b>	<b>16</b>
<b>3.5. Changes in the Conduct of the Study</b>	<b>17</b>
<b>3.6. Schedule of Events</b>	<b>17</b>

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

3.7.	Changes to Analysis from Protocol	17
4.	Planned Analyses	18
4.1.	Data and Safety Monitoring Board	18
4.2.	Interim Analysis	18
4.3.	Final Analysis	18
5.	Analysis Populations	18
5.1.	Safety [SAF] Population	19
5.2.	Per Protocol [PP] Population	19
5.3.	Effectiveness [EFF] Population	19
6.	General Considerations	19
6.1.	Reference Start Date and Study Day	19
6.2.	Baseline	20
6.3.	Derived Timepoints	23
6.4.	Retests, Unscheduled Visits, and Early Termination Data	26
6.5.	Windowing Conventions	26
6.6.	Statistical Tests	27
6.7.	Common Calculations	27
6.8.	Software Version	27

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

<b>7. Statistical Considerations</b>	<b>27</b>
<b>7.1. Adjustments for Covariates and Factors to be Included in Analyses</b>	<b>27</b>
<b>7.2. Multicenter Studies</b>	<b>28</b>
<b>7.3. Missing Data</b>	<b>28</b>
<b>7.4. Multiple Comparisons/ Multiplicity</b>	<b>28</b>
<b>7.5. Examination of Subgroups</b>	<b>28</b>
7.5.1. Derivation of Subgroups	31
<b>8. Output Presentations</b>	<b>32</b>
<b>9. Disposition and Withdrawals</b>	<b>32</b>
<b>9.1. Derivations</b>	<b>33</b>
<b>10. Important Protocol Deviations</b>	<b>34</b>
<b>11. Demographic and Other Baseline Characteristics</b>	<b>34</b>
<b>11.1. Derivations</b>	<b>38</b>
<b>12. Medical History</b>	<b>38</b>
<b>13. Medications</b>	<b>38</b>
<b>14. Study Medication Exposure</b>	<b>39</b>
<b>14.1. Derivations</b>	<b>40</b>
<b>15. Study Medication Compliance</b>	<b>40</b>
<b>15.1. Derivations</b>	<b>41</b>
<b>16. Effectiveness Outcomes</b>	<b>41</b>

Document:	PPD
Author:	PPD
Version Number:	1.0
Version Date:	06MAY2024

<b>16.1.</b>	<b>PANSS</b>	<b>41</b>
16.1.1.	PANSS Total Score	44
16.1.2.	Proportion of Subjects Who Achieve a Response	44
16.1.3.	PANSS Subscale Scores	45
16.1.4.	PANSS Marder Factor Scores	46
16.1.5.	PANSS UPSM factor scores and the UPSM total factor score	46
<b>16.2.</b>	<b>Clinical Global Impression-Severity</b>	<b>48</b>
<b>16.3.</b>	<b>Brief Negative Symptom Scale (BNSS) Total Score and Subscale Scores</b>	<b>48</b>
<b>16.4.</b>	<b>12-Item Short Form Survey (SF-12)</b>	<b>49</b>
<b>16.5.</b>	<b>PSP total score and individual domain scores</b>	<b>49</b>
<b>16.6.</b>	<b>Medication Satisfaction Questionnaire (MSQ)</b>	<b>51</b>
<b>16.7.</b>	<b>Clinical Global Impressions – Improvement Scale (CGI-I)</b>	<b>51</b>
<b>16.8.</b>	<b>Healthcare Resource Utilization</b>	<b>52</b>
<b>16.9.</b>	<b>Nicotine Use</b>	<b>52</b>
<b>16.10.</b>	<b>Missing Data Method</b>	<b>53</b>
<b>17.</b>	<b>Safety Outcomes</b>	<b>53</b>
<b>17.1.</b>	<b>Discontinuation due to Clinical Reasons</b>	<b>54</b>
<b>17.2.</b>	<b>Discontinuation due to Any Reasons</b>	<b>54</b>
<b>17.3.</b>	<b>Adverse Events and Pre-treatment Events</b>	<b>54</b>
17.3.1.	All AEs	57
17.3.1.1.	Severity	57
17.3.1.2.	Relationship to study medication	57

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

17.3.2.	AEs Leading to Discontinuation from Study	58
17.3.3.	AEs Leading to Study Medication Withdrawal	58
17.3.4.	AEs Leading to Study Medication Interruption, study dose increase and reduced	58
17.3.5.	Serious Adverse Events	58
17.3.6.	Adverse Events Leading to Death	59
17.3.7.	Adverse Events of Potential Drug Abuse and Dependence	59
17.3.8.	Extrapyramidal Adverse Events	59
17.3.9.	Adverse Events by Subgroups	59
17.3.10.	Psychiatric Adverse Events Leading to Discontinuation from Study (PAEDCs)	59
<b>17.4.</b>	<b>Laboratory Evaluations</b>	<b>60</b>
17.4.1.	Laboratory Specific Derivations	61
17.4.2.	Laboratory Reference Ranges	61
<b>17.5.</b>	<b>ECG Evaluations</b>	<b>62</b>
17.5.1.	QTc Interval Prolongation Criteria	63
17.5.2.	ECG Potentially Clinically Significant Criteria	64
<b>17.6.</b>	<b>Vital Signs</b>	<b>64</b>
17.6.1.	Vital Sign Specific Derivations	65
17.6.2.	Vital Sign Potentially Clinically Significant Criteria	66
<b>17.7.</b>	<b>Physical Examination</b>	<b>66</b>
<b>17.8.</b>	<b>Other Safety Assessments</b>	<b>67</b>
17.8.1.	Columbia Suicide Severity Rating Scale (C-SSRS)	67
17.8.2.	Abnormal Involuntary Movement Scale (AIMS)	70
17.8.3.	Barnes Akathisia Rating Scale (BARS)	70
17.8.4.	Simpson-Angus Scale (SAS)	71
17.8.5.	Pittsburgh Sleep Quality Index	72
<b>17.9.</b>	<b>Subgroup Analysis of Safety Variable(s)</b>	<b>72</b>
<b>18.</b>	<b>Pharmacokinetic Analysis</b>	<b>72</b>

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

<b>19. Data Not Summarized or Presented</b>	<b>73</b>
<b>20. References</b>	<b>73</b>
<b>APPENDIX 1. Programming Conventions for Outputs</b>	<b>75</b>
<b>IQVIA Output Conventions</b>	<b>75</b>
<b>Dates &amp; Times</b>	<b>76</b>
<b>Spelling Format</b>	<b>76</b>
<b>Presentation of Treatment Groups</b>	<b>76</b>
<b>Listings</b>	<b>77</b>
<b>APPENDIX 2. Partial Date Conventions</b>	<b>78</b>
<b>Algorithm for Adverse Events</b>	<b>78</b>
<b>Algorithm for Prior / Concomitant / Post-Treatment Medications</b>	<b>80</b>
<b>Partial Date Imputation Rules for Initial Onset of Schizophrenia</b>	<b>82</b>
<b>Partial Date Imputation Rules for Current Onset of Acute Exacerbation</b>	<b>82</b>
<b>Partial Date Imputation Rules for First Hospitalization</b>	<b>82</b>
<b>Partial Date Imputation Rules for First Anti-psychotic Drug Therapy</b>	<b>83</b>
<b>Partial Date Imputation Rules for Onset of Initial Behavioral Disturbance</b>	<b>83</b>
<b>Rules for Assigning DOSEON/DOSEA</b>	<b>84</b>
<b>APPENDIX 3. Uncorrelated PANSS Score Matrix (UPSM)</b>	<b>85</b>
<b>APPENDIX 4. Internationally Agreed Order for System Organ Class</b>	<b>87</b>
Document:	PPD
Author:	PPD
Version Number:	1.0
Version Date:	06MAY2024

APPENDIX 5.	Adverse Events of Potential Drug Abuse and Dependence	88	
APPENDIX 6.	Extrapyramidal Adverse Events	92	
APPENDIX 7.	Predefined Potentially Clinically Significant (PCS) Criteria in SI Units	96	
	Standard PCS Criteria for Laboratory Parameters – SI Units		96
APPENDIX 8.	PSQI Scoring Sheet	98	
APPENDIX 9.	Classification of Patient Type from UPSM Factor Scores	101	
APPENDIX 10.	Marder PANSS Negative Symptoms (MPNS) Heterogeneity Index Method	131	
APPENDIX 11.	Schedule of Events	133	

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 1. INTRODUCTION

This document describes the rules and conventions to be used in the presentation and analysis of safety, effectiveness and pharmacokinetic (PK) data for Protocol SEP361-308. It describes the data to be summarized and analyzed, including specifics of the statistical analyses to be performed.

This statistical analysis plan (SAP) is based on protocol version 5.00, dated 06NOV2023.

A Pre-Lock Data Review (PLDR) and Important Protocol Deviation (IPD) Review Plan will be written to describe the process and the outputs to be delivered during the IPD/BDR meetings.

The scope of this SAP does not include calculation and statistical analysis of PK parameters of SEP-363856; individual SEP-363856 PK parameters will be determined using population PK approach and results will not be reported in the clinical study report (CSR).

## 2. STUDY OBJECTIVES AND ENDPOINTS

### 2.1. STUDY OBJECTIVES

#### 2.1.1. PRIMARY OBJECTIVE

The primary objective is to evaluate the safety and effectiveness of switching clinically stable outpatients with schizophrenia from a typical or atypical antipsychotic to SEP-363856 over a period of 8 weeks as assessed by the percentage of subjects who discontinue from the study due to an adverse event or lack of efficacy

#### 2.1.2. SECONDARY OBJECTIVE

The secondary objective is to evaluate the safety and effectiveness of switching clinically stable outpatients with schizophrenia from a typical or atypical antipsychotic to SEP-363856 over a period of 8 weeks as assessed by the percentage of subjects who discontinue for any reason (ie, all causes of discontinuation)

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



**2.1.3. OTHER OBJECTIVES**

- To evaluate the tolerability and safety of switching clinically stable outpatients with schizophrenia from a typical or atypical antipsychotic to SEP-363856 over a period of 8 weeks using:
  - o Adverse event reports
  - o Clinical laboratory tests
  - o Vital sign measurements
  - o 12-lead electrocardiograms (ECG)
  - o Columbia – Suicide Severity Rating Scale (C-SSRS)
  - o Barnes Akathisia Rating Scale (BARS)
  - o Abnormal Involuntary Movement Scale (AIMS)
  - o Simpson-Angus Scale (SAS)
- To evaluate the effectiveness of SEP-363856 using:
  - o Positive and Negative Syndrome Scale (PANSS)
  - o Clinical Global Impression-Severity (CGI-S) scale
  - o Clinical Global Impression-Improvement (CGI-I) scale
  - o Brief Negative Symptom Scale (BNSS)
- To evaluate the effects of SEP-363856 on health-related quality of life as measured by the Short Form Health Survey (SF-12)
- To evaluate the effects of SEP-363856 on functional capacity as measured by the Personal and Social Performance Scale (PSP)
- To evaluate medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ)
- To evaluate sleep as measured by the Pittsburgh Sleep Quality Index (PSQI)
- To evaluate the impact of SEP-363856 on healthcare resource utilization (HCRU)

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 2.2. STUDY ENDPOINTS

### 2.2.1. PRIMARY ENDPOINT

- Percentage of subjects who discontinue for clinical reasons (ie, discontinued due to an adverse event [AE] or lack of efficacy)

### 2.2.2. SECONDARY ENDPOINT

- Percentage of subjects who discontinue for any reason (ie, all causes for discontinuation)

### 2.2.3. OTHER ENDPOINTS

- The incidence of overall AEs, serious adverse events [SAE]s, and AEs leading to discontinuation
- Observed values and changes from Baseline in clinical laboratory tests (hematology, chemistry and urinalysis)
- Observed values and changes from Baseline in vital signs (including body weight, body mass index [BMI], waist circumference, temperature, blood pressure [supine and standing], heart rate [supine and standing] and respiratory rate)
- Observed values and changes from Baseline in 12-lead ECG parameters
- Frequency of subjects with suicidal ideation and suicidal behavior based on the C-SSRS
- Changes from Baseline in BARS, AIMS and SAS scores
- Changes from Baseline to Week 8 in:
  - o PANSS total score and subscale scores (positive, negative, and general psychopathology)
  - o PANSS Marder Factor (five-factor) scores (positive, disorganized, negative, hostility, and depression/anxiety), and Uncorrelated PANSS Score Matrix (UPSM)

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- o CGI-S score
- o BNSS total score
- o SF-12 scores
- o PSP total score
- o MSQ score
- o PSQI global score
- CGI-I score at Week 8
- HCRU (including numbers of physician office visits, emergency room [ER] visits and hospitalizations, length of hospital stays, employment status and average number of hours caregiver(s) spends helping subjects per week.)
- Nicotine use at baseline and Week 8 (end of treatment [EOT]/early termination [ET])

### 3. STUDY DESIGN

#### 3.1. GENERAL DESCRIPTION

This is an 8-week, outpatient, multicenter, open-label, single-group, flexible-dose study designed to evaluate the safety and tolerability, as well as effectiveness of switching clinically stable adult subjects with schizophrenia from a typical or atypical antipsychotic to SEP-363856. This study is projected to enroll approximately 120 subjects into a single treatment group (SEP-363856). Over the 8-week treatment period, subjects will receive flexibly dosed SEP-363856 (50 to 100 mg/day) and the investigator will have the discretion to discontinue each subject's pre-switch antipsychotic treatment by the end of Week 2, 3, 4, 5, or 6.


Once the pre-switch antipsychotic has been fully discontinued, subjects will continue to receive SEP-363856 flexible 50 to 100 mg/day until study endpoint, at the end of Week 8. Study medication will be taken at the same time each evening at bedtime and can be taken with or without food.

The study will consist of three periods: Screening/Washout (up to 21 days), Treatment (8 weeks) and a Follow-up visit (7 ± 2 days after the last dose of study medication for those subjects who discontinue prior to the Week 8 visit or who complete the study but do not enroll in the open-label extension study SEP361-309). If necessary, subjects may return to the clinic at any time for an unscheduled visit.

A study schematic is presented in Figure 1.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

**Figure 1: Study schematic**



## 3.2. METHOD OF ASSIGNING SUBJECTS TO TREATMENT GROUPS

This is an open label study. There is no randomization planned in this study. All subjects will receive flexible dosing with SEP-363856 (50 to 100 mg/day).

## 3.3. BLINDING

This is an open-label study. All subjects will receive flexible dosing with SEP-363856 (50 to 100 mg/day).

## 3.4. DETERMINATION OF SAMPLE SIZE

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

The sample size was determined by the width of the 95% confidence interval for the proportion of subjects who may discontinue due to clinical reasons by Week 8 to ensure the precision of the estimate of the true discontinuation rate due to clinical reasons. Assuming, 1) 15% of SEP-363856 treated subjects will experience discontinuation due to clinical reasons by Week 8, and 2) 6.4% as the half width (the distance between the upper/lower limits to the point estimate) of the 95% confidence interval (ie, [8.6%, 21.4%]), approximately 120 subjects was planned for enrollment. Due to higher than predicted rates for enrollment, retention, and completers in study 308, the SMPA team decided to revisit the assumption of 15% SEP-363856 treated subjects discontinuation rate due to clinical reasons by Week 8. Using the proportion from the data at time of revisiting, the discontinuation rate due to clinical reasons by Week 8 was approximately 7.2%. With 7.2% as the assumption, 100 subjects would provide a half width of 5.1% half width and was deemed to be sufficient. 101 subjects were enrolled.

### 3.5. CHANGES IN THE CONDUCT OF THE STUDY

The first subject was screened on 19DEC2022 under protocol Version 3.00 (dated 12OCT2022). Additional protocol versions and amendments are listed below.

Protocol version 1.00 (24-Aug-2022)

Protocol version 2.00 (22-Sep-2022); Substantial Amendment 1.00 (22-Sep-2022)

Protocol version 3.00 (12-Oct-2022); Substantial Amendment 2.00 (12-Oct-2022)

Protocol version 4.00 (28-Mar-2023); Substantial Amendment 3.00 (28-Mar-2023)

Protocol version 5.00 (06-Nov-2023); Substantial Amendment 4.00 (06-Nov-2023)

### 3.6. SCHEDULE OF EVENTS

Schedule of events can be found in Section 1, Table 2 of the Clinical Study Protocol (CSP). These tables are also included in APPENDIX 11 of the SAP.

### 3.7. CHANGES TO ANALYSIS FROM PROTOCOL

There are no changes to analysis from the protocol.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 4. PLANNED ANALYSES

The following analyses will be performed for this study:

- Final Analysis

### 4.1. DATA AND SAFETY MONITORING BOARD

There is no DSMB planned for this study.

### 4.2. INTERIM ANALYSIS

There is no interim analysis planned for this study.

### 4.3. FINAL ANALYSIS

All final, planned analyses specified in this SAP will be performed by IQVIA following Sunovion authorization of this SAP, Sunovion authorization of Analysis Populations, Database Lock

Some minor modifications may be necessary to the planned design of tables, figures, and listings to accommodate data collected during the actual study conduct.

## 5. ANALYSIS POPULATIONS

Agreement and authorization of subjects included/excluded from each analysis population will be conducted prior to database lock.

Enrolled subjects in 361-308 will include all subjects who signed the informed consent form (ICF) of study 361-308 and did not screen fail.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 5.1. SAFETY [SAF] POPULATION

The safety population will consist of all subjects who are enrolled and receive study medication (SEP-363856). All safety and tolerability assessments will be performed using the safety population.

## 5.2. PER PROTOCOL [PP] POPULATION

The per protocol (PP) population will consist of all EFF population subjects who satisfy the following conditions:

- Have 7 days or more overall exposure to study medication
- Have no important protocol deviations that can potentially impact the integrity of the effectiveness endpoint analysis

Selected effectiveness endpoints will be analyzed using the PP population. Subjects will be analyzed according to the treatment to which they receive.

## 5.3. EFFECTIVENESS [EFF] POPULATION

The effectiveness population will consist of all subjects who are enrolled, have received at least one dose of study medication, and have a Baseline and at least one post-Baseline effectiveness measurement in PANSS or CGI-S. Subjects will be included in the population regardless of any protocol deviation. The effectiveness population will be the primary population for the effectiveness analyses.

## 6. GENERAL CONSIDERATIONS

Study medication refers to SEP-363856 unless otherwise specified.

### 6.1. REFERENCE START DATE AND STUDY DAY

Study Day will be calculated from the reference start date and will be used to show the start/stop day of assessments and events.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

Reference start date is defined as the date of the first dose of study medication (Day 1 is the Study Day of the first dose of study medication).

- If the date of assessment or event is prior to the reference start date, then:  
  
Study Day = (date of assessment or event - reference start date).
- If the date of assessment or event is on or after the reference start date, then:  
  
Study Day = (date of assessment or event - reference start date) + 1.

In the situation where the assessment or event date is partial or missing, Study Day and any corresponding durations will appear missing in the listings. Partial assessment or event dates will however be presented as is in the listings.

## 6.2. BASELINE

Unless otherwise specified, Baseline is defined as the last non-missing measurement taken prior to the first dose of study medication (including unscheduled assessments).

Whenever available, the time information should be accounted for in the derivation of Baseline values. In the case where time is not available and the date of the last non-missing measurement and the date of the first dose of study medication coincide, that measurement will be considered the Baseline.

Baseline will be derived for the following outcome measures:

- PANSS: total score, subscale scores, Marder factor scores, uncorrelated PANSS score matrix (UPSM) factor scores and total factor score, and individual item scores. For a given subject, the Baseline values for all PANSS summary and individual item scores should come from the same assessment (i.e., have the same visit number and assessment start date/time) and it should be the last assessment prior to first dose where PANSS total score is available (i.e., not set to missing). In the rare event where no PANSS total score is available before first dose due to partially completed assessments, the assessment prior to first dose with most PANSS item scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.
- CGI-S score.
- BNSS: total score, subscale scores, and individual item scores. For a given subject, the Baseline values for all BNSS summary and individual item scores should come from the same assessment and it should be the last assessment prior to first dose where BNSS total score is available. In the

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



rare event where no BNSS total score is available before first dose due to partially completed assessments, the assessment prior to first dose with most BNSS item scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.

- SF-12 Score.
- PSP: total score, individual domain scores, and the derived binary variables. For a given subject, the Baseline values for all PSP data should come from the same assessment and it should be the last assessment prior to first dose where PSP total score is available. In the rare event where no PSP total score is available before first dose due to partially completed assessments, the assessment prior to first dose with most PSP individual domain scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.
- MSQ score.
- C-SSRS: Suicidal ideation categories 1-5 (yes/no) and suicidal behavior categories 6-10 (yes/no); C-SSRS composite endpoints: any suicidal ideation (yes/no), any suicidal behavior (yes/no), any suicidality (yes/no); the suicidal ideation score (0-5). See [Section 17.8.1](#) for the definition of a C-SSRS Baseline.
- SAS: mean score and individual item scores. For a given subject, the Baseline values for all SAS summary and individual item scores should come from the same assessment and it should be the last assessment prior to first dose where SAS mean score is available. In the rare event where no SAS mean score is available before first dose due to partially completed assessments, the assessment prior to first dose with most SAS item scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.
- BARS: total score and individual item scores. For a given subject, the Baseline values for all BARS summary and individual item scores should come from the same assessment and it should be the last assessment prior to first dose where BARS total score is available. In the rare event where no BARS total score is available before first dose due to partially completed assessments, the assessment prior to first dose with most BARS item scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.
- AIMS: total score and individual item scores. For a given subject, the Baseline values for all AIMS summary and individual item scores should come from the same assessment and it should be the last assessment prior to first dose where AIMS total score is available. In the rare event where no AIMS total score is available before first dose due to partially completed assessments, the assessment prior to first dose with most AIMS item scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.
- PSQI: global score, component scores, and individual item scores. For a given subject, the Baseline values for all PSQI summary and individual item scores should come from the same assessment and it should be the last assessment prior to first dose where PSQI global score is available.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

In the rare event where no PSQI global score is available before first dose due to partially completed assessments, the assessment prior to first dose with most PSQI item scores available should be taken as the Baseline assessment for all raw and derived scores as applicable.

- Clinical laboratory parameters (blood chemistry, hematology, urinalysis, HOMA-IR (if collected)). For a given subject, the Baseline values for the clinical laboratory parameters do not have to all come from the same assessment; the only exception is: the Baseline flag for the counts of leukocytes and its differential should be applied to records from the same assessment and it should be the last assessment prior to first dose where counts of leukocytes and its differential are reported. Baseline flag does not need to be derived for RBC morphology findings, WBC morphology findings, and urinalysis microscopic examination findings (excluding urine erythrocytes and leukocytes).
- Urine drug screening: For a given subject, the Baseline values for all urine drug screening parameters should come from the same assessment and it should be the last assessment prior to first dose where a urine drug screening test was administered.
- Vital sign parameters (supine and standing systolic blood pressure [SBP], supine and standing diastolic blood pressure [DBP], supine and standing pulse rate, respiratory rate, oral temperature), height, weight, BMI, and waist circumference. For a given subject, the Baseline values for all vital sign parameters, height, weight, BMI, and waist circumference do not have to come from the same assessment; the only exceptions are: (1) the Baseline flag for weight and BMI should be applied to records from the same assessment and it should be the last assessment prior to first dose where weight is available, (2) the Baseline flag for supine SBP and DBP, standing SBP and DBP, and the derived corresponding orthostatic endpoints (i.e., standing SBP – supine SBP; standing DBP – supine DBP) should be applied to records from the same assessment and it should be the last assessment prior to first dose where all four BP measures are available, (3) the Baseline flag for supine and standing pulse rate and the derived corresponding orthostatic endpoint (i.e., standing pulse rate – supine pulse rate) should be applied to records from the same assessment and it should be the last assessment prior to first dose where both pulse rate measures are available.
- ECG parameters: For a given subject, the Baseline values for all ECG parameters do not have to come from the same assessment. Baseline flag does not need to be derived for ECG parameters in the category of “FINDINGS”.
- Nicotine use data: Baseline of this outcome measure should be taken strictly from the assessment given at Visit 1 without regard to its temporal relationship to the first dose of study medication.
- Healthcare resource utilization data: Baseline of this outcome measure should be taken strictly from the assessment given at Visit 2 without regard to its temporal relationship to the first dose of study medication.

The Baseline flag may be derived for additional outcome measures based on the needs during analyses.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

### 6.3. DERIVED TIMEPOINTS

The last non-missing post-Baseline (i.e., post-first dose) measurement collected during the study up to and including the Visit 10 (EOT/ET) measurement will be carried forward and defined as the last observation carried forward (LOCF) endpoint. Both scheduled and unscheduled assessments as well as the early termination assessments that are collected during this period will contribute to the derivation of the LOCF endpoint. However, unscheduled measurements taken after the Visit 10 (EOT/ET) measurement will not be used in the derivation.

The LOCF endpoint will be derived for the following outcome measures:

- PANSS: total score, subscale scores, Marder factor scores, UPSM factor scores and total factor score, individual item scores, and derived binary variables for PANSS response. For a given subject, the LOCF values for all PANSS summary and individual item scores and derived binary variables should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where PANSS total score is available. In the rare event where no PANSS total score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- CGI-S score.
- BNSS: total score, subscale scores, and individual item scores. For a given subject, the LOCF values for all BNSS summary and individual item scores should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where BNSS total score is available. In the rare event where no BNSS total score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- SF-12.
- PSP: total score, individual domain scores, and the derived binary variables. For a given subject, the LOCF values for all PSP data should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where PSP total score is available. In the rare event where no PSP total score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- MSQ score.
- C-SSRS suicidal ideation score (0-5).

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- SAS: mean score and individual item scores. For a given subject, the LOCF values for all SAS summary and individual item scores should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where SAS mean score is available. In the rare event where no SAS mean score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- BARS: total score and individual item scores. For a given subject, the LOCF values for all BARS summary and individual item scores should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where BARS total score is available. In the rare event where no BARS total score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- AIMS: total score and individual item scores. For a given subject, the LOCF values for all AIMS summary and individual item scores should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where AIMS total score is available. In the rare event where no AIMS total score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- PSQI: global score, component scores, and individual item scores. For a given subject, the LOCF values for all PSQI summary and individual item scores should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where PSQI global score is available. In the rare event where no PSQI global score is available after first dose due to partially completed assessments, the last post-Baseline assessment up to and including Visit 10 should be taken as the LOCF assessment for all raw and derived scores as applicable.
- CGI-I.
- Clinical laboratory parameters (blood chemistry, hematology, urinalysis, HOMA-IR (if collected)). For a given subject, the LOCF values for the clinical laboratory parameters do not have to all come from the same assessment; the only exception is: the LOCF flag for the counts of leukocytes and its differential should be applied to records from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where counts of leukocytes and its differential are reported. LOCF endpoint does not need to be derived for RBC morphology findings, WBC morphology findings, and urinalysis microscopic examination findings (excluding urine erythrocytes and leukocytes).
- Urine drug screening: For a given subject, the LOCF values for all urine drug screening parameters should come from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where a urine drug screening test was administered.
- Vital sign parameters (supine and standing SBP, supine and standing DBP, supine and standing pulse rate, respiratory rate, oral temperature), weight, BMI, and waist circumference. For a given subject, the LOCF values for all vital sign parameters, height, weight, BMI, and waist circumference do not have to come from the same assessment; the only exceptions are: (1) the LOCF flag for weight and BMI should be applied

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

to records from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where weight is available (2) the LOCF flag for supine SBP and DBP, standing SBP and DBP, and the derived corresponding orthostatic endpoints (i.e., standing SBP – supine SBP; standing DBP – supine DBP) should be applied to records from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where all four BP measures are available, (3) the LOCF flag for supine and standing pulse rate and the derived corresponding orthostatic endpoint (i.e., standing pulse rate – supine pulse rate) should be applied to records from the same assessment and it should be the last post-Baseline assessment up to and including Visit 10 where both pulse rate measures are available.

- ECG parameters: For a given subject, the LOCF values for all ECG parameters do not have to come from the same assessment. LOCF endpoint does not need to be derived for ECG parameters in the category of “FINDING”.
- Nicotine use data: LOCF of this outcome measure should come from the same assessment and it should be the last assessment post first dose up to and including Visit 10 where any data are reported.
- Healthcare resource utilization data: LOCF of this outcome measure should come from the same assessment and it should be the last assessment post first dose up to and including Visit 11 where any data are reported.

The study visits will be mapped to analysis visits for table summaries and statistical analyses where applicable (Table 1).

**Table 1: Mapping of study visits to analysis visits.**

Study Visit	Analysis Visit Number	Analysis Visit
Visit 1	1	Screening/Visit 1
Visit 2	2	Pre-switch Baseline/Visit 2
Visit 3	3	Week 1/Visit 3
Visit 4	4	Week 2/Visit 4
Visit 5	5	Week 3/Visit 5
Visit 6	6	Week 4/Visit 6
Visit 7	7	Week 5/Visit 7
Visit 8	8	Week 6/Visit 8

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

Study Visit	Analysis Visit Number	Analysis Visit
Visit 9	9	Week 7/Visit9
Visit 10 (if representing true EOT visit). For ET visit mapping see <a href="#">Section 6.4</a> .	10	Week 8/Visit 10
Visit 11	11	Week 9/Follow-up/Visit 11

Original study visit collected on the case report forms (CRFs) will be displayed in the listings.

## 6.4. RETESTS, UNSCHEDULED VISITS, AND EARLY TERMINATION DATA

In general, for by-visit summaries, data recorded at the planned visits where assessment is intended to be given will be presented, as well as the derived Baseline value and the LOCF value.

Unscheduled measurements will not be included in by-visit summaries as a separate time point. Unscheduled measurements collected prior to the first dose of study medication will contribute to the derivation of the Baseline value. Unscheduled measurements collected post Baseline will contribute to the derivation of the LOCF value, the potential clinically significant (PCS) value, and the best/worst case value where required (e.g., shift table).

In the case of a retest, the assessment recorded under the planned visit will be used for by-visit summaries, and the assessment(s) recorded under unscheduled visit(s) will be presented in listings only.

As per protocol, study Visit 10 can be a Week 8/End of Treatment (EOT) visit or an Early Termination (ET) visit. If a subject terminates early, his/her measurements taken at the ET visit will be mapped to the next planned visit (after the last scheduled visit the subject attended) during which that assessment was expected to be performed as specified by the Schedule of Assessments table in the protocol. This applies to both safety and effectiveness data.

Listings will include scheduled, unscheduled, retest and early discontinuation data with original dates and visits displayed.

## 6.5. WINDOWING CONVENTIONS

No visit windowing will be performed during the analysis for this study. Data will be analyzed according to the schedule outlined in the CSP.

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

## 6.6. STATISTICAL TESTS

The default significance level will be 5%; confidence intervals (CIs) will be 95%. All CIs will be two-sided, unless otherwise specified in the description of the analyses or the outputs.

## 6.7. COMMON CALCULATIONS

For quantitative measurements, change from Baseline will be calculated as:

- Test Value at Visit X - Baseline Value

For PANSS total score, percentage change from Baseline will be calculated as:

- $(\text{Test Value at Visit X} - \text{Baseline Value}) \times 100 / (\text{Baseline Value} - 30)$

For other quantitative measurements, percentage change from Baseline will be calculated as:

- $(\text{Test Value at Visit X} - \text{Baseline Value}) \times 100 / \text{Baseline Value}$

## 6.8. SOFTWARE VERSION

All analyses will be conducted using SAS version 9.4 or later.

## 7. STATISTICAL CONSIDERATIONS

### 7.1. ADJUSTMENTS FOR COVARIATES AND FACTORS TO BE INCLUDED IN ANALYSES

No statistical comparison will be conducted, so no adjustments for covariates and factors are to be considered.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 7.2. MULTICENTER STUDIES

This study will be conducted by multiple investigators at multiple centers in the US.

Center pooling will not be implemented in analyses for this study.

## 7.3. MISSING DATA

Individual missing items in any scale will not be imputed in any analysis. When calculating a total score, subscale score, or any summary scores based on more than one item, if one or more items are missing at a visit, then the associated summary score will be set to missing. For additional details, see the individual scale description sections.

- Handling of missing effectiveness data, if any, is described in Sections [16.10](#).
- Handling of missing safety data, if any, is described in Sections [17.3](#) and [17.8](#).
- See [APPENDIX 2](#) for details of handling incomplete/missing dates.

## 7.4. MULTIPLE COMPARISONS/ MULTIPLICITY

No statistical comparison will be conducted, so no multiplicity adjustment will be performed.

## 7.5. EXAMINATION OF SUBGROUPS

Subgroup analyses will be conducted for subjects as stated in Section [16.1](#) for PANSS, Section [16.2](#) for CGI-S, and Section [17.3.9](#) for Adverse Events.

The following subgroups will be assessed. The subgroup haloperidol (hal) equivalent doses will be based on appendix III of the protocol. For lumateperone, 5.5 mg is equivalent to 1 mg of haloperidol (Leucht-2020).

- Sex:

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



- o Female
  - o Male
- Age group:
  - o ≤40 years
  - o >40 years
- Race (in 3 categories):
  - o White (White)
  - o Black (Black or African American)
  - o Other (All other races combined)
- BMI (kg/m<sup>2</sup>) categories:
  - o Underweight: <18.5 kg/m<sup>2</sup>
  - o Normal: ≥18.5 to <25.0 kg/m<sup>2</sup>
  - o Overweight: ≥25.0 to <30.0 kg/m<sup>2</sup>
  - o Obese: ≥30.0 kg/m<sup>2</sup>
- Baseline patient type based on UPSM factor scores at Baseline ([Hopkins S. , Ogirala, Loebel, & Koblan, 2020](#)) (only used in the subgroup analysis of PANSS total score):
  - o Type 1: Prominently Disorganized
  - o Type 2: Prominently Negative
  - o Type 3: Prominently Hostile
  - o Type 4: Prominently Positive
  - o Type 5: Prominently Affective

Subjects will be classified into one of 5 patient types based on their PANSS UPSM factor scores at Baseline. See [APPENDIX 9](#) for details of how the classification will be made.
- Primary Reason for Switch:

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- Side Effect
  - Lack of Efficacy
- Duration of Switch:
  - 2 weeks
  - 3 weeks
  - 4 weeks
  - 5 weeks
  - 6 weeks
- Type of Pre-switch Antipsychotic
  - Partial Agonist
  - Strong M1/H1 Antagonist
  - Strong D2/3 Antagonist
  - Sedating
  - Non-sedating
- Pre-switch AP Dose Level
  - $\leq 6$  mg HAL equivalent
  - $> 6$  mg HAL equivalent
- Metabolic Status
  - Metabolic Syndrome
  - No Metabolic Syndrome

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- Reason for Clinical Discontinuation
  - Adverse Event
  - Lack of Efficacy

### 7.5.1. DERIVATION OF SUBGROUPS

#### Metabolic Status

If a male subject meets at least 3 out of 5 of the characteristics listed below, the subject is considered metabolically impaired at Baseline.

1. Baseline waist circumference  $\geq 102$  cm
2. Baseline fasting triglycerides  $\geq 150$  mg/dL (1.7 mmol/L) or use of drug treatment for elevated triglycerides at Baseline
3. Baseline fasting HDL  $< 40$  mg/dL (1.0 mmol/L) or use of drug treatment for reduced HDL at Baseline
4. (Baseline supine systolic blood pressure  $\geq 130$  mmHg and/or Baseline supine diastolic blood pressure  $\geq 85$  mmHg) or use of anti-hypertensive medications at Baseline
5. Baseline fasting glucose  $\geq 100$  mg/dL or use of antidiabetic medications at Baseline

If a female subject meets at least 3 out of 5 of the characteristics listed below, the subject is considered metabolically impaired at Baseline.

1. Baseline waist circumference  $\geq 88$  cm.
2. Baseline fasting triglycerides  $\geq 150$  mg/dL (1.7 mmol/L) or use of drug treatment for elevated triglycerides at Baseline
3. Baseline fasting HDL  $< 50$  mg/dL (1.3 mmol/L) or use of drug treatment for reduced HDL at Baseline
4. (Baseline supine systolic blood pressure  $\geq 130$  mmHg and/or Baseline supine diastolic blood pressure  $\geq 85$  mmHg) or use of anti-hypertensive medications at Baseline
5. Baseline fasting glucose  $\geq 100$  mg/dL or use of antidiabetic medications at Baseline

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 8. OUTPUT PRESENTATIONS

APPENDIX 1 shows conventions for presentation of data in outputs.

The templates provided with this SAP describe the presentations for this study and therefore the format and content of the summary tables, figures, and listings to be provided by IQVIA.

## 9. DISPOSITION AND WITHDRAWALS

Unless otherwise specified, the disposition summary tables will include the columns: SEP-363856 50 to 100 mg/day.

All subjects who were enrolled will be accounted for in this study.

The number and percentage of subjects who were screened, screen failed, enrolled in study SEP361-308, enrolled but did not receive study medication, received at least one dose of study medication, and completed or discontinued from the treatment period (including reasons for discontinuation) will be presented. In addition, the number and percentage of subjects who rolled over to the open-label extension study (SEP361-309) will be presented.

With respect to the above, the following definitions apply:

- Screened Subjects: Any subject who signed the study specific informed consent.
- Screen Failures: Any subject who signed the study specific informed consent but either failed to meet study requirements during screening or met study requirements at screening but was not dosed.

Subjects who were screened more than once will be counted only once in the disposition summary based on the outcome of the last screening. If a subject failed multiple screenings, they will only be counted once as a screen failure. If a subject is dosed after multiple screenings, they will only be counted once as an enrolled subject.

Discontinuation by visit will be summarized for the enrolled subjects.

The number and percentage of enrolled subjects will also be summarized by Site.

Lastly, the number and percentage of enrolled subjects included in and excluded from each analysis population will be summarized, along with the reason for exclusion.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

#### COVID-19 related analysis updates:

The number of subjects who failed screening due to COVID-19 related reasons, who discontinued early due to COVID-19 related reasons, and who completed the treatment period but did not roll over to the open-label extension study due to COVID-19 related reasons will be summarized in the disposition table.

Subjects affected by COVID-19 related study disruptions will be provided in data listings. These subjects will be identified as:

- Subjects who failed screening due to COVID-19.
- Subjects who were enrolled but discontinued from the treatment period due to COVID-19.
- Subjects who completed the treatment period but did not roll over to the open-label extension study (SEP361-309) due to COVID-19.
- Subjects who experienced a pre-treatment event / adverse event related to COVID-19.
- Subjects who had any protocol deviations related to COVID-19.
- Subjects who had any investigator comments related to COVID-19.

A subject may be identified in one or more categories listed above.

## 9.1. DERIVATIONS

- Time to discontinuation of the treatment in days.

For the purpose of this analysis, a subject's last dose date will be derived as follows:

- o If a subject's observed last dose date is before or on the date of Study Day 56, the derived last dose date will be set to the observed last dose date.
- o If a subject's observed last dose date is after the date of Study Day 56, the derived last dose date will be set to the date of Study Day 56.

Time to discontinuation (days) = Derived last dose date – First dose date + 1.

The event of interest is the discontinuation of treatment. Subjects who completed the treatment will be censored on the derived last dose date.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 10. IMPORTANT PROTOCOL DEVIATIONS

Important protocol deviations (IPDs) will be identified and documented based on data listings and the protocol deviations log; the data will be presented separately.

Unless otherwise specified, the IPD summary tables will include the following columns: SEP-363856 50 to 100mg/day.

The IPD categories may include, but may not be limited to:

- Did not satisfy inclusion and/or exclusion criteria.
- Received prohibited medication.
- Overall compliance rate <75% or >125%.

IPDs will be identified and presented in a data listing. The number and percentage of subjects within each IPD category will be summarized for the SAF population.

A dedicated listing will present protocol deviations related to COVID-19.

## 11. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Unless otherwise specified, the demographic and Baseline characteristics summary tables will include the column: SEP-363856 50 to 100 mg/day.

Demographic data and other Baseline characteristics will be presented for the SAF population, EFF population, and PP population. The data will be presented by the treatment group.

No statistical testing will be carried out for demographic or other Baseline characteristics.

The following demographic and other Baseline characteristics will be reported for this study.

Age (years) - calculated relative to date of informed consent; as a continuous variable

- Age (years) categories:
  - <18 years

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- ☐ ≥18 to ≤40 years
  - ☐ >40 to ≤65 years
  - ☐ >65 years
- Age (years) categories for ClinicalTrials.gov (CTR.GOV):
  - ☐ ≤18 years
  - ☐ >18 to <65 years
  - ☐ ≥65 years
- Age (years) categories for European Union Drug Regulating Authorities Clinical Trials Database (EudraCT):
  - ☐ <12 years
  - ☐ ≥12 to <18 years
  - ☐ ≥18 to <65 years
  - ☐ ≥65 years
- Sex:
  - ☐ Female
  - ☐ Male
- Race:
  - ☐ American Indian or Alaska Native
  - ☐ Asian
  - ☐ Black or African American
  - ☐ Native Hawaiian or Other Pacific Islander
  - ☐ White
  - ☐ Multiracial
  - ☐ Other
- Ethnicity:
  - ☐ Hispanic or Latino
  - ☐ Not Hispanic or Latino

---

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- Country :
  - United States
- Baseline Height (cm), as a continuous variable
- Baseline Weight (kg), as a continuous variable
- Baseline BMI (kg/m<sup>2</sup>), as a continuous variable
- Baseline BMI (kg/m<sup>2</sup>) category:
  - Underweight: <18.5 kg/m<sup>2</sup>
  - Normal: ≥18.5 to <25.0 kg/m<sup>2</sup>
  - Overweight: ≥25.0 to <30.0 kg/m<sup>2</sup>
  - Obese: ≥30.0 kg/m<sup>2</sup>
- Baseline Waist Circumference (cm), as a continuous variable
- Baseline PANSS Total Score, as a continuous variable
- Baseline PANSS Total Score categories:
  - < Overall median Baseline value
  - ≥ Overall median Baseline value
- Baseline PANSS Subscale Scores, as continuous variables
- Baseline PANSS Subscale Score categories:
  - < Overall median Baseline value
  - ≥ Overall median Baseline value
- Baseline PANSS Positive vs Negative Subscale Score categories:

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



- Positive Subscale Score < Negative Subscale Score
  - Positive Subscale Score ≥ Negative Subscale Score
- Patient type based on Baseline UPSM factor scores:
  - Type 1: Prominently Disorganized
  - Type 2: Prominently Negative
  - Type 3: Prominently Hostile
  - Type 4: Prominently Positive
  - Type 5: Prominently Affective
- Baseline CGI-S Score, as a continuous variable
- Baseline CGI-S Score categories:
  - <4
  - ≥4 to ≤5
  - >5
- Prior Antipsychotic Drug Administration
  - 1
  - 2
- Number of subjects who agreed to tokenization
- DSM-5 schizophrenia subtype diagnosis:
  - 295.90 Schizophrenia
  - 293.89 Schizophrenia with Catatonia
- Any other current psychiatric disorders:
  - Yes
  - No

Diagnosis and DSM-5 code for any other current psychiatric disorders will be summarized in a separate table. These other current psychiatric disorders will be coded using Medical Dictionary for Regulatory Activities (MedDRA) central coding dictionary, Version 22.0 or higher, and presented by System Organ Class (SOC) and Preferred Term (PT).

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 11.1. DERIVATIONS

- BMI expressed in  $\text{kg}/\text{m}^2$ :  
 $\text{Weight (kg)} / \text{height (m)}^2$ .

## 12. MEDICAL HISTORY

Unless otherwise specified, the medical and surgical history summary tables will include the column: SEP-363856 50 to 100 mg/day.

Medical and surgical history information, including both past and concomitant medical conditions and major surgical history, as collected on the “Medical History” CRF form, will be coded using MedDRA, Version 22.0 or higher, and presented by SOC and PT for the SAF population by the actual treatment group. Data will be sorted by SOC based on the internationally agreed order ([APPENDIX 4](#)) and by PT in decreasing frequency.

## 13. MEDICATIONS

Unless otherwise specified, the medications summary tables will include the following columns: SEP-363856 50 to 100 mg/day.

Medications will be coded to Anatomical Therapeutic Chemical (ATC) Levels and Preferred Names according to World Health Organization Drug (WHODRUG) dictionary, Version 01MAR2019 or later.

Whenever available, the time information should be accounted for in the derivation of prior, concomitant, and post-treatment medications. See [APPENDIX 2](#) for the handling of partial dates for medications. In the case where it is not possible to define a medication as prior, concomitant, or post treatment, the medication will be classified by the worst case; i.e., concomitant.

- Prior medications are medications which stopped prior to the first dose of study medication.
- Concomitant medications are medications which started at the same time of or after the first dose of study medication and at the same time of or before the last dose of study medication; or started prior to and ended at the same time of or after the first dose of study medication; or started at the same time of or prior to the last dose of study medication and marked as ongoing.
- Post-treatment medications are medications which started after the last dose of study medication.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

Prior and concomitant medication use will be summarized by ATC Level 3 and Preferred Base Name for the SAF population by the actual treatment group. Medications will be sorted by ATC Level 3 alphabetically and by Preferred Base Name in decreasing frequency in the “SEP-363856 50 to 100 mg/day” column. Similar summary for primary and secondary prior antipsychotic drug administration will also be presented separately.

Descriptive statistics of primary prior antipsychotic drug dosage at each visit will be presented. The number of subjects who complete the down tapering will also be presented by week.

Prior, concomitant, and post-treatment medications will be provided in data listings.

Psychotropic and/or Sedating Medications taken by subjects prior to each visit as collected on the “*Timing of last dose of Psychotropic and/or Sedating Medications*” CRF form will be summarized by ATC Level 3 and Preferred Base Name for the SAF population by the actual treatment group and visit.

## 14. STUDY MEDICATION EXPOSURE

Unless otherwise specified, the study medication exposure summary tables will include the column: SEP-363856 50 to 100 mg/day.

Exposure to study medication data will be summarized for the SAF population by the actual treatment group.

Duration of exposure (in days) will be summarized both as a continuous variable for the treatment period and categorically:

- Number and percentage of subjects with exposure  $\geq 1$ ,  $\geq 7$ ,  $\geq 14$ ,  $\geq 21$ ,  $\geq 28$ ,  $\geq 35$ ,  $\geq 42$ ,  $\geq 49$ , and  $\geq 56$  days
- Number and percentage of subjects with exposure for 1 - 6, 7 - 13, 14 - 20, 21 - 27, 28 - 34, 35 - 41, 42 - 48, 49 - 55 and  $\geq 56$  days

Total person-years of exposure will be calculated for all subjects.

Mean daily dose and modal daily dose will be calculated for the treatment period and summarized.

The dose adjustment decision at each visit will be summarized in a shift table.

Lastly, the number of days that a subject received the 50 mg/day dose level, the 75 mg/day dose level and 100 mg/day dose level will be summarized for the SAF population both as a continuous variable and categorically:

- Number and percentage of subjects with exposure to a particular dose level for 1 - 6, 7 - 13, 14 - 20, 21 - 27, 28 - 34, 35 - 41, 42 - 48, 49 - 55 and  $\geq 56$  days

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 14.1. DERIVATIONS

- Duration of exposure (days) = date of last dose of study drug – date of first dose of study drug + 1. Interruptions in exposure (i.e., missed doses) and dose changes (if any) are not considered in the calculation of overall exposure.
- Total person-years of exposure is the sum of all durations of exposure in days / 365.25.
- Mean daily dose (mg/day):

$$\frac{\sum \text{Dose per tablet for Visit } j * (\# \text{ Tablets Dispensed for Visit } j - \# \text{ Tablets Returned for Visit } j - \# \text{ Tablets Lost for Visit } j)}{\text{Duration of Exposure}}$$

If the number of tablets dispensed, returned, and/or lost as collected on the “Study Treatment Administration as Collected / Drug Accountability Log” CRF form is missing for one or more visits, the mean daily dose will be calculated based on visits with complete drug accountability data available. That is, the numerator of the formula above will only include visits with the number of tablets dispensed, returned, and lost available, and the denominator should be adjusted to exclude dosing periods covered by visits excluded from the calculation (i.e., Duration of Exposure – dosing periods [sum of (EXENDTC – EXSTDTC+1)] covered by visits with missing or incomplete accountability data). If the dose level of a visit is unknown, that visit should be excluded from the calculation as well in both the numerator and the denominator.

- Modal daily dose will be determined as the daily dose that is taken for the most time (in terms of number of days) among all doses taken. A subject’s modal daily dose may fall in one of the categories below:
  - SEP-363856 50 mg/day
  - SEP-363856 75 mg/day
  - SEP-363856 100 mg/day
  - Tie between xx and yy (i.e. the subject was on xx mg/day and yy mg/day for the same amount of time) (if needed)

## 15. STUDY MEDICATION COMPLIANCE

Unless otherwise specified, the study medication compliance summary tables will include the column SEP-363856 50 to 100 mg/day.

Compliance to study medication will be presented for the SAF population, by the actual treatment group.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

Percent compliance will be calculated overall for the treatment period. Non-compliance is defined as less than 75% or more than 125% non-missing compliance for the treatment period. Subjects with missing compliance will not be classified as non-compliant. Compliance will be summarized both as a continuous variable and categorically (i.e., number and percentage of subjects with compliance < 75%, 75% - 125%, > 125%, and missing).

## 15.1. DERIVATIONS

Overall Compliance (%) to study medication in percentage will be calculated as follows:

$$\frac{\sum(\# \text{ Tablets Dispensed for Visit } j - \# \text{ Tablets Returned for Visit } j - \# \text{ Tablets Lost for Visit } j)}{\# \text{ Tablets should be taken per day} \times \text{Duration of Exposure}} \times 100\%$$

If the number of tablets dispensed, returned, and/or lost as collected on the “Study Treatment Administration / Drug Accountability Log” CRF form is missing for one or more visits, the overall compliance will be calculated based on visits with complete drug accountability data available. That is, the numerator of the formula above will only include visits with the number of tablets dispensed, returned, and lost available, and the denominator should be adjusted to exclude dosing periods covered by visits excluded from the calculation (i.e., change “Duration of Exposure” to be Duration of Exposure – dosing periods [sum of (EXENDTC – EXSTDTC+1)] covered by visits with missing or incomplete accountability data).

## 16. EFFECTIVENESS OUTCOMES

Unless otherwise specified, the effectiveness analysis and summary tables will include the columns: SEP-363856 50 to 100 mg/day.

All analyses of the effectiveness variables will be based on the EFF population and, for selected variables/analyses, the PP population by the actual treatment group.

Descriptive statistics presented for effectiveness outcomes include sample size, mean, standard deviation, minimum, median, maximum, and a 95% confidence interval. Confidence intervals will be based on means and standard deviations estimated without adjustment for any center or baseline effects.

### 16.1. PANSS

The PANSS (Positive and Negative Syndrome Scale) is an interview-based measure of the severity of psychopathology in adults with psychotic disorders and comprises 30 items and 3 subscales. The positive subscale assesses hallucinations, delusions, and related

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

symptoms (7 items); the negative subscale assesses emotional withdrawal, lack of motivation, and related symptoms (7 items); and the general psychopathology subscale assesses other symptoms such as anxiety, somatic concern, and disorientation (16 items). An anchored Likert scale from 1 to 7 (1 = absent, 7 = extreme, with values of 2 and above indicating the presence of progressively more severe symptoms) is used to score each item.

Individual items are summed to derive the following scores:

Total score = sum of all 30 items. Total score ranges from 30 to 210.

Subscale scores = sum of items within each of the following subscales:

- Positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility. The subscale score ranges from 7 to 49.
- Negative subscale: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. This subscale score ranges from 7 to 49.
- General psychopathology subscale: somatic concern, anxiety, guilt feelings, tensions, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, active social avoidance. This subscale score ranges from 16 to 112.

Marder factor scores = sum of items within each of the following factors (Marder, Davis, Chouinard. 1997):

- Negative symptoms: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation, active social avoidance. This Marder factor score ranges from 7 to 49.
- Positive symptoms: delusions, hallucinatory behavior, grandiosity, suspiciousness/persecution, stereotyped thinking, somatic concern, unusual thought content, lack of judgment and insight. This Marder factor score ranges from 8 to 56.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- Disorganized thought: conceptual disorganization, difficulty in abstract thinking, mannerisms and posturing, poor attention, disturbance of volition, preoccupation, disorientation. This Marder factor score ranges from 7 to 49.
- Uncontrolled hostility/excitement: excitement, hostility, uncooperativeness, poor impulse control. This Marder factor score ranges from 4 to 28.
- Anxiety/depression: anxiety, guilt feelings, tension, depression. This Marder factor score ranges from 4 to 28.

UPSM (Uncorrelated PANSS Score Matrix) factor scores = PANSS item scores of each subject at each visit transformed using the UPSM to obtain scores of 7 transformed PANSS factors (Hopkins et al. 2018):

- POS: Positive
- DIS: Disorganized
- NAA: Negative apathy/avolition
- NDE: Negative deficit of expression
- HOS: Hostility
- ANX: Anxiety
- DEP: Depression

The transformation will be done as follows:

- $[\text{Transformed PANSS Factor Data}]_{(N \times 7)} = [\text{PANSS Data}]_{(N \times 30)} * [\text{UPSM}]_{(30 \times 7)}$
- where

$[\text{Transformed PANSS Factor Data}]_{(N \times 7)}$  is the transformed matrix with N sets of scores for the 7 transformed PANSS factors.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

[PANSS Data]<sub>(N×30)</sub> is a matrix with N PANSS assessments and 30 columns containing the scores of 30 PANSS items ordered in the same way as shown in UPSM.

[UPSM]<sub>(30×7)</sub> is a matrix with 30 rows (one for each PANSS item) and 7 columns (one for each of the 7 transformed PANSS factors). This matrix is presented in [APPENDIX 3](#).

UPSM total factor score = sum of the 7 UPSM factor scores.

PANSS is assessed at these study visits: Visit 1, Visit 2, Visit 3, Visit 4, Visit 6, Visit 8 and Visit 10.

### 16.1.1. PANSS TOTAL SCORE

PANSS is assessed at these study visits: Visit 1, Visit 2, Visit 3, Visit 4, Visit 6, Visit 8, and Visit 10. The Baseline PANSS total score will be derived as described in [Section 6.2](#). The change from Baseline in PANSS total score at Week 8, as well as at the other post-Baseline time points, will be derived as described in [Section 6.7](#).

The observed PANSS total score and the change from Baseline values will also be summarized descriptively by treatment group and visit.

The observed PANSS total score and the change from Baseline values will also be summarized descriptively by treatment group and visit for each subgroup listed in [Section 7.5](#).

### 16.1.2. PROPORTION OF SUBJECTS WHO ACHIEVE A RESPONSE

PANSS response is defined as a 20% or greater improvement (i.e. decrease) in PANSS total score from Baseline.

The percent change in PANSS total score from Baseline will be calculated by:

$$\frac{\text{PANSS total score at a visit or the Week 8 LOCF endpoint} - \text{PANSS total score at Baseline}}{\text{PANSS total score at Baseline} - 30} \times 100\%$$

For each subject, the responder indicator will be set to 1 if the percent change is negative and the magnitude is equal to or greater than 20%. The indicator will be set to 0 if the percentage is negative but the magnitude is less than 20% or the percentage is non-negative. The

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



indicator will be set to missing if the percentage is missing.

In addition, PANSS response defined by two more stringent thresholds will be assessed; that is, having a 30% or greater and 50% or greater improvement in PANSS total score from Baseline.

PANSS response at all three thresholds will be derived for all post-Baseline time points.

The number and percentage of subjects who achieve a PANSS response will also be summarized descriptively by treatment group and visit.

The proportion of subjects achieving a given percentage change threshold in PANSS total score from Baseline at the LOCF endpoint will be calculated for each treatment group. This calculation will be performed at multiple thresholds, starting from -100% and increases at 5% increments or until all subjects are accounted for in all treatment groups, with 5% increments.

### 16.1.3. PANSS SUBSCALE SCORES

Individual items from the PANSS scale are summed to derive the following subscale scores:

- Positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility. This subscale score ranges from 7 to 49.
- Negative subscale: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. This subscale score ranges from 7 to 49.
- General psychopathology subscale: somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, active social avoidance. This subscale score ranges from 16 to 112.

PANSS is assessed at these study visits: Visit 1, Visit 2, Visit 3, Visit 4, Visit 6, Visit 8, and Visit 10. The Baseline PANSS subscale scores will be derived as described in Section 6.2. The change from Baseline in PANSS subscale scores at each post-Baseline time point will be derived as described in Section 6.7.

The observed values of PANSS subscale scores at Baseline and each scheduled post-Baseline visit will be summarized descriptively. The Baseline PANSS subscale scores will be derived as described in Section 6.2.

The change from Baseline in PANSS subscale scores will be summarized for each scheduled post-Baseline visit. The change from Baseline in PANSS

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

subscale scores will be derived as described in [Section 6.7](#).

#### 16.1.4. PANSS MARDER FACTOR SCORES

Individual items from the PANSS scale are summed to derive the following Marder factors (Marder, Davis, & Chouinard, 1997;58:538–46):

- Negative symptoms: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation, and active social avoidance. This Marder factor score ranges from 7 to 49.
- Positive symptoms: delusions, hallucinatory behavior, grandiosity, suspiciousness/persecution, stereotyped thinking, somatic concern, unusual thought content, and lack of judgment and insight. This Marder factor score ranges from 8 to 56.
- Disorganized thought: conceptual disorganization, difficulty in abstract thinking, mannerisms and posturing, poor attention, disturbance of volition, preoccupation, and disorientation. This Marder factor score ranges from 7 to 49.
- Uncontrolled hostility/excitement: excitement, hostility, uncooperativeness, and poor impulse control. This Marder factor score ranges from 4 to 28.
- Anxiety/depression: anxiety, guilt feelings, tension, and depression. This Marder factor score ranges from 4 to 28.

PANSS is assessed at these study visits: Visit 1, Visit 2, Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, Visit 8, and Visit 10. The Baseline PANSS Marder factor scores will be derived as described in Section 6.2. The change from Baseline in PANSS Marder factor scores at each post-Baseline time point will be derived as described in [Section 6.7](#).

The observed values of PANSS Marder factor scores at Baseline and each scheduled post-Baseline visit will be summarized descriptively. The Baseline PANSS Marder factor scores will be derived as described in [Section 6.2](#).

The change from Baseline in PANSS Marder factor scores will be summarized for each scheduled post-Baseline visit. The change from Baseline in PANSS Marder factor scores will be derived as described in [Section 6.7](#).

#### 16.1.5. PANSS UPSM FACTOR SCORES AND THE UPSM TOTAL FACTOR SCORE

The PANSS item scores of each subject at each visit will be transformed using the UPSM, to obtain the scores of 7 transformed PANSS factors (Hopkins S. , Ogirala, Loebel, & Koblan, 2018;44(3):593-602):

- POS: Positive

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- DIS: Disorganized
- NAA: Negative apathy/avolition
- NDE: Negative deficit of expression
- HOS: Hostility
- ANX: Anxiety
- DEP: Depression

The transformation will be done as follows:

$$[\text{Transformed PANSS Factor Data}]_{(N \times 7)} = [\text{PANSS Data}]_{(N \times 30)} * [\text{UPSM}]_{(30 \times 7)}$$

where

- o  $[\text{Transformed PANSS Factor Data}]_{(N \times 7)}$  is the transformed matrix with N sets of scores for the 7 transformed PANSS factors.
- o  $[\text{PANSS Data}]_{(N \times 30)}$  is a matrix with N PANSS assessments and 30 columns containing the scores of 30 PANSS items ordered in the same way as shown in UPSM.
- o  $[\text{UPSM}]_{(30 \times 7)}$  is a matrix with 30 rows (one for each PANSS item) and 7 columns (one for each of the 7 transformed PANSS factors). This matrix is presented in [APPENDIX 3](#).

Lastly, the UPSM total factor score will be calculated as the sum of the 7 UPSM factor scores.

PANSS is assessed at these study visits: Visit 1, Visit 2, Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, Visit 8, and Visit 10. The Baseline PANSS UPSM factor scores and UPSM total factor score will be derived as described in Section 6.2. The change from Baseline in PANSS UPSM factor scores and UPSM total factor score at each post-Baseline time point will be derived as described in [Section 6.7](#).

The observed values of PANSS UPSM factor scores at Baseline and each scheduled post-Baseline visit will be summarized descriptively. The Baseline PANSS UPSM factor scores will be derived as described in Section 6.2.

The change from Baseline in PANSS UPSM factor scores will be summarized for each scheduled post-Baseline visit. The change from Baseline in PANSS UPSM factor scores will be derived as described in [Section 6.7](#).

The observed values of PANSS UPSM total factor score at Baseline and each scheduled post-Baseline visit will be summarized descriptively. The Baseline PANSS UPSM total factor score will be derived as described in Section 6.2.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

The change from Baseline in PANSS UPSM total factor score will be summarized for each scheduled post-Baseline visit. The change from Baseline in PANSS UPSM total factor score will be derived as described in [Section 6.7](#).

## 16.2. CLINICAL GLOBAL IMPRESSION-SEVERITY

The CGI-S (Clinical Global Impression-Severity) is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity. The CGI-S score takes one of the following values: 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill patients).

CGI-S is assessed at these study visits: Visit 1, Visit 2, Visit 3, Visit 4, Visit 6, Visit 8, and Visit 10. The Baseline CGI-S score will be derived as described in [Section 6.2](#). The change from Baseline in CGI-S score at Week 8, as well as at the other post-Baseline time points, will be derived as described in [Section 6.7](#).

The observed CGI-S score and the change from Baseline values will also be summarized descriptively by treatment group and visit.

The observed CGI-S score and the change from Baseline values will also be summarized descriptively by treatment group and visit for each subgroup.

## 16.3. BRIEF NEGATIVE SYMPTOM SCALE (BNSS) TOTAL SCORE AND SUBSCALE SCORES

The BNSS (Brief Negative Symptom Scale) is a rating scale that measures the current level of severity of negative symptoms in schizophrenia and schizoaffective disorder. The measure is comprised of 13 individual items organized into 6 subscales: blunted affect (items 9, 10, 11), avolition (items 7, 8), anhedonia (items 1, 2, 3), asociality (items 5, 6), and distress (item 4). Each of the items are scored on a Likert-type 7-point scale from 0-6, where values of 0 indicates the symptom is absent and a value of 6 means the symptom is a severe form. The subscale scores are calculated by summing the individual items within each scale. The 13 items are also summed to provide a total score which ranges from 0 to 78.

BNSS is assessed at these study visits: Visit 2, Visit 6, Visit 10.

The observed values of BNSS total score and BNSS subscale scores at Baseline and each scheduled post-Baseline visit will be summarized descriptively. The Baseline BNSS total score and BNSS subscale scores will be derived as described in [Section 6.2](#).

The change from Baseline in BNSS total score and BNSS subscale scores will be summarized for each scheduled post-Baseline visit. The change from Baseline in BNSS total score and BNSS subscale scores will be derived as described in [Section 6.7](#).

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 16.4. 12-ITEM SHORT FORM SURVEY (SF-12)

The SF-12 is a 12-item self-reported questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales including: Physical functioning, Role-physical, Bodily pain, General health, Vitality, Social Functioning, Role emotional, and Mental health. The responses are reported on a 3- or 5-point Likert scale, depending on the question. The SF-12 uses 2-items each to estimate scores for 4 of the 8 health concepts (physical functioning, role-physical, role-emotional, and mental health). Score for the remaining 4 healthy concepts (bodily pain, general health, vitality, and social functioning) are estimated using 1 item each. Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) are computed using the scores of 12 questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The norm-based subdomain scores are the scores normed to the US population to have a mean of 50 and standard deviation of 10.

The observed values of the SF-12 for each subdomain (both raw and norm-based) such as general health, physical functioning, role physical, bodily pain, vitality, role emotional, mental health, social functioning, and both PCS and MCS composite scores and health utility index score at Baseline and each scheduled post-Baseline visit will be summarized descriptively.

The change from Baseline will be summarized for each scheduled post-Baseline visit.

## 16.5. PSP TOTAL SCORE AND INDIVIDUAL DOMAIN SCORES

The PSP (Personal and Social Performance Scale) is a 100-point single-item rating scale of personal and social functioning. The 100-point rating scale is subdivided into 10 equal intervals (or 10-point categories). The rating is based on the assessment of a patient's functioning in four areas: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behaviors. Each area is evaluated using the degree of severity: Absent, Mild, Manifest, Marked, Severe and Very Severe. For the purpose of analysis, the following numerical values will be assigned to the degrees of severity:

0 = Absent

1 = Mild

2 = Manifest

3 = Marked

4 = Severe

5 = Very Severe

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

A PSP total score (range 1 to 100) is assigned by the rater based on the subject's functioning in the four areas.

Higher PSP total scores indicate better functioning. Scores of 1-30 indicate functioning so poor that intensive support or supervision is needed; scores of 31-70 indicate varying degrees of difficulty; and scores of 71-100 reflect only mild difficulties.

PSP is assessed at these study visits: Visit 2 and Visit 10. The Baseline PSP total score will be derived as described in Section 6.2. The change from Baseline in PSP total score at each post-Baseline time point will be derived as described in Section 6.7.

In addition, the following binary outcomes based on PSP total score will be derived:

- PSP total score  $\geq 71$  at Baseline and each scheduled visit (Week 8/Visit 10)
- Improvement of  $\geq 1$  PSP 10-point category from Baseline to each scheduled visit (Week 8/Visit 10)

For each subject, the indicator for each of the binary outcomes described above will be set to Y if the subject satisfied the condition, and N if the subject failed to satisfy the condition. The indicator will be set to missing if the data necessary for the derivation is missing (e.g., the PSP total score is missing at a particular time point).

The observed PSP total score and individual domain scores and the change from Baseline values will also be summarized descriptively by treatment group and visit.

The number and percentage of subjects satisfying each binary outcome listed below at Week 8/Visit 10 will be summarized descriptively by treatment group and visit.

- PSP total score  $\geq 71$  at Baseline and each scheduled visit (Week 8/Visit 10)
- Improvement of  $\geq 1$  PSP 10-point category from Baseline to each scheduled visit (Week 8/Visit 10)

In addition, the number and percentage of subjects that fall in each of the following PSP categories will be summarized descriptively by treatment group and visit:

- o Total score 100-71 (mild to no impairment).
- o Total score 70-51 (moderate impairment)
- o Total score 50-31 (marked impairment)
- o Total score 30-1 (severe impairment)

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 16.6. MEDICATION SATISFACTION QUESTIONNAIRE (MSQ)

The MSQ is a single-item, patient-rated, rater administered questionnaire that requires the subject to use a 7-point, Likert-type scale to rate how satisfied they are with their current antipsychotic medication. The subject will be asked the following question: “Overall, how satisfied are you with your current antipsychotic medication”.

Subjects will select 1 of 7 potential responses based on their level of satisfaction from extremely dissatisfied (1) to extremely satisfied (7) as follows:

- (1) Extremely dissatisfied
- (2) Very dissatisfied
- (3) Somewhat dissatisfied
- (4) Neither dissatisfied nor satisfied
- (5) Somewhat satisfied
- (6) Very satisfied
- (7) Extremely satisfied

MSQ is assessed at these study visits: Visit 2 and Visit 10. The Baseline MSQ score will be derived as described in [Section 6.2](#). The change from Baseline in MSQ score at each post-Baseline time point will be derived as described in [Section 6.7](#).

The analysis of MSQ data will be limited to subjects who were being treated with an antipsychotic medication at the time of screening or had been treated with antipsychotic medications within 30 days prior to the Screening visit.

The observed MSQ score and the change from Baseline values will also be summarized descriptively by treatment group and visit. In addition, the frequency distribution of the MSQ score will be summarized descriptively by treatment group and visit.

## 16.7. CLINICAL GLOBAL IMPRESSIONS – IMPROVEMENT SCALE (CGI-I)

The CGI-I scale is a standard 7-point scale (Guy-1976) that requires the clinician to assess how much the subject's overall symptoms have improved or worsened relative to a baseline state.

The observed CGI-S score and the change from Baseline values will also be summarized descriptively by treatment group and visit.

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

The observed CGI-S score and the change from Baseline values will also be summarized descriptively by treatment group and visit for each subgroup.

## 16.8. HEALTHCARE RESOURCE UTILIZATION

Healthcare resource utilization is assessed at these study visits: Visit 2 and Visit 10.

The number of physician's office visits, ER visits, and hospitalizations (for any reason and those related to schizophrenia) per month at Baseline and at Week 8/Visit 10, as well as the average length of hospital stays (for any reason and those related to schizophrenia) at Baseline and at Week 8/Visit 10, will be summarized. The frequency and percentage of subjects receiving unpaid care at Baseline and at Week 8/Visit 10, along with the average number of hours a caregiver spends per week helping the subject, will also be summarized.

The change in the number of physician's office visits, ER visits, and hospitalizations, the average length of hospital stays, and the average number of hours a caregiver spends per week helping the subject from Baseline at Week 8/Visit 10 will be summarized.

Shift from Baseline to Week 8/Visit 10 in whether the subjects receive unpaid care will also be summarized.

## 16.9. NICOTINE USE

Nicotine use is assessed at these study visits: Visit 1 and Visit 10. Nicotine use data will be summarized descriptively by treatment group and visit.

For each nicotine type, the amount being used at Week 8/Visit 10 and LOCF in comparison with the amount being used at Baseline will be classified as "increased", "decreased", or "unchanged" for every subject, based on the reported amount used in a given period. If a subject quit using a particular type of nicotine since Baseline, the amount used for that nicotine type will be classified as "decreased". If a subject newly started or restarted using a particular type of nicotine since Baseline, the amount used for that nicotine type will be classified as "increased".

Then for subjects whose changes in amount for all nicotine types between Baseline and each scheduled post-Baseline visit (Week 8/Visit 10 and LOCF) are not in opposite directions, a subject's overall nicotine consumption at each scheduled post-Baseline visit in comparison with Baseline will be classified as "increased", "decreased", or "unchanged" based on the following:

- If the change in amount for each nicotine type is either "increased" or "unchanged", the subject's overall consumption will be classified as "increased".
- If the change in amount for each nicotine type is either "decreased" or "unchanged", the subject's overall consumption will be classified as "decreased".

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



- If the change in amount for all nicotine types is “unchanged”, the subject’s overall consumption will be classified as “unchanged”.

The number and percentage of subjects in each overall consumption amount change category will be summarized by treatment group.

In addition, for subjects who reported using “Cigarettes” at either Baseline or each scheduled post-Baseline visit (Week 8/Visit 10 and LOCF) or at both time points, the number of cigarettes used per day will be derived for both time points. The following conversion will be applied if necessary:

- Amount: 1 Pack = 20 Cigarettes.
- Time period: 1 Week = 7 Days; 1 Month = 30 Days.

The amount of cigarette used per day and the change from Baseline values will be summarized by treatment group and visit.

## 16.10. MISSING DATA METHOD

Any individual missing item in any scale will not be imputed.

For derived scores that depend on more than one individual item (e.g., PANSS total score, PANSS subscale scores, PANSS Marder factor scores, PANSS UPSM factor scores and UPSM total factor score, BNSS total score, BNSS subscale scores, MADRS total score), if one or more items are missing at a visit, the derived score will be set to missing. The corresponding change from Baseline value at a given post-Baseline time point will be set to missing if the Baseline derived score is missing or if the derived score at that time point is missing.

For PANSS response, any subject with a missing PANSS total score at Baseline or at any post-Baseline time point will have their PANSS response set to missing for that time point.

For PSP binary variables based on the PSP total score, if the PSP total score is missing at Baseline or at any post-Baseline time point, the affected binary variable will be set to missing.

## 17. SAFETY OUTCOMES

Unless otherwise specified, the safety analysis and summary tables will include the column SEP-363856 50 to 100 mg/day

All analyses of the safety outcomes will be based on the SAF Population, by treatment group.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 17.1. DISCONTINUATION DUE TO CLINICAL REASONS

Discontinuation for clinical reasons is defined as reasons due to AE or lack of efficacy. AE will follow the definition as in section [17.3](#).

The percentage of subjects who discontinued for clinical reasons will be calculated by a proportion consisting of the number of subjects who experience a discontinuation event due to clinical reasons as the numerator divided by the number of subjects in the safety population as the denominator multiplied by 100 along with a corresponding 95% confidence interval (CI).

The number and percentage of subjects, who discontinued early from the open-label treatment period (including both clinical reasons, ie, discontinued due to an AE or lack of efficacy (primary endpoint) and any reason for discontinuation (secondary endpoint)) will be presented.

The time-to-discontinuation for clinical reasons will be summarized descriptively, (eg, n, median, 25th percentile, 75th percentile, minimum and maximum, and 95% CI on median, where possible).

Time to discontinuation for clinical reasons since first dose of study medication will be plotted using Kaplan-Meier curves for the safety population by treatment group. Probability of remaining on treatment at Day 56, median time to discontinuation, and their 95% confidence intervals will be estimated using the Kaplan-Meier method for the safety population by treatment group.

## 17.2. DISCONTINUATION DUE TO ANY REASONS

The percentage of subjects who discontinued for any reason (ie, all cause discontinuation). The percentage will be calculated similarly as that of the primary endpoint along with a corresponding 95% CI.

Kaplan-Meier analysis as in section [17.1](#) will be performed for time to discontinuation for any reasons.

## 17.3. ADVERSE EVENTS AND PRE-TREATMENT EVENTS

Adverse events (AEs) and pre-treatment events will be coded using MedDRA central coding dictionary, Version 22.0 or higher.

Any COVID-19 related Adverse Events and pre-treatment events will be identified using a pre-defined search:

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

**Table 2: Predefined search criteria for COVID-19 related adverse events or pre-treatment events.**

Lower Level Term	Lower Level Term Code	Preferred Term	Preferred Term Code	Search Criteria for COVID-19 Related Adverse Events or Pre-treatment Events
Coronavirus test positive	1007025	Coronavirus test positive	10070255	Preferred Term Code = 10070255 or 10053983
Coronavirus infection	10051905	Corona virus infection	10053983	

AEs are defined as untoward medical occurrences that started at the same time of or after the first dose of study drug. Untoward medical occurrences that started prior to the first dose of study drug are pre-treatment events.

Whenever available, the time information should be accounted for in the derivation of AEs vs. pre-treatment events. In the case where time is not available, untoward medical occurrences that started on or after the day of the first dose of study drug will be considered AEs; those that started before the day of the first dose of study drug will be considered pre-treatment events.

See [APPENDIX 2](#) for handling of partial dates for AEs. In the case where it is unclear whether an untoward medical occurrence is an AE or a pre-treatment event, the algorithm uses a conservative approach where the untoward medical occurrence is classified by the worst case; i.e., AE.

AEs (including serious adverse events (SAEs)) are collected into the clinical database until the last study visit. For subjects who do not roll over to study 361-309, the last study visit will be Visit 11 (the follow-up visit) which per protocol should occur 7 ( $\pm$  2) days after the last dose of study drug. For subjects continuing into study 361-309, the last 361-308 study visit will be Visit 10 (the end of treatment visit). If an AE (or a pre-treatment event) started in 361-308 and was ongoing at rollover, this adverse event (pre-treatment event) will be marked Ongoing in the 361-308 database. It will also be re-entered into the 361-309 database and its outcome will be monitored and updated in the 361-309 database.

Overall summary of the incidence of all AEs, AEs related to COVID-19, study medication-related AEs, severe AEs, serious AEs, AEs leading to discontinuation from study, AEs leading to study medication withdrawal, AEs leading to study medication interruption, and AEs leading to death will be provided by treatment group. This overall incidence summary will also be separately presented for the following subgroups: country, sex, age group, number of prior hospitalizations for treatment of schizophrenia, duration of schizophrenia, and BMI category.

Listings will be provided for all AEs, AEs related to COVID-19, study medication-related AEs, severe AEs, serious AEs, AEs leading to discontinuation from the study, AEs leading to study medication withdrawal, AEs leading to study medication interruption, AEs leading to death, AEs of potential drug abuse and dependence and extrapyramidal AEs. A listing of the pre-treatment events will also be presented. When complete event start date and complete event end date are available, duration of AEs/pre-treatment events will be calculated as: event end date – event start date + 1. Duration will be presented in data listings.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

For all summaries, each subject will be counted only once within each category (e.g., an AE type, a severity level, a relationship category, a SOC, a high level term (HLT), and a PT). If not otherwise specified, all summaries will present the number and percentage of subjects as well as the number of events. For summaries by SOC and PT, AEs will be sorted by SOC based on the internationally agreed order (see [APPENDIX 4](#)) and then by PT in decreasing frequency in the “SEP-363856 50 to 100 mg/day” column. For summaries by SOC, HLT, and PT, AEs will be sorted by SOC based on the internationally agreed order and then by HLT and PT in decreasing frequency in the “SEP-363856 50 to 100 mg/day” column.

COVID-19 related pre-treatment events related pre-treatment events and AEs will be displayed similarly as any other pre-treatment events and AEs.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

**17.3.1. ALL AEs**

All AEs will be summarized by PT, by SOC and PT, as well as by SOC, HLT, and PT. The summary by SOC and PT will also be presented for the following subgroups: sex, age group and BMI category.

Summary tables (by SOC and PT) will be generated for those AEs starting after the last dose of study drug and those AEs starting more than 1 day after the last dose of study drug.

AEs reported by  $\geq 2.0\%$  (without rounding) of subjects in any treatment group will be summarized by SOC and PT.

Non-serious AEs reported by  $> 5.0\%$  (without rounding) of subjects will be summarized by SOC and PT.

The summary by SOC and PT will be broken down further by maximum severity and by strongest relationship to study medication. These summaries are described in the sections below.

**17.3.2. SEVERITY**

Severity is classed as mild/ moderate/ severe (increasing severity). AEs with a missing severity will be classified as severe.

If a subject reported an AE more than once within the same SOC/ PT with different severity levels, the subject will be assigned to a severity level for that SOC/ PT based on the worst case severity (i.e., maximum severity). Event counts will not be included in this summary.

In a separate table, severe AEs will be summarized by SOC and PT.

**17.3.3. RELATIONSHIP TO STUDY MEDICATION**

Relationship to study medication, as indicated by the Investigator, is classed as “not related”/ “possible”/ “probable”/ “definite” (increasing strength of relationship). A “related” AE is defined as an AE with a relationship to study medication as “possible”, “probable” or “definite”. AEs with a missing relationship to study medication will be regarded as related to the study medication. For this summary, AEs will be presented in 2 categories, related and not related.

If a subject reported an AE more than once within the same SOC/ PT in different relationship categories, the subject will be assigned to a category for that SOC/ PT based on the worst case relationship (i.e., strongest relationship). Event counts will not be included in this summary.

In separate tables, study medication-related AEs will be summarized by SOC and PT and summarized by PT.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

#### 17.3.4. AEs LEADING TO DISCONTINUATION FROM STUDY

AEs leading to discontinuation from the study are those AEs with “Caused Study Discontinuation” = “Yes” on the “Adverse Events” CRF form.

AEs leading to discontinuation from the study will be summarized by SOC and PT.

#### 17.3.5. AEs LEADING TO STUDY MEDICATION WITHDRAWAL

AEs leading to permanent withdrawal from the study medication are those AEs with “Action Taken with Study Treatment” = “Drug Withdrawn” on the “Adverse Events” CRF form.

AEs leading to study medication withdrawal will be summarized by SOC and PT.

#### 17.3.6. AEs LEADING TO STUDY MEDICATION INTERRUPTION, STUDY DOSE INCREASE AND REDUCED

AEs leading to study medication interruption, study dose increase, study dose reduce are those AEs with “Action Taken with Study Treatment” = “Drug Interrupted”, “Action Taken with Study Treatment” = “Dose Increased”, “Action Taken with Study Treatment” = “Dose Reduced” respectively on the “Adverse Events” CRF form.

AEs leading to study medication interruption will be summarized by SOC and PT.

#### 17.3.7. SERIOUS ADVERSE EVENTS

SAEs are those AEs recorded as “Serious” on the “Adverse Events” CRF form.

SAEs will be summarized by SOC and PT. The summary will also be presented for the following subgroups: country, sex, age group, number of prior hospitalizations for treatment of schizophrenia, duration of schizophrenia, and BMI category.

.

In a separate table, SAEs starting within 7 days, after the last dose of study drug will be summarized by SOC and PT as well.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

**17.3.8. ADVERSE EVENTS LEADING TO DEATH**

AEs leading to death are those AEs with “Outcome” = “Fatal” on the “Adverse Events” CRF form.

AEs leading to death will be summarized by SOC and PT.

**17.3.9. ADVERSE EVENTS OF POTENTIAL DRUG ABUSE AND DEPENDENCE**

AEs associated with potential drug abuse and dependence will be identified as described in [APPENDIX 5](#).

These AEs will be summarized by PT only.

**17.3.10. EXTRAPYRAMIDAL ADVERSE EVENTS**

Extrapyramidal AEs will be identified by MedDRA SMQ 20000095 Extrapyramidal syndrome as described in [APPENDIX 6](#).

These AEs will be summarized by PT only.

**17.3.11. ADVERSE EVENTS BY SUBGROUPS**

The subgroup factors of interest for AE summaries include: country, sex, age group, number of prior hospitalizations for treatment of schizophrenia, duration of schizophrenia, and BMI category (see [Section 7.5](#)). AE by subgroup summaries are described in the individual sections above.

**17.3.12. PSYCHIATRIC ADVERSE EVENTS LEADING TO DISCONTINUATION FROM STUDY (PAEDCs)**

Additional information is collected for the non-serious psychiatric AEs that led to discontinuation from the study as well as for all serious psychiatric AEs within the study. The information is recorded in separate trackers and not part of the CRF. This information will be presented in separate data listings only.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 17.4. LABORATORY EVALUATIONS

Results from the central laboratory to be reported for this study include Hematology, Chemistry (including lipid panel and thyroid panel), Urinalysis, Urine drug screening, Rapid Urine Drug Screening, Serology panel, Serum pregnancy ( $\beta$ -HcG) (in female subjects only), Urine pregnancy (in female subjects only), Rapid Urine Pregnancy Test (in female subjects only), Follicle stimulating hormone (FSH) (in female subjects with suspected menopause).

Serum and urine pregnancy results in female subjects, FSH level in female subjects, serology panel in subjects, and any unexpected lab parameters not specified in protocol Section 22 (APPENDIX IV. CLINICAL LABORATORY TESTS) will only be listed. Laboratory parameters prespecified in protocol Section 22 under the categories of “HEMATOLOGY”, “BLOOD CHEMISTRIES” (plus HOMA-IR if collected), “URINALYSIS”, and “URINE DRUG SCREENING/ RAPID URINE DRUG SCREENING” will be summarized in tables as well as presented in listings.

Listing presentations will use both standard international (SI) Units and conventional units (CV). Table summaries will also be provided using both SI units and conventional units.

Quantitative laboratory measurements reported as “< X”, i.e., below the lower limit of quantification (BLQ), or “> X”, i.e., above the upper limit of quantification (ULQ), will be converted to X for the purpose of quantitative summaries, but they will be presented as recorded, i.e., as “< X” or “> X” in the listings.

The following summaries will be provided:

- By-visit summary of observed values and change from Baseline values for quantitative measurements in hematology, chemistry, and urinalysis. Serum prolactin results will be summarized overall and separately by sex. Glucose, insulin and lipid panel results (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) will be summarized by fasting status: fasting only and overall (fasting, non-fasting, or fasting status unknown combined). Change from Baseline for glucose, insulin and lipid panel results will only be calculated if post-Baseline fasting status is matching Baseline fasting status.
- By-visit summary of the number and percentage of subjects in each outcome category for qualitative measurements in urinalysis (as applicable) and for urine drug screening results. Urine drug screening results will be reported as “Positive”/ “Negative”.
- Shift in laboratory results (chemistry, hematology, urinalysis) from Baseline to Week 8/Visit 10 and LOCF Endpoint according to the reference range criteria. The existing reference range indicators provided by the central laboratory will be mapped as needed to categories of “Normal” (within the reference range) / “Abnormal” (outside the reference range) for urinalysis non-pH results, and to categories of “Low” (below the reference range) / “Normal” (within the reference range) / “High” (above the reference range) for chemistry and hematology results as well as urinalysis pH results.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



- Number and percentage of subjects with at least one potentially clinically significant (PCS) laboratory value (see [APPENDIX 7](#)) post Baseline. The period of evaluation includes the follow-up period, including unscheduled visits. Subjects will be counted in a particular PCS category if they met that PCS criteria at least once post Baseline, regardless of their Baseline value.

All laboratory data will be provided in data listings, with the values outside the reference ranges flagged. In addition, separate listings will be provided to present the laboratory data that met the PCS criteria.

Boxplots will be created to present Baseline and Week 8/Visit 10 values by treatment group for lipid parameters (total cholesterol, LDL, HDL, and triglycerides), glucose, insulin by fasting status: fasting only and overall (fasting, non-fasting, or fasting status unknown combined). In addition, boxplots will be created to present Baseline and Week 8/Visit 10 prolactin values by treatment group by sex: Overall, males, females. Lastly, the values of HbA1c will be presented for Baseline and Week 8/Visit 10 by treatment group in boxplots as well. Each of these boxplots will be repeated to present the change from Baseline values.

#### 17.4.1. LABORATORY SPECIFIC DERIVATIONS

No applicable derivations.

#### 17.4.2. LABORATORY REFERENCE RANGES

Laboratory reference range indicators will be provided by the laboratory vendor and used in statistical analyses. Only if a reference range indicator is missing in the data transfer will it be derived in the analysis step as described below.

- Quantitative laboratory measurements (that are not urinalysis erythrocytes or urinalysis leukocytes) will be compared with the relevant laboratory reference ranges in original units and categorized as:
  - Low: Below the lower limit of the laboratory reference range.
  - Normal: Within the laboratory reference range (upper and lower limit included).
  - High: Above the upper limit of the laboratory reference range.
- For laboratory parameters with categorical outcomes as well as urinalysis erythrocytes and urinalysis leukocytes, if the result is within the reference range, the indicator is "NORMAL"; if the result is not within range, the indicator is "ABNORMAL".

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 17.5. ECG EVALUATIONS

Data from the centrally over-read ECG (Electrocardiogram) results will be included in the reporting of this study.

The following ECG parameters will be reported for this study:

- PR Interval (msec)
- RR Interval (msec)
- QRS Duration (msec)
- QRS Axis (deg)
- QT Interval (msec)
- QTcF Interval (msec) (Fridericia's Correction of QT interval)
- QTcB Interval (msec) (Bazett's Correction of QT interval)
- Heart Rate (bpm)
- Overall assessment of ECG as determined by the central over-read:
  - o Normal
  - o Abnormal, Insignificant
  - o Abnormal, Potentially Significant
  - o Abnormal, Significant
  - o Exclusion Alert (only given for the Screening visit). In table summaries, the category of "Exclusion Alert" will be combined into the category of "Abnormal, Significant".
  - o Not Evaluable
- ECG findings

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

ECG findings will only be listed. Other ECG data will be summarized in tables as well as presented in listings.

The following summaries will be provided:

- By-visit summary of observed values and change from Baseline values for quantitative measurements.
- By-visit summary of ECG overall assessment results as determined by the central over-read (“Normal”, “Abnormal, Insignificant”, “Abnormal, Potentially Significant”, “Abnormal, Significant”, “Not Evaluable”).
- Shift in ECG overall assessment as determined by the central over-read from Baseline to Week 8/Visit 10, and LOCF endpoint.
- Number and percentage of subjects who met each of the QTc interval prolongation criteria (see [Section 17.5.1](#)). The period of evaluation includes both the treatment period and the follow-up period, including unscheduled visits.
- Number and percentage of subjects with at least one PCS ECG value (see [Section 17.5.2](#)) post Baseline. The period of evaluation includes both the treatment period and the follow-up period, including unscheduled visits. Subjects will be counted in a particular PCS category if they met that PCS criteria at least once post Baseline, regardless of their Baseline value.

All ECG parameters, overall assessment as determined by the central over-read, and findings will be provided in a data listing. In addition, separate listings will be generated to present the QTc interval data of subjects who met at least one QTc prolongation criterion and the ECG data that met the PCS criteria.

### 17.5.1. QTc INTERVAL PROLONGATION CRITERIA

QTc interval prolongation will be identified in accordance with the following predefined criteria (same criteria apply to both QTcF and QTcB):

- > 450 msec at any post-Baseline time point (including unscheduled visits) not present at Baseline
- > 480 msec at any post-Baseline time point (including unscheduled visits) not present at Baseline
- > 500 msec at any post-Baseline time point (including unscheduled visits) not present at Baseline
- ≥ 30 msec increase from Baseline for at least one post-Baseline measurement (including unscheduled visits) and < 60 msec increase from Baseline for all post-Baseline measurements (including unscheduled visits)

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- $\geq 60$  msec increase from Baseline for at least one post-Baseline measurement (including unscheduled visits)

### 17.5.2. ECG POTENTIALLY CLINICALLY SIGNIFICANT CRITERIA

Potentially clinically significant ECG measurements will be identified in accordance with the following predefined PCS criteria:

**Table 3: Predefined ECG PCS criteria.**

ECG Parameter	PCS Low	PCS High
Heart Rate (beats/min)	--	$\geq 100$
PR Interval (msec)	--	$\geq 210$
QRS Interval (msec)	--	$\geq 120$

## 17.6. VITAL SIGNS

The following vital sign measurements will be reported for this study:

- Supine and Standing Systolic Blood Pressure (mmHg)
- Supine and Standing Diastolic Blood Pressure (mmHg)
- Supine and Standing Pulse Rate (bpm)
- Respiratory Rate (breaths/min)
- Temperature ( $^{\circ}\text{C}$ )
- Height (cm)
- Weight (kg)

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- BMI (kg/m<sup>2</sup>)
- Waist Circumference (cm)

Height will be summarized as part of the Baseline characteristics only.

The following summaries will be provided:

- By-visit summary with 95% CI of the mean of observed values and change from Baseline values for vital sign measurements, including Week 9/Follow-up/Visit 11.
- Number and percentage of subjects with at least one PCS vital sign value (see [Section 17.6.2](#)) post Baseline. The period of evaluation includes both the treatment period and the follow-up period, including unscheduled visits. Subjects will be counted in a particular PCS category if they met that PCS criteria at least once post Baseline, regardless of their Baseline value.
- Number and percentage of subjects with orthostatic hypotension and/or orthostatic tachycardia (see [Section 17.6.1](#)). The data will be summarized for Baseline and the overall post-Baseline period (which covers both the treatment period and the follow-up period, including unscheduled visits), as well as by visit, including Week 9/Follow-up/Visit 11.
- By-visit summary of BMI category (see [Section 7.5](#)) and shift in BMI category from Baseline to each post-Baseline time point.
- By-visit summary with 95% CI of the mean of observed values and change from Baseline values for vital signs measurements by BMI category (see [Section 7.5](#)).

All vital signs data will be provided in a data listing. In addition, a separate listing will be generated to present the vital signs data that met the PCS criteria. All occurrences of orthostatic hypotension and orthostatic tachycardia will also be presented in a listing.

Boxplots will be created to present weight data by time point and treatment group. The boxplots will be repeated to present the change from Baseline values.

### 17.6.1. VITAL SIGN SPECIFIC DERIVATIONS

- BMI expressed in kg/m<sup>2</sup> = Weight (kg)/ height (m)<sup>2</sup>.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

The height collected at Visit 1 will be used to derive BMI where needed throughout the study.

- Orthostatic hypotension is defined as a decrease of  $\geq 20$  mmHg in systolic blood pressure or  $\geq 10$  mmHg in diastolic blood pressure after a subject has been standing for at least 2 to 4 minutes, compared to the systolic blood pressure and diastolic blood pressure measured in the supine position, respectively.
- Orthostatic tachycardia is defined as a heart rate increase of  $\geq 20$  bpm after a subject has been standing for at least 2 to 4 minutes compared to the heart rate measured in the supine position, and a heart rate of  $> 100$  bpm after the subject has been standing for at least 2 to 4 minutes.

### 17.6.2. VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CRITERIA

Potentially clinically significant vital sign measurements will be identified in accordance with the following predefined PCS criteria:

**Table 5: Predefined vital sign PCS criteria.**

Vital Sign Parameter	PCS Low	PCS High
Systolic Blood Pressure (Supine, Standing) (mmHg)	Value $\leq 90$ and $\geq 20$ decrease from Baseline	Value $\geq 180$ and $\geq 20$ increase from Baseline
Diastolic Blood Pressure (Supine, Standing) (mmHg)	Value $\leq 50$ and $\geq 15$ decrease from Baseline	Value $\geq 105$ and $\geq 15$ increase from Baseline
Pulse Rate (Supine, Standing) (beats/min)	Value $\leq 50$ and $\geq 15$ decrease from Baseline	Value $\geq 120$ and $\geq 15$ increase from Baseline
Weight (kg)	$\geq 7\%$ decrease from Baseline	$\geq 7\%$ increase from Baseline
Temperature ( $^{\circ}\text{C}$ )	NA	Value $\geq 38.3^{\circ}\text{C}$ and $\geq 0.8^{\circ}\text{C}$ increase from Baseline

## 17.7. PHYSICAL EXAMINATION

As all physical and neurological findings will be recorded as medical history or AEs, no specific analysis of physical and neurological

Document: PPD  
 Author: PPD  
 Version Number: 1.0  
 Version Date: 06MAY2024

examination will be performed.

## 17.8. OTHER SAFETY ASSESSMENTS

### 17.8.1. COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS)

The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for lifetime, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior. The C-SSRS Baseline/Screening Version is used at the screening visit and the C-SSRS Since Last Visit Version is used from Visit 2 and onward. Subjects with Type 4 (active suicidal ideation with some intent to act, without specific plan) or Type 5 (active suicidal ideation with specific plan and intent) suicidal ideation during the study will be discontinued from the study and referred to a mental health professional.

C-SSRS includes two main sections: Suicidal Ideation and Suicidal Behavior.

The following outcomes are C-SSRS categories and have binary responses (yes/no). The categories are re-ordered from the scale to facilitate the definitions of the C-SSRS endpoints, and to provide clarity in the presentation of the results.

- Suicidal ideation is measured by 5 categories, representing 5 subtypes of suicidal ideation with increasing severity:
  - o Category 1: Wish to be Dead
  - o Category 2: Non-specific Active Suicidal Thoughts
  - o Category 3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
  - o Category 4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan
  - o Category 5: Active Suicidal Ideation with Specific Plan and Intent
- Suicidal behavior is measured by 5 categories, representing 5 subtypes of suicidal behavior:
  - o Category 6: Preparatory Acts or Behavior
  - o Category 7: Aborted Attempt
  - o Category 8: Interrupted Attempt
  - o Category 9: Actual Attempt (non-fatal)
  - o Category 10: Completed Suicide

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

The 10 categories above are not mutually exclusive. Subjects will be counted in each category for which they have an event.

Self-injurious behavior without suicidal intent is a non-suicide-related C-SSRS outcome, and also has a binary response (yes/no).

For the purpose of C-SSRS analysis, “Baseline” and the overall “post-Baseline” periods are defined as follows.

Time point	Study Visit	C-SSRS Version	Derivation Rule
Baseline	Visit 1	Baseline/Screening – Past 1 Month for Suicidal Ideation / Past 6 Months for Suicidal Behavior	Most severe outcome
	Visit 2*	Since Last Visit	
Post-Baseline	All post-Baseline visits up to and including Visit 10 (the follow-up visit), including unscheduled visits	Since Last Visit	Most severe outcome

\* Note: The Visit 2 C-SSRS assessment must be administered prior to the first dose of study medication in order to be used in the C-SSRS Baseline derivation.

The following C-SSRS composite endpoints will be derived for each time point of interest (i.e., Baseline, overall post-Baseline, and each scheduled visit including Week 9/Follow-up/Visit 11) as follows:

- Any suicidal ideation: A “yes” answer to any one of the 5 suicidal ideation questions on C-SSRS (Categories 1-5).
- Any suicidal behavior: A “yes” answer to any one of the 5 suicidal behavior questions on the C-SSRS (Categories 6-10).
- Any suicidality: A “yes” answer to any one of the 10 suicidal ideation and behavior questions on the C-SSRS (Categories 1-10).

For each subject, the suicidal ideation score at each time point of interest (i.e., Baseline, overall post-Baseline, the LOCF endpoint, and each scheduled visit including Week 9/Follow-up/Visit 11) is defined as the maximum suicidal ideation category (1-5) present for the time point of interest. If no ideation is present a score of 0 is assigned.

The number and percentage of subjects with any suicidality, any suicidal ideation and subtypes of ideation, any suicidal behavior and subtype of

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



behavior, and any non-suicidal self-injurious behavior will be presented for:

- Baseline (as defined above)
- The overall post-Baseline period (as defined above)
- Each scheduled visit: Screening/Visit 1 (lifetime; past 1 month for ideation/past 6 months for behavior), Pre-switch Baseline/Visit 2, Week1/Visit 3, Week2/Visit 4, Week 3/Visit 5, Week 4/Visit 6, Week 5/Visit 7, Week 6/Visit 8, Week 7/Visit 9, Week 8/Visit 10 and Week 9/Follow-up/Visit 11.

Shift in suicidal ideation score from Baseline to the overall post-Baseline period, to each of the scheduled visits (Week1/Visit 3, Week2/Visit 4, Week 3/Visit 5, Week 4/Visit 6, Week 5/Visit 7, Week 6/Visit 8, Week 7/Visit 9, Week 8/Visit 10 and Week 9/Follow-up/Visit 11), and to the LOCF endpoint will be presented.

Intensity of ideation for the most severe ideation subtype is measured in terms of frequency, duration, controllability, deterrents, and reasons for ideation. Each is measured with responses ranging from 1 to 5 for frequency and duration, and from 0 to 5 for controllability, deterrents, and reasons for ideation. The ideation intensity total score is the sum of responses to the five items and can range from 2 to 25 for subjects with endorsed suicidal ideation. For subjects with endorsed suicidal ideation, if one or more of these five items are missing at an assessment, the total score will be set to missing. If a subject did not endorse any suicidal ideation, a score of 0 for the ideation intensity total score will be given.

Actual lethality associated with actual attempts is rated on a 6-point scale from 0 = 'No physical damage or very minor physical damage' to 5 = 'Death'. Potential lethality of actual attempts (if actual lethality = 0) is rated on a 3-point scale from 0 = 'Behavior not likely to result in injury' to 2 = 'Behavior likely to result in death despite available medical care'.

Responses to each C-SSRS question will be listed. The ideation intensity total score and the actual lethality and potential lethality of actual attempts will only be presented in data listings.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

### 17.8.2. ABNORMAL INVOLUNTARY MOVEMENT SCALE (AIMS)

The AIMS is a clinician-rated assessment of abnormal movements consisting of unobtrusive observation of the subject at rest (with shoes removed) and several questions or instructions directed toward the subject. It contains seven items related to: facial, lip, jaw, and tongue movements (items 1 - 4), upper and lower extremity movements (items 5 - 6), and trunk movements (item 7). Three other items assess the subject at a global level (items 8 - 10), and two items assess dental status (items 11 - 12).

The (non-global) AIMS total score is the sum of items 1 through 7. (Items 8 through 12 are not used in AIMS total score calculation.) The possible range for AIMS total score is 0 to 28. Higher values of the AIMS total score indicate increased severity in abnormal movement. If one or more of the 7 items contributing to AIMS total score calculation are missing at a visit, the total score will be set to missing for that visit.

AIMS total score at each visit is classified as ‘abnormal’ if: either at least two items (out of items 1 - 7) have a response of ‘Mild’ or higher (i.e., item score  $\geq 2$ ); or at least one item (out of items 1 - 7) has a response of ‘Moderate’ or higher (i.e., item score  $\geq 3$ ). Otherwise, the non-missing AIMS total scores is classified as ‘normal’.

Item 8 of AIMS represents the global severity score. Post-Baseline AIMS global severity scores will be classified as ‘worsened’, ‘unchanged’, or ‘improved’, relative to a subject’s Baseline response to item 8. A higher score than that of the Baseline would be classified as ‘worsened’. Conversely, a lower score would be classified as ‘improved’. If the score is equal to that of Baseline, the score will be classified as ‘unchanged’.

AIMS is assessed at these study visits: Visit 2 and Visit 10.

The observed AIMS total score and the change from Baseline values will also be summarized descriptively by treatment group and visit. In addition, the observed AIMS total score and the change from Baseline values will be summarized descriptively by the subgroups of concomitant medication use for treatment of movement disorders.

Shift from Baseline in AIMS total score category (Normal/Abnormal) to each post-Baseline scheduled visit (Week 8/Visit 10) and to the overall post-Baseline period (including both the treatment period and the follow-up period) will be summarized descriptively by treatment group.

The observed AIMS global severity score and the change from Baseline values will be summarized descriptively by treatment group and visit. In addition, the frequency distribution of the AIMS global severity item will be summarized descriptively by treatment group and visit. Post-Baseline changes in AIMS global severity score (Worsened/Unchanged/Improved) will also be summarized descriptively by treatment group and visit.

### 17.8.3. BARNES AKATHISIA RATING SCALE (BARS)

The BARS is a rating scale geared toward assessment of neuroleptic-induced akathisia, though it can be used to measure akathisia associated with other drugs as well. The BARS consists of four items, including one item assessing objective restlessness (item 1), two items targeting subjective

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

restlessness (awareness and related distress; items 2 - 3), and one global clinical assessment of akathisia item (item 4). The objective and subjective items are anchored and utilize a 4-point scale. The global assessment item has a 6-point scale (from absence of akathisia through severe akathisia).

The BARS total score is the sum of items 1 through 3 and ranges from 0 to 9. Higher values of the BARS total score indicate higher severity of akathisia. If one or more of items 1 to 3 are missing at a visit, the BARS total score will be set to missing for that visit.

The post-Baseline BARS Global Clinical Assessment of Akathisia responses will be classified as 'worsened', 'unchanged', or 'improved', relative to a subject's Baseline response to this item. A higher score than that of the Baseline would be classified as 'worsened'. Conversely, a lower score would be classified as 'improved'. If the score is equal to that of Baseline, the score will be classified as 'unchanged'.

BARS is assessed at these study visits: Visit 2 and Visit 10.

The observed BARS total score and the change from Baseline values will also be summarized descriptively by treatment group and visit. In addition, the observed BARS total score and the change from Baseline values will be summarized descriptively by the subgroups of concomitant medication use for treatment of movement disorders.

Post-Baseline changes in BARS global clinical assessment score (Worsened/Unchanged/Improved) will be summarized descriptively by treatment group and visit.

Lastly, the observed BARS item scores and the change from Baseline values will be summarized descriptively by treatment group and visit. In addition, the frequency distribution of each BARS item will be summarized descriptively by treatment group and visit.

#### 17.8.4. SIMPSON-ANGUS SCALE (SAS)

The SAS is a clinician-rated assessment of neuroleptic-induced Parkinsonism consisting of 10 items. Items are anchor-based, rated on a 5-point scale (ranging between 0 and 4), and address rigidity, gait (bradykinesia), tremor, akathisia, shoulder shaking, glabellar tap, and salivation.

SAS mean score is defined as the average of all 10 items and ranges between 0 and 4. Lower values of the SAS mean score indicate milder symptoms. If one or more of the SAS items are missing at a visit, the SAS mean score will be set to missing for that visit.

The SAS mean score at each visit will be classified as 'abnormal' if it exceeds 0.3 (Rush, et al., 2000). Otherwise, the non-missing SAS mean score will be classified as 'normal'.

SAS is assessed at these study visits: Visit 2 and Visit 10.

The observed SAS mean score and the change from Baseline values will also be summarized descriptively by treatment group and visit. In addition, the observed SAS mean score and the change from Baseline values will be summarized descriptively by the subgroups of concomitant medication use for treatment of movement disorders.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

Shift from Baseline in SAS mean score category (Normal/Abnormal) to each post-Baseline scheduled visit (Week 8/Visit 10) and to the overall post-Baseline period (including both the treatment period and the follow-up period) will be summarized descriptively by treatment group.

#### 17.8.5. PITTSBURGH SLEEP QUALITY INDEX

The Pittsburgh Sleep Quality Index (PSQI) consists of 19 self-rated questions and 5 questions rated by the bed partner or roommate (if one is available). It is used to measure the quality and patterns of sleep in adults. Only self-rated questions are included in the scoring. It differentiates “poor” from “good” sleep quality by measuring seven “component” scores, each of which has a range of 0-3 points: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction due to sleepiness over the last month.

The seven component scores are then summed to yield one global PSQI score, with a range of 0-21 points, “0” indicating no difficulty and “21” indicating severe difficulties in all areas (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).

The PSQI scoring algorithm as downloaded from the University of Pittsburgh Sleep and Chronobiology Center is inserted in APPENDIX 8. The seven component scores and the PSQI global score will be derived according to this algorithm. If one or more of the component scores are missing at a visit, the PSQI global score will be set to missing for that visit.

PSQI is assessed at these study visits: Visit 2, Visit 6 and Visit 10.

The observed PSQI global score and the change from Baseline values will be summarized descriptively by treatment group and visit.

### 17.9. SUBGROUP ANALYSIS OF SAFETY VARIABLE(S)

The subgroup analyses for AE data, vital signs data, and AIMS/BARS/SAS scales are described in their respective sections.

## 18. PHARMACOKINETIC ANALYSIS

Plasma concentrations of SEP-363856 and SEP-363854 (metabolite of SEP-363856) of all enrolled subjects will be presented in a data listing.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## 19. DATA NOT SUMMARIZED OR PRESENTED

The variables and/or domains not summarized or presented are:

- Subject initials
- Any data collected on screen failures other than disposition, basic demographics, and pre-treatment events.
- Any data collected during previously failed screening(s) for randomized subjects who were screened more than once except Adverse Events.

These domains and/or variables will not be summarized or presented but will be available in the clinical study database and SDTM datasets.

## 20. REFERENCES

- Buyse, D., Reynolds, C., Monk, T., Berman, S., & Kupfer, D. (1989). The Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. *Psychiatry Research*, 28(2), 193-213.
- Hopkins, S., Ogirala, A., Loebel, A., & Koblan, K. (2018;44(3):593-602). Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. . *Schizophrenia Bull* .
- Hopkins, S., Ogirala, A., Loebel, A., & Koblan, K. (2020). Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM). *Psychiatry Research*.
- Keefe, R., Philip, H., Terry, G., James, G., Trina, W., Courtney, K., & Kirsten, H. (2008). Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). *Schizophrenia Research*, 108-115.
- Leucht S, Crippa A, Sifakis S, Patel MX, Orsini N, Davis JM. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. *American Journal of Psychiatry*. 2020 Apr 1;177(4):342-53.
- Marder, S., Davis, J., & Chouinard, G. (1997;58:538–46). The effects of risperidone on the five dimensions of schizophrenia. *J Clin Psychiatry* .
- Rush, A., Pincus, H., First, M., Blacker, D., Endicott, J., Keith, S., . . . Zarin, D. (2000). *Handbook of Psychiatric Measures*. American Psychiatric Association.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

---

Document: PPD

Author: PPD

Version Number: 1.0

Version Date: 06MAY2024

## APPENDIX 1. PROGRAMMING CONVENTIONS FOR OUTPUTS

### IQVIA OUTPUT CONVENTIONS

The following output conventions are to be followed:

- General presentation:
  - o The first row in the body of the table or listing should be blank
  - o Rounding should be done with the SAS function ROUND.
  - o Numbers in tables should be rounded, not truncated.
  - o The first letter of a text entry should be capitalized.
- Univariate Statistics: If the raw data has N decimal places, then the summary statistics should have the following decimal places:
  - o Minimum and maximum: N
  - o Mean, median, Q1, and Q3: N + 1
  - o SD: N + 2
  - o For lab data only, in the rare case where raw data has more than 3 decimal places, summary statistics will be presented for the scenario of N = 3. All decimals will be presented in Listings.
  - o For CGI-S score, 2 decimal places will be presented for mean, median, Q1, Q3, LS mean, LS mean difference, and 95% CI; 3 decimal places will be presented for SD and SE; 0 decimal places will be presented for min and max. 0 decimal places will be presented in listings.
  - o For UPSM scores, 3 decimal places will be presented for mean, median, Q1, Q3, LS mean, LS mean difference, and 95% CI; 4 decimal places will be presented for SD and SE; 2 decimal places will be presented for min and max. Up to 2 decimal places will be presented in Listings. No rounding will be applied in the ADaM datasets.
- Frequencies and percentages (n and %):
  - o Percentages will be reported to one decimal place, except cases where percent <100.0% but >99.9% will be presented as '>99.9%' (e.g., 99.99% is presented as >99.9%); and cases where percent < 0.1% will be presented as '<0.1%' (e.g., 0.08% is presented as <0.1%). Rounding will be applied after the <0.1% and >99.9% rule.
  - o Where counts are zero, no percentage should appear in the output.
- Confidence Intervals:

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- o Confidence intervals and estimates are presented to one place more than the raw data, and standard errors to two places more than the raw data.
- o Boundary values of confidence intervals should be separated by a comma.
- P-values should be reported to three decimal places, except values <1.000 but >0.999 will be presented as '>0.999' (e.g., 0.9998 is presented as >0.999); and values <0.001 will be presented as '<0.001' (e.g., 0.0009 is presented as <0.001). Rounding will be applied after the <0.001 and >0.999 rule.
- Ratios should be reported to one more decimal place than the raw data.
- Missing values:
  - o A "0" should be used to indicate a zero frequency.
  - o A "-" will be used to indicate missing data in an end-of-text table or subject listing.
  - o

## DATES & TIMES

Depending on data available, dates and times will take the form yyyy-mm-ddThh:mm:ss .

## SPELLING FORMAT

English US.

## PRESENTATION OF TREATMENT GROUPS

For outputs, treatment groups will be represented as follows and in that order:

Treatment Group	For Tables (Column Order)	For Listings and Graphs (Order)
SEP-363856 50 to 100 mg/day	SEP-363856 50 to 100 mg/day	SEP-363856 50 to 100 mg/day

Document: PPD

Author: PPD

Version Number: 1.0

Version Date: 06MAY2024



## LISTINGS

All listings will be ordered by the following (unless otherwise indicated in the template):

- Enrolled subjects who did not receive any study medication will be presented at the end and labelled “Not Treated”.
- Subject ID.
- Visit (where applicable)
- Original date/time (where applicable).

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## APPENDIX 2. PARTIAL DATE CONVENTIONS

The actual dates as collected on the CRF will be presented in the listings. Imputed dates will not be presented in the listings unless otherwise specified.

### ALGORITHM FOR ADVERSE EVENTS

As a general rule, if the start date of an AE is available and the start time of the AE is not available, the AE will be considered to have started after the study drug dose administered on the day of the AE start date.

In case of partial or missing AE start and/or end dates, impute partial or missing event start and/or end dates (if not ongoing) using the algorithm below. If an AE has some missing components in both the start and end dates, first impute the end date.

#### AE end date imputation

- If year and month (YYYY-MM) of AE end date are known, then impute the missing day to be the earlier of (last day of the month; date of last contact).
- If only year (YYYY) of AE end date is known, then impute the missing month and day to be the earlier of (31<sup>st</sup> December; date of last contact).
- If AE end date is completely missing and AE is not ongoing, then impute AE end date to be date of last contact.

#### AE start date imputation

- If year and month (YYYY-MM) of AE start date are known and YYYY-MM = year and month of 361-30 study med start date, then impute AE start date to be the earlier of (361-308 study med start date; full or imputed AE end date [if non-missing]).
- If year and month (YYYY-MM) of AE start date are known and YYYY-MM  $\neq$  year and month of 361-308 study med start date, then impute AE start date to be YYYY-MM-01.
- If only year (YYYY) of AE start date is known and YYYY = year of 361-308 study med start date, then impute AE start date to be the earlier of (361-308 study med start date; full or imputed AE end date [if non-missing]).
- If only year (YYYY) of AE start date is known and YYYY  $\neq$  year of 361-308 study med start date, then impute AE start date to be YYYY-01-01.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- If AE start date is completely missing, then impute AE start date to be the earlier of (361-308 study med start date; full or imputed AE end date [if non-missing]).

Using the full or imputed event dates, assign events into pre-treatment events vs. AE as described below.

If both event start date/time and 361-308 study med start date/time are available:

- If event start date/time < 361-308 study med start date/time, then pre-treatment event.
- If event start date/time  $\geq$  361-308 study med start date/time, then AE.

If (event start date is available and time is not available) and/or (361-308 study med start date is available and time is not available):

- If event start date < 361-308 study med start date, then pre-treatment event.
- If event start date  $\geq$  361-308 study med start date, then AE.

---

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

## ALGORITHM FOR PRIOR / CONCOMITANT / POST-TREATMENT MEDICATIONS

In case of partial or missing medication start and/or stop dates, impute the partial or missing dates using the algorithm below.

If a medication has some missing components in both the start and stop dates, first impute the stop date.

### Impute stop date as latest possible date

- If only day unknown, impute to the earlier of (last day of the month; date of 361-308 last contact).
- If month and day unknown, impute to the earlier of (31<sup>st</sup> December; date of 361-308 last contact).
- If stop date is completely unknown and medication is not ongoing, impute to date of 361-308 last contact.

### Impute start date as earliest possible date

*CRF questions: 'Started prior to first dose?' = Yes; 'Started after last dose of study medication?' = No.*

- If only day unknown, impute to the later of (first day of the month; date of birth [if full date is available]).
- If month and day unknown, impute to the later of (1<sup>st</sup> January; date of birth [if full date is available]).
- If start date is completely unknown, impute to the earlier of (date of informed consent\*; full or imputed medication stop date [if not missing]).

*CRF questions: 'Started prior to first dose?' = No; 'Started after last dose of study medication?' = Yes.*

- If only day unknown, impute to the later of (first day of the month; 361-308 study med end date + 1).
- If month and day unknown, impute to the later of (1<sup>st</sup> January; 361-308 study med end date + 1).
- If start date is completely unknown, impute to 361-308 study med end date + 1.

*CRF questions: 'Started prior to first dose?' = No; 'Started after last dose of study medication?' = No.*

- If only day unknown, impute to the later of (first day of the month; 361-308 study med start date).
- If month and day unknown, impute to the later of (1<sup>st</sup> January; 361-308 study med start date).
- If start date is completely unknown, impute to 361-308 study med start date.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

**Then assign a medication into prior, concomitant, or post-treatment**

The concept of “date” below should also include time information whenever time is available for both comparators.

- If medication stop date < 361-308 study med start date, assign as prior.
- If (medication stop date ≥ 361-308 study med start date or medication is ongoing) and medication start date ≤ 361-308 study med end date, assign as concomitant.
- If medication start date > 361-308 study med end date, assign as post-treatment.

**Overriding rule**

For the case where the medication start date is known and is equal to 361-308 study med end date and the medication start time is unknown, or the case where the imputed medication start date is equal to 361-308 study med end date:

- If CRF question ‘*Started after last dose of study medication?*’ = *No*, then assign as concomitant.
- If CRF question ‘*Started after last dose of study medication?*’ = *Yes*, then assign as post-treatment.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## PARTIAL DATE IMPUTATION RULES FOR INITIAL ONSET OF SCHIZOPHRENIA

For subjects with partial onset date of schizophrenia, impute the onset date using the following rules:

- If only day unknown, impute as the earlier of: 15<sup>th</sup> of the month, or date of ICF\*.
- If both month and day unknown, impute as the earlier of: June 30<sup>th</sup> of the year, or date of ICF\*.

\*For adolescent subjects, the later of the ICF date and IAF date should be used.

## PARTIAL DATE IMPUTATION RULES FOR CURRENT ONSET OF ACUTE EXACERBATION

For subjects with partial onset date of acute exacerbation, impute the onset date using the following rules:

- If only day unknown and the known year and month is earlier than the year and month of ICF\*, impute as the later of: 15<sup>th</sup> of the month, or date of initial onset of schizophrenia (actual or imputed).
- If only day unknown and the known year and month is the same as the year and month of ICF\*, impute as the later of: earlier of (date of ICF\*, 15<sup>th</sup> of the month), or date of initial onset of schizophrenia (actual or imputed).
- If both month and day unknown and the known year is earlier than the year of ICF\*, impute as the later of: June 30<sup>th</sup> of the year, or date of initial onset of schizophrenia (actual or imputed).
- If both month and day unknown and the known year is the same as the year of ICF\*, impute as the later of: earlier of (date of ICF\*, June 30<sup>th</sup> of the year), or date of initial onset of schizophrenia (actual or imputed).

\*For adolescent subjects, the later of the ICF date and IAF date should be used.

## PARTIAL DATE IMPUTATION RULES FOR FIRST HOSPITALIZATION

For subjects with partial date of first hospitalization for treatment of schizophrenia, impute the date using the following rules:

- If only day unknown, impute as the earlier of: 15<sup>th</sup> of the month, or date of ICF\*.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

- If both month and day unknown, impute as the earlier of: June 30<sup>th</sup> of the year, or date of ICF\*.

\*For adolescent subjects, the later of the ICF date and IAF date should be used.

For subjects whose date of first hospitalization for treatment of schizophrenia is completely missing AND the number of prior hospitalizations for treatment of schizophrenia is 0, impute the date of first hospitalization to be the “*Date of admission for this study hospitalization*” collected on the “*Psychiatric Hospitalization (HOSP)*” CRF form.

## PARTIAL DATE IMPUTATION RULES FOR FIRST ANTI-PSYCHOTIC DRUG THERAPY

For subjects with partial start date for the first anti-psychotic drug therapy of at least 2 weeks duration intended for treatment of schizophrenia, impute the start date using the following rules:

- If only day unknown, impute as the earlier of: 15<sup>th</sup> of the month, or date of ICF\*.
- If both month and day unknown, impute as the earlier of: June 30<sup>th</sup> of the year, or date of ICF\*.

## PARTIAL DATE IMPUTATION RULES FOR ONSET OF INITIAL BEHAVIORAL DISTURBANCE

For adolescent subjects with partial onset date of initial behavioral disturbance, impute the onset date using the following rules:

- If only day unknown, impute as the earlier of: 15<sup>th</sup> of the month, or the later of (date of ICF and date of IAF).
- If both month and day unknown, impute as the earlier of: June 30<sup>th</sup> of the year, or the later of (date of ICF and date of IAF).

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## RULES FOR ASSIGNING DOSEON/DOSEA

- In general, DOSEON/DOSEA should be the dose level immediately before the start of an AE or an assessment. In case the AE or the assessment start date/time coincides with the first dosing start date/time of the study, the DOSEON/DOSEA should be assigned to the dose level associated with that first dosing start date/time. In case the AE or the assessment start date/time coincides with a dosing start date/time other than the first dosing start date/time, the DOSEON/DOSEA should be assigned to the dose level associated with the previous dosing start date/time.
- In case of missing AE start time, missing assessment (start) time, and/or missing dosing start time, DOSEON/DOSEA should be assigned using the algorithm in the table below.

Scenario	Data	Rules
Dosing start date and start time both available	Adverse Events	If AE start date is available and AE start time is missing, dose on the same day as AE start should be assigned as DOSEON.
	Scales/Questionnaires, Vitals, Labs, ECG	If assessment start date is available and assessment start time is missing, dose on the previous day of the assessment should be assigned as DOSEA.
Dosing start date available but start time missing	Adverse Events	Regardless of whether AE start time is available, dose on the same day as AE start should be assigned as DOSEON.
	Scales/Questionnaires, Vitals, Labs, ECG	Regardless of whether assessment start time is available, dose on the previous day of the assessment should be assigned as DOSEA.

- In case of partial or missing AE start date, the imputed AE start date will be used for the purpose of assigning DOSEON.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



### APPENDIX 3. UNCORRELATED PANSS SCORE MATRIX (UPSM)

PANSS	UPSM-POS	UPSM-DIS	UPSM-NAA	UPSM-NDE	UPSM-HOS	UPSM-ANX	UPSM-DEP
PANSS01	0.5792730597	-0.1547126840	-0.0828932650	0.0071927220	-0.0593031510	-0.0735449620	0.0020484408
PANSS02	0.0292444390	0.1975824582	-0.0260173260	-0.0234753800	-0.0368756010	-0.0012396240	-0.0361645050
PANSS03	0.2065788330	-0.0179419820	-0.0250663450	-0.0133031880	-0.0300507070	0.0001506005	0.0293001724
PANSS04	-0.0336790630	0.0115284348	0.0011652392	-0.0723891460	0.1379358628	0.1108194656	-0.1045224460
PANSS05	-0.0341508580	-0.0301875430	-0.0041019560	-0.0233459100	-0.0069204000	-0.0313277060	0.0308288417
PANSS06	0.3537254634	-0.0626270750	0.0477329954	0.0012126712	0.0192067437	-0.0161398140	0.0063264235
PANSS07	-0.0383468990	-0.1767919370	-0.0299340700	0.0314652864	0.5025411101	-0.0997121200	0.0573604084
PANSS08	-0.0054230270	-0.0291400280	0.0568702938	0.2474176209	-0.0388464000	0.0188235393	-0.0091524870
PANSS09	-0.0315765690	-0.0243925850	0.3317907576	-0.0228204580	-0.0507096280	-0.0145653830	0.0112689069
PANSS10	-0.0742072890	-0.0401313020	-0.0097485120	0.0161513666	0.0245536353	-0.0176161520	-0.0172218040
PANSS11	-0.0943532590	-0.0856364190	0.4611503804	-0.0286825100	-0.0189062390	-0.0185825180	-0.0130433890
PANSS12	0.0043338689	0.1062496353	0.0255910591	-0.0301470410	-0.0133497570	0.0096065791	-0.0686802390
PANSS13	0.0041274699	0.0051521898	0.0009558861	0.2576813501	-0.0085004640	0.0194235006	-0.1037459520
PANSS14	-0.0111267300	0.1462268689	-0.0276416260	0.0023017188	-0.0055291270	-0.0118427800	0.0040128786
PANSS15	-0.0356272010	0.0552508287	-0.0382627720	0.0110152489	-0.0309176290	0.04444944076	0.1059845189
PANSS16	-0.0331052830	-0.0821894470	-0.0327376640	-0.0533178140	-0.0386473380	0.4576579818	0.1197800301
PANSS17	-0.0368854600	-0.0004363100	-0.0020681500	-0.0407976460	-0.0272172130	-0.0253163640	0.2459654614
PANSS18	-0.0931367690	-0.0332617600	-0.0132943930	0.0231904701	-0.0287529750	0.5123850161	-0.0312522560
PANSS19	-0.0455199430	0.0494113554	-0.0324174560	0.1026255664	-0.0136676190	0.0293507269	-0.0441735260
PANSS20	-0.0344751890	-0.0688197670	-0.0412738350	0.0381793764	0.0042219619	-0.0635101090	0.4514426846
PANSS21	-0.0348890020	-0.0366137810	-0.0779782830	0.4409895205	-0.0073240410	-0.0192655290	0.0464131877
PANSS22	-0.0803690920	0.0334025939	-0.0088488890	-0.0200483170	0.2858700784	-0.0567167860	-0.0531076130
PANSS23	0.1428966744	0.0939213700	-0.0326143600	-0.0367524640	-0.0675856980	-0.0209072840	-0.0177890070
PANSS24	-0.0383047770	-0.0324584080	-0.0255393890	-0.0180115340	-0.0266180700	-0.0210068530	-0.0176029110
PANSS25	-0.1036311520	0.2814367260	-0.0478918640	0.0029986238	0.0037656449	-0.0226520240	0.0401351054
PANSS26	0.0142987589	0.1548635741	-0.0306089330	-0.0331581690	0.0262295986	-0.0576293550	-0.0626180490
PANSS27	-0.0573513270	0.1867914227	-0.0143489160	0.0581534153	-0.0145494330	-0.0371788310	0.0455412078
PANSS28	-0.0748387810	0.0166272025	-0.0267498020	-0.0031632780	0.2546669938	-0.0201249190	-0.0076420280
PANSS29	-0.0520812460	0.2912295497	0.0029775475	-0.0324350460	-0.0442337350	-0.0047991290	0.0567191230

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

PANSS30	-0.0112030990	-0.0007246980	0.2860136812	-0.0606201430	0.0183598393	-0.0302347770	0.0370748725
---------	---------------	---------------	--------------	---------------	--------------	---------------	--------------

---

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

## APPENDIX 4. INTERNATIONALLY AGREED ORDER FOR SYSTEM ORGAN CLASS

Internationally Agreed Order
Infections and infestations
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blood and lymphatic system disorders
Immune system disorders
Endocrine disorders
Metabolism and nutrition disorders
Psychiatric disorders
Nervous system disorders
Eye disorders
Ear and labyrinth disorders
Cardiac disorders
Vascular disorders
Respiratory, thoracic and mediastinal disorders
Gastrointestinal disorders
Hepatobiliary disorders
Skin and subcutaneous tissue disorders
Musculoskeletal and connective tissue disorders
Renal and urinary disorders
Pregnancy, puerperium and perinatal conditions
Reproductive system and breast disorders
Congenital, familial and genetic disorders
General disorders and administration site conditions
Investigations
Injury, poisoning and procedural complications
Surgical and medical procedures
Social circumstances
Product issues

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## APPENDIX 5. ADVERSE EVENTS OF POTENTIAL DRUG ABUSE AND DEPENDENCE

To ensure comprehensive and consistent selection of terminology used for analyses of drug abuse and dependence in ongoing / planned studies of SEP-363856, MedDRA preferred terms were identified from the following sources:

FDA Guidance for Industry: Assessment of Abuse Potential of Drugs (CDER, 2017; noted that the Guidance reflects MedDRA version 20.0 terminology)

MedDRA version 22.0 SMQ: Drug abuse and dependence [20000101], Broad

FDA FMQ: Study Agent Abuse Potential, Broad (released at FDA public workshop “Advancing Premarket Safety Analytics”, held September 14, 2022)

### Description:

Preferred terms were tabulated using MedDRA version 22.0 from the sources listed above. All preferred terms (PTs) within the FDA Abuse Potential Guidance were included. All PTs listed in the MedDRA version 22.0 SMQ for Drug abuse and dependence [20000101] were included. For the FDA Study Agent Abuse Potential FMQ: No associated MedDRA PT was found for the term “Hypnagogic hallucination”, and this is therefore not included. Sunovion evaluates ‘Drug withdrawal’ as a unique medical concept using MedDRA version 22.0 SMQ for Drug withdrawal [20000102] (Broad); any overlapping PTs from the Drug withdrawal SMQ which are listed in the FDA Study Agent Abuse Potential FMQ are not included. All other PTs listed in the FDA FMQ were included.

The table below depicts the preferred terms by source.

**Table 7: Drug Abuse and Dependence Preferred Terms Using MedDRA v 22.0**

FDA Guidance 2017		SMQ 20000101		FDA FMQ	
PT	Code	PT	Code	PT	Code
-	-	Accidental overdose	10000381	Accidental overdose	10000381
-	-	-	-	Acute psychosis	10001022
Aggression	10001488	-	-	-	-
Behavioural addiction	10081939	-	-	-	-
Confusional state	10010305	-	-	-	-
-	-	-	-	Delusion of grandeur	10012241
-	-	-	-	Delusional perception	10012258
Dependence	10012335	Dependence	10012335	Dependence	10012335
-	-	-	-	Depersonalisation	10012357
-	-	-	-	Derealisation disorder	10077810
-	-	-	-	Detoxification	10061814
-	-	-	-	Disinhibition	10013142
Disorientation	10013395	-	-	-	-
-	-	Disturbance in social behaviour	10061108	-	-
Dizziness	10013573	-	-	-	-
Dopamine dysregulation syndrome	10067468	Dopamine dysregulation syndrome	10067468	-	-

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

FDA Guidance 2017		SMQ 20000101		FDA FMQ	
PT	Code	PT	Code	PT	Code
-	-	Drug abuse	10013654	Drug abuse	10013654
-	-	Drug abuser	10061111	Drug abuser	10061111
-	-	Drug dependence	10013663	Drug dependence	10013663
Drug dependence, antepartum	10013675	Drug dependence, antepartum	10013675	Drug dependence, antepartum	10013675
Drug dependence, postpartum	10013676	Drug dependence, postpartum	10013676	Drug dependence, postpartum	10013676
-	-	Drug detoxification	10052237	Drug detoxification	10052237
-	-	Drug diversion	10066053	Drug diversion	10066053
-	-	Drug level above therapeutic	10061132	-	-
-	-	Drug level increased	10013722	-	-
-	-	Drug screen	10050837	-	-
-	-	Drug screen positive	10049177	-	-
Drug tolerance	10052804	Drug tolerance	10052804	-	-
Drug tolerance decreased	10052805	Drug tolerance decreased	10052805	-	-
Drug tolerance increased	10052806	Drug tolerance increased	10052806	-	-
Drug use disorder	10079381	Drug use disorder	10079381	Drug use disorder	10079381
-	-	Drug use disorder, antepartum	10079382	Drug use disorder, antepartum	10079382
-	-	Drug use disorder, postpartum	10079383	Drug use disorder, postpartum	10079383
-	-	-	-	Energy increased	-
Euphoric mood	10015535	-	-	Euphoric mood	10015535
Feeling abnormal	10016322	-	-	-	-
Feeling drunk	10016330	-	-	Feeling drunk	10016330
-	-	-	-	Feeling jittery	10016338
Feeling of relaxation	10016352	-	-	Feeling of relaxation	10016352
-	-	-	-	Flight of ideas	10016777
Hallucination	10019063	-	-	Hallucination	10019063
Hallucination, auditory	10019070	-	-	Hallucination, auditory	10019070
Hallucination, gustatory	10019071	-	-	Hallucination, gustatory	10019071
Hallucination, olfactory	10019072	-	-	Hallucination, olfactory	10019072
Hallucination, synaesthetic	10062824	-	-	Hallucination, synaesthetic	10062824
Hallucination, tactile	10019074	-	-	Hallucination, tactile	10019074
Hallucination, visual	10019075	-	-	Hallucination, visual	10019075
Hallucinations, mixed	10019079	-	-	Hallucinations, mixed	10019079
Inappropriate affect	10021588	-	-	Hallucination, gustatory	10019071
-	-	-	-	Hypersomnia	10020765
-	-	-	-	Hypervigilance	10048533
-	-	-	-	Hypnagogic hallucination	10020927

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

FDA Guidance 2017		SMQ 20000101		FDA FMQ	
PT	Code	PT	Code	PT	Code
-	-	-	-	Hypnagogic hallucination	No such code
-	-	-	-	Hypnopompic hallucination	10020928
-	-	-	-	Inappropriate affect	10021588
-	-	-	-	Infant sedation	10082187
-	-	-	-	Intentional misuse of drug delivery system	10081675
-	-	Intentional overdose	10022523	Intentional overdose	10022523
-	-	Intentional product misuse	10074903	Intentional product misuse	10074903
-	-	Intentional product use issue	10076308	-	-
-	-	-	-	Mania	10026749
-	-	Maternal use of illicit drugs	10026938	-	-
-	-	Medication overuse headache	10072720	-	-
-	-	-	-	Mixed delusion	10076429
Mood altered	10027940	-	-	Mood altered	10027940
Mood swings	10027951	-	-	-	-
-	-	Narcotic bowel syndrome	10072286	-	-
-	-	Needle track marks	10028896	-	-
-	-	Neonatal complications of substance abuse	10061862	-	-
-	-	-	-	Neonatal oversedation	10050395
-	-	Overdose	10033295	-	-
-	-	-	-	Paranoia	10033864
-	-	-	-	Post-injection delirium sedation syndrome	10072851
-	-	Prescription drug used without a prescription	10076639	-	-
-	-	Prescription form tampering	10067669	Prescription form tampering	10067669
-	-	-	-	Psychomotor hyperactivity	10037211
Psychotic disorder	10061920	-	-	-	-
-	-	Reversal of opiate activity	10039004	-	-
-	-	-	-	Sedation	10039897
-	-	-	-	Sedation complication	10079741
Somnolence	10041349	-	-	Somnolence	10041349
-	-	-	-	Somnolence neonatal	10041350

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

FDA Guidance 2017		SMQ 20000101		FDA FMQ	
PT	Code	PT	Code	PT	Code
-	-	-	-	Stupor	10042264
-	-	Substance abuse	10066169	Substance abuse	10066169
-	-	Substance abuser	10067688	Substance abuser	10067688
-	-	Substance dependence	10076595	Substance dependence	10076595
-	-	Substance use	10070964	-	-
Substance use disorder	10079384	Substance use disorder	10079384	Substance use disorder	10079384
-	-	Substance-induced mood disorder	10072387	Substance-induced mood disorder	10072387
-	-	Substance-induced psychotic disorder	10072388	Substance-induced psychotic disorder	10072388
-	-	-	-	Suspected product tampering	10079404
Thinking abnormal	10043431	-	-	-	-
-	-	Toxicity to various agents	10070863	-	-
-	-	-	-	Transient psychosis	10056326
-	-	-	-	Withdrawal hypertension	10048007

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

## APPENDIX 6. EXTRAPYRAMIDAL ADVERSE EVENTS

To ensure comprehensive and consistent selection of terminology used for analyses of extrapyramidal signs and symptoms in ongoing / planned studies of SEP-363856, MedDRA preferred terms were identified from the following source:

MedDRA version 22.0 SMQ: Extrapyramidal syndrome [20000095], Broad, including all 4 sub-SMQs (Akathisia [20000096], Dyskinesia [20000097], Dystonia [20000098], and Parkinson-like events [20000099])

### Description:

All preferred terms listed in the MedDRA version 22.0 SMQ for Extrapyramidal syndrome [20000095] were included. The table below depicts the preferred terms by sub-SMQ.

**Table 8: Extrapyramidal Syndrome SMQ Using MedDRA v 22.0**

Akathisia		Dyskinesia		Dystonia		Parkinson-like	
PT	Code	PT	Code	PT	Code	PT	Code
Akathisia	10001540	-	-	-	-	-	-
-	-	-	-	-	-	Akinesia	10001541
-	-	Athetosis	10003620	-	-	-	-
-	-	Ballismus	10058504	-	-	-	-
-	-	-	-	-	-	Bradykinesia	10006100
-	-	Buccoglossal syndrome	10006532	-	-	-	-
-	-	Chorea	10008748	-	-	-	-
-	-	Choreoathetosis	10008754	-	-	-	-
-	-	-	-	-	-	Cogwheel rigidity	10009848
-	-	Dopamine dysregulation syndrome	10067468	-	-	-	-
-	-	-	-	Dopa-responsive dystonia	10080034	-	-
-	-	Dyskinesia	10013916	-	-	-	-
-	-	Dyskinesia neonatal	10013922	-	-	-	-
-	-	Dyskinesia oesophageal	10013924	-	-	-	-
-	-	-	-	Dystonia	10013983	-	-
-	-	-	-	Dystonic tremor	10073210	-	-
-	-	-	-	Early onset primary dystonia	10076668	-	-
-	-	-	-	Emprosthotonus	10014566	-	-
-	-	-	-	-	-	Freezing phenomenon	10060904
-	-	Grimacing	10061991	-	-	-	-
-	-	-	-	-	-	Hypertonia	10020852

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024



Akathisia		Dyskinesia		Dystonia		Parkinson-like	
PT	Code	PT	Code	PT	Code	PT	Code
-	-	-	-	-	-	Hypertonia neonatal	10048615
-	-	-	-	-	-	Hypokinetic dysarthria	10082243
-	-	-	-	Meige's syndrome	10027138		
-	-	-	-	-	-	Muscle rigidity	10028330
-	-	Oculogyric crisis	10030071	Oculogyric crisis	10030071		
-	-	-	-	-	-	On and off phenomenon	10030312
-	-	-	-	Opisthotonus	10030899	-	-
-	-			Oromandibular dystonia	10067954	-	-
-	-	-	-	-	-	Parkinsonian crisis	10048868
-	-	-	-	-	-	Parkinsonian gait	10056242
-	-	-	-	-	-	Parkinsonian rest tremor	10056437
-	-	-	-	-	-	Parkinsonism	10034010
-	-	-	-	-	-	Parkinsonism hyperpyrexia syndrome	10071243
-	-	-	-	-	-	Parkinson's disease	10061536
-	-	-	-	-	-	Parkinson's disease psychosis	10074835
-	-	Pharyngeal dyskinesia	10070912	-	-	-	-
-	-	-	-	Pharyngeal dystonia	10081226	-	-
-	-	-	-	Pleurothotonus	10035628	-	-
-	-	-	-			Propulsive gait	10082328
-	-	Protrusion tongue	10037076	-	-	-	-
-	-	Rabbit syndrome	10068395	-	-	-	-
-	-	Respiratory dyskinesia	10057570	-	-	-	-
-	-	-	-	-	-	Resting tremor	10071390
-	-	-	-	Spasmodic dysphonia	10067672	-	-
-	-	Tardive dyskinesia	10043118	-	-	-	-
-	-	-	-	Torticollis	10044074	-	-
-	-	-	-	Trismus	10044684	-	-
-	-	-	-	Writer's cramp	10072249	-	-

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

Akathisia		Dyskinesia		Dystonia		Parkinson-like	
PT	Code	PT	Code	PT	Code	PT	Code
-	-	Abnormal involuntary movement scale	10075002	-	-	-	-
-	-	-	-	-	-	Action tremor	10072413
-	-	-	-	Blepharospasm	10005159	-	-
-	-	-	-	-	-	Bradyphrenia	10050012
-	-	Chronic tic disorder	10076661	Chronic tic disorder	10076661	-	-
-	-	Complex tic	10076663	Complex tic	10076663	-	-
-	-	Drooling	10013642	Drooling	10013642	Drooling	10013642
-	-	-	-	-	-	Dysphonia	10013952
Extrapyramidal disorder	10015832	Extrapyramidal disorder	10015832	Extrapyramidal disorder	10015832	Extrapyramidal disorder	10015832
-	-	-	-	Facial spasm	10063006	-	-
-	-	-	-	-	-	Fine motor skill dysfunction	10076288
-	-	-	-	-	-	Gait disturbance	10017577
-	-	-	-	Gait inability	10017581	-	-
Hyperkinesia	10020651	-	-	-	-	-	-
Hyperkinesia neonatal	10020652	-	-	-	-	-	-
-	-	-	-	-	-	Hypokinesia	10021021
-	-	-	-	-	-	Hypokinesia neonatal	10021022
-	-	-	-	-	-	Laryngeal tremor	10078751
-	-	-	-	Laryngospasm	10023891	-	-
-	-	-	-	-	-	Micrographia	10057333
-	-	-	-	-	-	Mobility decreased	10048334
Motor dysfunction	10061296	Motor dysfunction	10061296	Motor dysfunction	10061296	Motor dysfunction	10061296
Movement disorder	10028035	Movement disorder	10028035	Movement disorder	10028035	Movement disorder	10028035
-	-	Muscle twitching	10028347	-	-	-	-
-	-	-	-	Muscle contractions involuntary	10028293	-	-
-	-	-	-	Muscle spasms	10028334	-	-
-	-	-	-	Muscle spasticity	10028335	-	-
-	-	-	-	Muscle tightness	10049816	-	-
-	-	-	-	Muscle tone disorder	10072889	Muscle tone disorder	10072889
-	-	-	-	Muscle twitching	10028347	-	-

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

Akathisia		Dyskinesia		Dystonia		Parkinson-like	
PT	Code	PT	Code	PT	Code	PT	Code
-	-	-	-	Musculoskeletal stiffness	10052904	Musculoskeletal stiffness	10052904
-	-	-	-	Oesophageal spasm	10030184	-	-
-	-	-	-	Oropharyngeal spasm	10031111	-	-
-	-	-	-	Posture abnormal	10036436	-	-
-	-	-	-	-	-	Postural reflex impairment	10067206
-	-	-	-	-	-	Postural tremor	10073211
-	-	-	-	Posturing	10036437	-	-
-	-	Provisional tic disorder	10076694	Provisional tic disorder	10076694	-	-
Psychomotor hyperactivity	10037211	-	-	-	-	-	-
-	-	-	-	-	-	Reduced facial expression	10078576
Restlessness	10038743	-	-	-	-	-	-
-	-	-	-	Risus sardonicus	10039198	-	-
-	-	Secondary tic	10076702	Secondary tic	10076702	-	-
-	-	Tic	10043833	Tic	10043833	-	-
-	-	-	-	Tongue spasm	10043981	-	-
-	-	-	-	Torticollis psychogenic	10044076	-	-
-	-	-	-	-	-	Tremor	10044565
-	-	-	-	-	-	Tremor neonatal	10044575
-	-	-	-	Uvular spasm	10050908	-	-
-	-	-	-	-	-	-	-
-	-	-	-	-	-	Walking disability	10053204

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

## APPENDIX 7. PREDEFINED POTENTIALLY CLINICALLY SIGNIFICANT (PCS) CRITERIA IN SI UNITS

### STANDARD PCS CRITERIA FOR LABORATORY PARAMETERS – SI UNITS

Category Parameter Name Age/Sex Restriction, if any	PCS Low	PCS High
<b>HEMATOLOGY</b>		
<b>WBC</b>	$\leq 2.8 \times 10^9/L$	$\geq 16 \times 10^9/L$
<b>Neutrophils (abs)</b>	$< 0.5 \times 10^9/L$	$> 13.5 \times 10^9/L$
<b>Lymphocytes (abs)</b>	N/A	$> 12 \times 10^9/L$
<b>Monocytes (abs)</b>	N/A	$> 2.5 \times 10^9/L$
<b>Eosinophils (abs)</b>	N/A	$> 1.6 \times 10^9/L$
<b>Basophils (abs)</b>	N/A	$> 1.6 \times 10^9/L$
<b>Neutrophils (relative)</b>	$\leq 0.15$	$> 0.85$
<b>Lymphocytes (relative)</b>	N/A	$\geq 0.75$
<b>Monocytes (relative)</b>	N/A	$\geq 0.15$
<b>Eosinophils (relative)</b>	N/A	$\geq 0.10$
<b>Basophils (relative)</b>	N/A	$\geq 0.10$
<b>Hemoglobin</b>		
Male	$\leq 115 \text{ g/L}$	$\geq 190 \text{ g/L}$
Female	$\leq 95 \text{ g/L}$	$\geq 175 \text{ g/L}$
<b>Hematocrit</b>		
Male	$\leq 0.37$	$\geq 0.60$
Female	$\leq 0.32$	$\geq 0.54$
<b>RBC</b>	$\leq 3.5 \times 10^{12}/L$	$\geq 6.4 \times 10^{12}/L$
<b>Platelet Count</b>	$\leq 75 \times 10^9/L$	$\geq 700 \times 10^9/L$
<b>SERUM CHEMISTRY</b>		
<b>Sodium</b>	$< 130 \text{ mmol/L}$	$> 150 \text{ mmol/L}$
<b>Potassium</b>	$< 3 \text{ mmol/L}$	$> 5.5 \text{ mmol/L}$
<b>Chloride</b>	$\leq 90 \text{ mmol/L}$	$\geq 118 \text{ mmol/L}$
<b>Calcium</b>	$< 1.75 \text{ mmol/L}$	$\geq 3.1 \text{ mmol/L}$
<b>Phosphate</b>	$< 0.65 \text{ mmol/L}$	$> 1.65 \text{ mmol/L}$
<b>Bicarbonate</b>	$< 15.1 \text{ mmol/L}$	$> 34.9 \text{ mmol/L}$
<b>Magnesium</b>	$< 0.4 \text{ mmol/L}$	$> 1.23 \text{ mmol/L}$
<b>AST</b>	N/A	$\geq 3 \times \text{ULN}$
<b>ALT</b>	N/A	$\geq 3 \times \text{ULN}$
<b>Alkaline Phosphatase</b>	N/A	$\geq 1.5 \times \text{ULN}$
<b>CK</b>	N/A	$> 2.5 \times \text{ULN}$
<b>Creatinine</b>	N/A	$\geq 177 \text{ umol/L}$
<b>BUN</b>	N/A	$\geq 10.7 \text{ mmol/L}$
<b>Total bilirubin</b>	N/A	$\geq 34.2 \text{ umol/L OR } > 2 \times \text{ULN}$
<b>Total protein</b>	$\leq 45 \text{ g/L}$	$\geq 100 \text{ g/L}$
<b>Albumin</b>	$\leq 25 \text{ g/L}$	N/A
<b>Total Cholesterol</b>	N/A	$> 7.76 \text{ mmol/L}$
<b>HDL-Cholesterol</b>	$< 0.78 \text{ mmol/L}$	N/A
<b>LDL-Cholesterol</b>	N/A	$> 4.9 \text{ mmol/L}$
<b>Triglycerides</b>	N/A	$> 3.42 \text{ mmol/L}$

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

<b>Uric acid</b>		
Male	N/A	> 595 $\mu$ mol/L
Female	N/A	> 476 $\mu$ mol/L
<b>Glucose</b>	< 2.78 mmol/L	> 13.9 mmol/L
<b>HbA1c</b>	N/A	$\geq$ 0.075
<b>Prolactin</b>	N/A	$\geq$ 5 $\times$ ULN
<b>URINALYSIS</b>		
<b>RBC</b>	N/A	> 25 hpf
<b>WBC</b>	N/A	> 25 hpf

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

## APPENDIX 8. PSQI SCORING SHEET

PSQI scoring reference as defined by BUYSSE is provided in following website:

<https://www.sleep.pitt.edu/instruments/#psqi>

---

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024

## Pittsburgh Sleep Quality Index (PSQI)

### Form Administration Instructions, References, and Scoring

#### Form Administration Instructions

The range of values for questions 5 through 10 are all 0 to 3.

Questions 1 through 9 are not allowed to be missing except as noted below. If these questions are missing then any scores calculated using missing questions are also missing. Thus it is important to make sure that all questions 1 through 9 have been answered.

In the event that a range is given for an answer (for example, '30 to 60' is written as the answer to Q2, minutes to fall asleep), split the difference and enter 45.

#### Reference

Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Research* 28:193-213, 1989.

#### Scores – reportable in publications

On May 20, 2005, on the instruction of Dr. Daniel J. Buysse, the scoring of the PSQI was changed to set the score for Q5J to 0 if either the comment or the value was missing. This may reduce the DISTB score by 1 point and the PSQI Total Score by 1 point.

#### **PSQIDURAT**

##### **DURATION OF SLEEP**

IF  $Q4 \geq 7$ , THEN set value to 0

IF  $Q4 < 7$  and  $\geq 6$ , THEN set value to 1

IF  $Q4 < 6$  and  $\geq 5$ , THEN set value to 2

IF  $Q4 < 5$ , THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

#### **PSQIDISTB**

##### **SLEEP DISTURBANCE**

IF  $Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j$  (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0) = 0, THEN set value to 0

IF  $Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j$  (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0)  $\geq 1$  and  $\leq 9$ , THEN set value to 1

IF  $Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j$  (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0)  $> 9$  and  $\leq 18$ , THEN set value to 2

IF  $Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j$  (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0)  $> 18$ , THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

#### **PSQILATEN**

##### **SLEEP LATENCY**

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

**First, recode Q2 into Q2new thusly:**

IF  $Q2 \geq 0$  and  $\leq 15$ , THEN set value of Q2new to 0  
IF  $Q2 > 15$  and  $\leq 30$ , THEN set value of Q2new to 1  
IF  $Q2 > 30$  and  $\leq 60$ , THEN set value of Q2new to 2  
IF  $Q2 > 60$ , THEN set value of Q2new to 3

**Next**

IF  $Q5a + Q2new = 0$ , THEN set value to 0  
IF  $Q5a + Q2new \geq 1$  and  $\leq 2$ , THEN set value to 1  
IF  $Q5a + Q2new \geq 3$  and  $\leq 4$ , THEN set value to 2  
IF  $Q5a + Q2new \geq 5$  and  $\leq 6$ , THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIDAYDYS**
**DAY DYSFUNCTION DUE TO SLEEPINESS**

IF  $Q8 + Q9 = 0$ , THEN set value to 0  
IF  $Q8 + Q9 \geq 1$  and  $\leq 2$ , THEN set value to 1  
IF  $Q8 + Q9 \geq 3$  and  $\leq 4$ , THEN set value to 2  
IF  $Q8 + Q9 \geq 5$  and  $\leq 6$ , THEN set value to 3  
Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIHSE**
**SLEEP EFFICIENCY**

Diffsec = Difference in seconds between day and time of day Q1 and day Q3  
Diffhour = Absolute value of diffsec / 3600  
newtib = IF diffhour > 24, then newtib = diffhour - 24  
IF diffhour  $\leq 24$ , THEN newtib = diffhour  
(NOTE, THE ABOVE JUST CALCULATES THE HOURS BETWEEN GNT (Q1)  
AND GMT (Q3))  
tmphse =  $(Q4 / \text{newtib}) * 100$

IF  $\text{tmphse} \geq 85$ , THEN set value to 0  
IF  $\text{tmphse} < 85$  and  $\geq 75$ , THEN set value to 1  
IF  $\text{tmphse} < 75$  and  $\geq 65$ , THEN set value to 2  
IF  $\text{tmphse} < 65$ , THEN set value to 3  
Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQISLPQUAL**
**OVERALL SLEEP QUALITY**

Q6  
Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIMEDS**
**NEED MEDS TO SLEEP**

Q7  
Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQI**
**TOTAL**

DURAT + DISTB + LATEN + DAYDYS + HSE + SLPQUAL + MEDS  
Minimum Score = 0 (better); Maximum Score = 21 (worse)  
Interpretation: TOTAL  $\leq 5$  associated with good sleep quality  
TOTAL > 5 associated with poor sleep quality

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024



## APPENDIX 9. CLASSIFICATION OF PATIENT TYPE FROM UPSM FACTOR SCORES

Guided machine learning via linear support vector machine (L-SVM) algorithm in MATLAB will be used to classify subjects into 5 patient types based on UPSM factor scores. There are 5 distinct patient types described in the table below.

TYPE	PATIENT TYPE
1	Prominently Disorganized
2	Prominently Negative
3	Prominently Hostile
4	Prominently Positive
5	Prominently Affective

The classification will occur in two steps:

- Step 1: Train L-SVM in MATLAB to classify subjects into 1 of 5 patient types using 7 columns of UPSM data. Training dataset is given in the table below.
- Step 2: Use the now trained classifier function in MATLAB to classify subjects into 1 of 5 patient types using 7 columns of UPSM data.

**Table 9: Training Dataset**

UPSM-HOS	UPSM-DIS	UPSM-POS	UPSM-NAA	UPSM-ANX	UPSM-NDE	UPSM-DEP	TYPE
0.110138	1.960813	0.478927	3.298293	1.382828	2.114771	0.391504	1
1.431769	1.616874	3.310726	2.225812	0.541127	1.542821	0.22721	4
0.537462	2.293898	3.358519	2.713077	2.582309	1.584137	2.762624	5
1.458801	0.51371	3.162632	4.179415	2.367169	0.687056	2.014098	5
0.491282	1.47429	0.583566	2.633944	4.227873	1.12837	3.735909	5
2.124307	2.621508	2.553096	1.81619	1.463642	0.857061	1.801388	3
0.229749	4.356682	3.900132	2.980611	1.59104	2.825456	2.487569	1
0.65872	1.492003	3.98728	1.558729	1.721153	1.716735	2.567419	4
4.311785	3.13258	3.26397	-0.53456	3.583895	0.246863	3.063737	3
1.673673	2.982224	2.381804	0.168301	2.017634	2.223616	2.420761	3
-0.28911	1.117716	3.325504	4.394722	0.710643	2.619891	1.77449	4
-0.40258	1.164411	3.68884	2.699136	3.395212	2.032147	2.131544	5
0.120462	2.660464	3.395254	2.078197	2.900268	0.261296	2.725002	4
1.361992	3.411795	4.64508	0.18819	1.223746	2.532468	1.366811	4
3.667904	3.136446	2.321715	2.125103	3.409371	1.537432	-0.2218	3
4.879887	3.475862	2.076838	-0.59349	1.113849	1.688076	0.123996	3
-0.02164	2.41729	2.779121	3.079331	2.108443	1.951256	1.676715	1
-0.3092	2.157215	2.674034	2.803489	1.084307	0.996332	1.994321	4
0.196083	2.475004	2.878793	1.351682	1.201559	0.816825	2.181635	4
0.030238	3.526967	4.532129	0.380547	0.326149	1.986222	1.517082	4
2.275873	2.640193	3.251667	0.839343	2.051567	0.58417	2.170745	3
0.664909	2.042059	2.76595	2.366495	1.440192	0.733822	2.402925	5
1.243306	1.337145	4.074218	2.793057	2.698381	2.51747	3.318289	5
3.22947	2.860181	3.577492	3.502082	2.628584	0.298051	3.390157	5
0.901195	1.663412	2.142304	3.688469	1.330552	2.56257	2.640387	5
2.593164	3.648882	3.709823	3.206283	1.011247	1.094186	3.558644	3
-0.51118	2.448093	2.437806	1.15006	2.797663	3.063268	2.065887	1
-0.11226	1.666885	2.743509	1.415346	0.850013	2.305111	1.401516	4
0.461343	2.627467	4.224476	0.273361	1.87481	0.626399	1.981483	4
2.984818	3.119943	1.817018	0.766638	2.093436	1.529787	0.320228	3
3.77918	4.634406	1.565869	3.283619	0.239241	1.954698	0.044583	2

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

2.144653	2.782737	3.498727	0.538967	1.545457	0.710868	0.792113	3
0.894321	4.51713	0.328192	4.038478	0.461848	4.202648	0.153093	2
-0.36753	4.43122	3.945508	3.314841	3.447207	2.09228	1.277813	1
-0.54075	4.778543	0.863248	4.518782	2.584591	3.675675	1.102248	1
0.567503	3.24148	3.050335	3.616151	2.485309	1.23559	1.194027	1
-0.14361	3.811718	1.934878	4.106673	2.496619	1.883645	1.255909	1
2.074899	4.309083	3.67494	2.931829	2.158336	1.564656	0.532635	2
-0.19755	3.56726	2.443049	2.469007	2.522924	2.551866	4.876176	1
1.77413	1.53753	2.847139	1.882985	0.272108	1.812518	3.542881	5
1.620442	2.629055	2.66762	-0.09426	2.112038	0.781558	3.528088	3
0.284396	1.770956	2.033619	2.009207	3.469858	0.528655	2.227344	5
3.932854	4.528324	2.861762	1.430475	2.837778	1.200249	2.254885	3
-0.56969	0.692111	4.179689	2.437995	1.95239	1.874127	3.146663	5
4.750689	2.427282	4.856594	3.187711	1.452157	-0.41915	0.793141	3
3.405697	1.355663	3.002656	3.832785	3.044058	1.05007	2.012123	5
3.246586	1.094777	3.274349	3.670523	2.797322	0.536438	3.19334	5
-0.73954	2.073529	3.517236	4.06399	3.114689	3.682423	3.860445	5
-0.52019	1.761008	4.510467	2.327021	2.304678	3.148164	2.974405	4
2.014756	2.407895	2.295336	2.006102	1.24862	3.567501	2.040139	2
0.617758	2.661608	1.536687	3.738151	1.672221	2.392486	-0.23323	2
2.207155	1.517604	2.625454	1.804154	0.763335	0.901574	1.873668	3
1.23422	2.210916	2.561197	2.528093	1.527851	1.183324	0.255261	4
0.021092	1.402188	2.331655	1.812051	2.72359	0.272525	2.258971	5
-0.954	5.328812	2.839309	3.194626	2.923765	1.602491	3.133907	1
3.167057	3.125152	1.146554	4.533739	1.648505	1.456163	2.409444	2
0.076614	2.337764	1.24781	1.632617	2.307237	1.494694	0.092505	1
1.769865	3.050355	3.584774	3.050455	0.435454	0.965985	1.414732	4
-0.14345	2.274485	3.363205	2.516223	1.298419	0.84683	0.939489	4
0.73008	2.109659	1.353254	2.267853	1.683644	1.547878	2.385081	1
1.99611	2.845866	2.776477	2.253987	2.519993	1.293208	0.830398	3
0.070748	2.973237	2.458206	2.670777	0.933532	0.498741	0.68469	4
0.876838	1.702267	2.500296	1.205238	1.988358	1.73428	1.88312	5
2.539879	1.866446	1.194986	2.380642	1.503776	2.970662	0.607604	2
1.394134	3.329297	3.029867	2.34767	2.089692	0.610036	3.175958	5
1.370158	3.673851	0.853038	2.542066	2.93799	2.377451	1.666476	1
1.873059	1.656544	2.282509	0.870666	2.632208	0.4312	1.362965	3
2.587309	1.766566	1.972871	2.451865	2.200703	1.026357	0.802177	3
3.83788	1.83301	2.241711	3.814479	1.270124	0.82664	0.010026	3
1.139727	1.009246	2.171023	2.861618	1.94202	1.469105	2.310987	5
0.399375	1.269958	3.185143	3.451366	2.536612	1.873559	3.891391	5
1.155282	0.720076	1.978406	2.550957	1.676011	2.227286	1.931072	5
1.344237	1.329165	2.176408	2.522749	2.36858	1.113254	1.862452	5
1.884397	0.811162	2.366897	3.193561	1.903167	0.529586	3.039549	5
0.857138	1.991846	4.143588	3.203741	2.567467	1.723389	2.662205	5
0.316037	0.913369	3.265191	3.908459	2.02769	2.805904	3.226179	5
0.941557	1.611534	3.550319	2.397795	2.465604	1.637112	2.268425	5
1.001373	0.053415	2.59386	3.243315	2.765545	1.745535	1.070277	5
0.503857	0.731232	2.859462	3.221411	1.999709	0.617281	0.785101	4
0.606582	1.644987	2.617478	3.87998	1.79895	0.52075	1.931541	5
0.028959	0.051636	2.679662	3.743596	1.258786	0.796158	2.684655	5
1.346641	0.874823	2.367707	3.081821	1.922213	0.204586	1.535142	5
1.860828	2.605349	3.667323	4.365784	-0.09249	1.265363	1.238416	2
3.841476	0.719424	2.257701	4.478491	1.331765	0.100831	1.896058	5
1.661837	1.572432	2.894384	4.184757	1.296394	0.92299	2.19499	5
1.639518	1.463103	2.652642	1.584517	2.156156	1.371609	1.96164	5
0.422721	1.235118	2.915662	1.806378	1.774961	1.461898	1.782514	5
1.706561	2.255214	2.013119	3.335592	1.432492	1.106246	0.37835	2
1.400759	1.11035	3.176518	2.727226	1.683432	1.484354	2.072159	5
0.261743	1.846856	2.95069	1.604365	1.313196	2.201688	2.045153	4

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

0.589363	1.63248	2.607093	3.117401	1.985862	1.962965	2.226981	5
-0.25198	1.221123	3.025169	3.361783	1.767464	1.630335	2.390124	5
2.291071	0.293838	3.270165	3.243712	2.442306	-0.00452	2.387481	5
1.537487	0.068818	3.108614	1.546074	2.023246	1.696579	2.706242	5
0.582496	1.908653	2.366867	2.51433	1.475041	0.41553	1.263473	4
2.181457	1.917974	2.429864	2.922081	1.514385	-0.21779	1.973444	3
2.263951	0.29547	3.331314	1.415383	2.346612	1.031364	2.892756	5
2.009356	1.113335	3.138889	3.341652	1.883817	0.109166	1.958678	5
0.172439	1.489999	3.292475	2.720522	1.176231	1.605558	2.641559	5
-0.17314	1.356652	4.442061	3.10633	2.049317	0.791991	1.912506	4
1.388335	1.095188	3.220865	1.628662	1.732311	1.352052	2.405447	5
1.205138	2.024409	3.791492	2.398941	3.006668	1.787416	2.920256	5
0.464397	1.684218	3.40262	2.726862	3.013933	1.189662	3.61535	5
1.628768	1.308049	2.95217	2.745054	1.327077	2.028925	3.357957	5
0.586597	2.536766	2.916748	3.252801	2.392646	2.207333	3.37449	5
0.668672	0.21496	3.401807	3.499059	2.747658	2.264928	3.708938	5
1.85842	1.032293	3.81473	3.017692	2.560804	1.060393	2.687179	5
0.421477	1.193203	3.072718	3.197042	2.410182	2.327653	3.342285	5
0.705007	2.094874	1.758942	2.993589	1.631168	1.769052	2.175233	1
1.341319	2.511154	2.487053	0.737579	1.309727	1.172314	2.21039	3
-0.10475	3.201991	2.494132	3.312053	0.911785	2.561984	0.543735	2
1.26418	1.34083	2.50963	3.164473	0.66512	1.883488	1.486237	2
2.135516	2.140969	2.155306	4.111724	2.433874	1.272746	2.910099	5
0.11181	3.029033	2.241817	4.074078	2.229162	1.485626	1.801666	1
0.57075	4.309476	3.042631	3.640668	1.121444	1.676763	0.985236	2
2.368828	2.078152	1.757995	3.68918	2.238158	0.832056	3.202517	5
0.460592	3.343601	1.369653	3.591892	3.052149	1.590111	1.853283	1
1.039519	2.73413	2.797452	4.794559	3.188477	1.32171	2.069804	1
-0.10856	3.283553	2.221476	2.861392	2.916771	1.670176	1.495856	1
1.635721	1.670994	2.776531	3.481021	3.648923	1.09168	3.517521	5
-0.28728	1.550428	3.027047	1.569179	3.495302	1.675143	3.72542	5
0.629977	1.356138	4.076404	1.705047	2.22813	1.423955	2.063269	4
2.307646	2.236448	2.680489	0.969736	2.569013	-0.08536	2.277701	3
2.477069	3.263651	2.163565	2.139497	1.721061	-0.00358	0.65799	3
1.243638	2.913075	4.107979	2.66461	0.995093	-0.14437	1.22687	4
0.527388	1.958446	1.279965	3.081775	0.643036	1.853639	2.172642	1
0.424628	2.137735	2.088917	1.156878	1.766872	1.219234	1.53977	1
2.527044	0.76957	4.013747	2.360512	3.03441	-0.3789	4.007144	5
-0.19304	1.261063	2.340497	2.776243	2.052291	1.922053	3.962693	5
0.533501	1.87061	4.417346	2.075672	3.323951	-0.27006	4.225107	5
2.411661	1.882853	4.355587	1.036112	1.98607	0.055844	1.311082	3
-0.48578	1.752793	4.45535	3.947321	1.094441	2.902358	2.033406	4
0.464869	3.413253	2.635796	2.121825	2.8906	1.996746	3.22642	1
4.132441	0.401081	2.381923	3.456109	0.953315	3.096096	0.555434	2
0.218247	3.435941	1.849422	1.196065	2.511003	1.363478	0.35237	1
-0.32981	4.544489	1.360392	3.024887	1.106194	2.727317	0.572736	1
0.544813	4.282196	2.116876	2.290366	2.541964	1.369559	1.818978	1
-0.47234	4.088985	0.577244	2.967936	2.63388	2.877609	2.381399	1
-0.55527	4.84008	1.960686	2.982342	2.094423	1.626178	1.184506	1
0.263513	3.736018	1.959549	1.758239	1.640343	1.004376	1.472666	1
0.705893	3.718196	2.301378	0.926439	1.774488	0.994932	1.79793	1
0.069405	3.026261	2.43983	3.17107	3.19792	2.883761	1.97275	1
-0.32695	0.330879	2.510527	3.441654	2.057765	2.304866	2.878307	5
2.690017	0.693133	1.730133	3.88509	2.562458	1.455035	1.213344	5
0.46547	1.287936	2.939181	1.394492	3.396399	2.015295	2.080734	5
1.394982	1.559578	2.471032	3.161232	2.57522	0.992441	2.406263	5
0.672309	2.393359	1.896502	2.598218	0.993053	3.154678	1.696235	1
1.693716	1.325886	0.880014	5.37448	1.164323	3.653433	2.895248	5
1.356159	2.406733	2.037301	2.919935	1.869511	3.465406	1.13788	2

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

1.027015	1.062603	0.659294	4.357499	2.82001	3.266347	4.132878	5
1.436698	-0.58649	1.964863	3.95011	3.191804	0.377813	4.488555	5
4.058956	-0.66886	1.317517	4.606702	1.160914	2.731827	3.099033	5
1.416783	1.490505	2.933091	1.730763	3.560499	0.430518	2.821162	5
0.824231	-0.19387	4.748215	0.202208	2.896445	0.69977	4.873985	5
-0.36924	2.678109	3.163096	1.596358	0.59506	3.346233	1.61617	4
2.327808	1.715927	3.390249	3.327197	-0.07099	1.647033	1.876406	2
1.146957	1.732186	2.467294	4.312694	0.967439	3.606223	2.364763	2
-0.08434	2.371234	1.923559	2.551661	2.780099	-0.41496	2.607441	5
2.330935	1.249285	1.977942	-0.29365	1.750854	1.887952	3.34313	5
-0.29097	2.579936	4.03501	2.453226	1.223345	1.756084	1.578965	4
2.433418	1.586402	2.744031	2.943148	2.595221	-0.15045	4.456784	5
1.686219	2.133575	3.063004	2.625084	1.837615	0.138859	2.505072	5
2.182811	2.480894	3.512331	2.528045	3.359501	1.174893	2.358992	5
1.726701	2.611469	3.08875	2.914048	3.581237	1.05601	1.522262	1
0.604793	3.12306	2.124151	2.637198	2.7244	2.472494	1.200589	1
3.236433	3.290153	2.702033	2.314023	3.316992	0.3816	1.895082	3
1.425043	3.692046	3.472158	4.057196	2.405972	0.434079	2.869765	1
2.201707	3.084578	2.151076	4.021647	2.182574	2.301893	1.407549	2
1.815693	2.134869	4.303099	4.369005	1.882038	0.949098	1.847457	4
1.20209	3.064755	4.217095	3.649783	2.915971	0.357701	1.225159	4
0.046373	2.916968	4.455808	2.885248	3.107358	0.426352	2.008252	4
-0.01844	3.893585	3.026784	1.817709	0.913144	3.254477	2.670709	1
0.15412	3.328443	1.620771	1.879719	2.673819	2.668971	2.431268	1
-0.07332	4.359244	3.52468	1.723178	0.553973	1.862672	0.970363	4
0.708979	3.65687	2.295132	2.084227	1.178033	3.673556	0.603624	2
1.454947	3.430231	2.232895	2.447069	2.309456	2.631151	2.32591	1
0.583852	3.473869	2.416568	2.141427	0.479351	2.977283	1.947473	2
0.284904	3.74932	2.086627	3.204144	-0.07831	2.28367	1.519997	2
0.882449	3.863615	3.044836	2.195771	-0.10572	1.730727	0.181928	2
0.180445	1.883516	1.562047	2.663036	2.63216	2.250718	2.436309	1
0.378782	2.931791	1.708711	2.980852	2.771396	2.111069	0.610343	1
0.352732	1.89972	2.265854	3.230448	1.11399	1.21381	2.019503	5
-0.07905	1.7187	0.81324	3.213864	2.58132	2.072825	1.596053	1
-0.04268	2.161476	1.854841	2.9067	2.572292	2.05655	3.250114	1
0.532978	3.478254	2.049047	1.952408	2.807302	1.696268	1.824182	1
0.155656	3.999629	3.146047	1.349007	2.792547	1.478153	1.4613	1
0.796148	2.634837	3.132603	3.222581	2.680883	1.854805	2.030157	1
0.86594	2.609557	2.546813	1.751367	1.740951	1.533923	2.228512	1
1.01185	2.816307	2.912837	1.669116	2.542537	1.330716	1.168323	1
1.350645	1.989788	1.74757	3.198019	2.213117	0.804664	1.34773	1
0.349145	2.756305	1.716076	2.68973	2.739907	1.656974	1.623306	1
0.342705	1.679803	1.833402	2.032994	2.960676	1.663841	2.120364	1
1.484201	1.539412	1.50688	2.924464	2.475359	1.705127	1.683536	5
1.562951	3.030532	1.644437	2.014339	1.595521	1.644179	1.164406	1
3.029619	2.819386	1.874296	2.742982	1.788343	2.269874	1.542436	2
0.78352	1.877238	2.074483	2.627216	2.240644	2.194709	2.377748	5
0.710665	2.849776	2.364681	1.919057	2.747839	1.648826	1.233827	1
0.798178	2.933791	3.35471	2.705446	0.796685	3.192393	0.488374	2
1.905889	4.839237	3.456346	0.724097	2.164524	0.999083	1.83366	3
-0.42893	2.354318	2.48451	3.358162	0.714569	2.794577	2.607276	1
2.197681	2.953134	3.844426	1.086876	0.80736	-0.01227	2.050991	3
1.175299	4.850591	4.181569	1.539452	1.490182	0.734061	1.239397	4
-0.50935	3.131051	2.46547	2.550862	1.514948	3.740844	1.942203	1
-0.47872	2.432521	2.670089	3.345092	1.896522	3.066479	3.392814	1
1.647404	2.212889	0.922094	2.565279	2.766181	2.737955	1.599062	1
2.466112	2.010557	3.626749	3.847344	2.514457	1.560699	3.442844	5
3.004502	2.637176	2.798804	3.711184	2.463544	1.57843	2.123784	3
1.241437	2.778655	1.589605	2.563038	2.012834	1.91169	3.491985	1

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

2.391924	2.637746	2.374582	0.755083	2.629425	2.330716	2.941087	3
1.486578	3.128626	2.487837	1.743571	2.003073	1.737516	1.329548	1
2.586535	2.877124	2.287801	2.632841	1.387282	2.363598	2.453764	2
1.66655	2.838318	2.35911	1.973314	1.859279	2.225311	2.915387	1
1.589938	3.65255	2.956482	2.565466	0.975133	1.615948	0.499501	2
1.945618	3.050839	2.514292	3.234862	2.203473	1.822279	1.99805	1
1.755469	2.075945	3.480556	2.94479	1.519334	1.681199	0.758004	4
2.935053	2.718756	3.31552	2.504717	1.889886	1.201849	1.460136	3
2.119775	3.394806	2.506338	2.120552	2.614302	0.679575	0.89525	3
2.458961	2.329016	2.154788	3.310596	1.474675	2.59347	1.591725	2
1.244654	1.73021	1.827923	2.489334	1.383575	2.073081	1.360675	1
-0.20744	1.946772	4.276268	1.584494	1.25229	0.51958	1.276463	4
1.074974	1.973074	1.265671	1.897755	2.948865	0.870864	1.737043	1
-0.14189	-0.04374	3.164932	3.531256	1.980725	0.632499	3.87712	5
3.376984	0.831567	2.275181	2.779673	1.98059	1.308505	1.968036	5
0.410408	1.295473	3.211679	2.991182	2.99265	1.394861	2.979216	5
0.412831	0.728305	2.774347	3.476108	2.485126	0.143779	1.325316	5
0.395383	1.266636	3.547077	3.848593	2.41841	0.233631	1.330153	4
0.303011	0.68115	3.431149	2.896138	2.845076	0.290205	2.987518	5
0.623263	2.844467	2.011102	3.13837	1.748296	2.03984	2.51607	1
0.430849	2.024006	2.387261	2.938496	1.830338	1.725661	1.602135	1
0.302646	3.078668	1.809565	2.02404	2.874748	0.986561	3.022366	1
0.217969	2.234125	3.086551	2.801215	2.881359	1.925122	2.6483	1
1.148024	4.715529	1.712537	1.143191	1.448075	0.735696	1.255713	1
0.17321	2.714301	3.093773	2.731845	3.555077	0.30472	1.964692	1
1.628505	1.333563	2.279517	3.023174	2.166503	1.909445	2.062154	5
1.460183	2.173385	1.803192	2.793002	2.444099	0.941715	2.221664	5
0.443037	2.964066	1.915887	2.678915	1.792021	2.577074	1.45575	1
0.462123	1.136766	3.163593	3.69979	3.024302	-0.067	2.09806	5
-0.00933	2.530804	3.25533	3.315988	1.517136	0.677362	2.642933	4
1.040869	1.969233	2.705048	4.084591	2.318205	0.820581	2.483245	5
0.146118	1.409769	2.792843	2.852647	2.966719	0.792185	2.797111	5
0.957539	1.814681	2.711	3.043293	1.665616	0.197362	2.822844	5
1.552961	2.008691	3.036311	3.633731	2.497589	-0.00887	1.003566	4
1.250273	3.122429	2.403355	3.189958	1.795676	0.107745	0.924363	1
1.322036	1.215882	3.921602	3.003509	2.284119	-0.24933	1.806291	5
0.251952	2.113829	2.664782	3.034502	1.648737	0.259419	2.65026	5
0.59895	3.329155	2.836852	2.202842	1.497784	1.607472	2.583754	1
0.565399	5.191211	2.58232	2.271006	2.778369	1.798438	0.76725	1
1.891514	1.030671	2.378489	2.521739	2.470474	1.713408	1.830049	5
2.251343	1.964833	2.782653	2.173102	2.552897	0.928943	2.420509	5
0.827273	1.676045	1.79413	2.599383	2.936736	2.290989	1.069859	1
0.933062	4.872175	1.858903	3.41357	1.483246	3.481183	0.717352	2
1.319798	3.170397	2.467164	3.559172	3.259405	2.329196	0.779611	1
1.159981	2.887268	2.048998	1.864787	1.714485	1.964015	0.851252	1
2.594349	4.47202	1.935226	2.39397	0.807125	1.443819	1.010001	2
2.259674	2.817409	2.241478	3.232779	1.265977	2.904775	1.005764	2
3.853234	3.442007	3.483622	1.254111	2.035139	0.95848	2.220828	3
0.107242	2.316128	1.787862	2.913061	2.647041	1.852659	1.796499	1
4.540121	2.034294	1.273216	4.195778	0.812797	3.901634	2.414239	2
1.940409	1.744759	2.334533	3.048773	2.032325	1.673573	2.156116	5
1.771326	1.136763	2.607683	3.880771	1.931054	1.665451	2.462573	5
2.056638	0.596344	2.676342	3.652917	1.954028	1.575281	2.359132	5
1.998099	1.080433	2.593327	4.200915	1.916664	1.49471	2.380617	5
1.973644	0.455134	3.08072	4.16708	1.829094	1.683288	2.447056	5
1.836602	0.707831	2.460104	4.184537	1.830863	1.615467	2.488581	5
1.970747	1.071085	2.266924	3.64906	3.038635	1.177264	2.83891	5
2.048913	1.390075	2.210913	3.567033	2.003754	1.363302	2.075113	5
1.017331	2.182473	3.564923	0.448758	2.352833	2.376049	3.255035	5

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024



1.725945	3.009119	2.694312	0.112874	3.046849	1.046677	2.597689	3
0.631709	2.429373	2.904648	1.845756	1.753777	3.513261	1.93335	1
-0.23163	3.002049	3.345794	2.547498	3.554414	1.593511	3.265845	1
-0.21477	2.923092	2.388016	3.395137	2.936315	2.417217	2.608649	1
2.292153	2.412309	2.891003	2.297742	1.884942	0.821511	1.938632	3
1.826434	3.195578	1.861429	3.285702	2.60437	0.337541	1.982752	1
1.081747	2.024036	3.051124	2.759296	2.689623	2.411139	3.523435	5
1.726368	2.23849	3.132346	2.316369	2.459357	2.194413	2.921579	5
0.273047	2.916457	1.761402	3.342903	1.357142	2.447486	1.642088	1
2.061364	2.246574	2.274476	2.84223	2.513461	1.435599	1.663619	5
-0.44394	1.990884	2.120804	2.786634	1.973897	3.156599	3.453843	1
0.965206	1.901004	1.431642	3.042105	2.183742	2.33692	2.365446	1
1.658993	1.392341	3.179016	2.725544	1.270456	1.609023	2.18851	5
1.841815	2.190828	2.24286	3.811443	2.195616	0.758591	2.922796	5
1.22653	1.421029	2.261803	2.765931	2.425561	1.732311	3.372288	5
-0.23487	2.062772	2.559663	2.79011	1.445805	2.657801	2.760422	1
0.245227	2.689176	1.443797	1.973458	2.887213	1.25989	2.374189	1
2.215864	1.754762	2.859705	4.169328	2.445922	1.18503	2.197257	5
2.827656	1.672037	1.272949	2.704282	2.616846	2.725432	3.720687	5
3.199189	1.422016	2.654105	4.302128	3.544407	1.718565	4.051834	5
2.403098	2.968469	4.036389	2.438671	1.294979	0.563823	1.703829	3
2.45239	3.234068	2.759748	1.024698	1.562684	1.112423	2.375853	3
1.502019	2.281229	1.340381	1.610793	2.423306	1.047639	1.624365	1
1.77479	1.921922	3.237566	1.352774	2.492678	1.049467	2.512043	5
1.663432	3.019771	1.897049	0.759906	3.501306	1.569326	1.914466	1
2.94352	2.35016	2.281449	0.951598	2.511059	1.019162	1.526363	3
1.68009	2.045579	1.887194	2.357748	1.978092	1.635593	2.811834	5
0.808124	-0.13738	2.953735	3.906694	1.947323	1.380431	2.901026	5
1.209549	-0.67634	4.084019	3.428157	1.289318	1.264035	2.480664	5
1.733745	-0.34144	2.996359	2.729753	1.784482	-0.03631	2.462543	5
1.619052	0.150902	4.359022	2.334887	2.914195	-0.11285	1.33825	5
-0.13043	0.923062	2.34262	2.347549	0.138352	3.16152	1.597485	4
1.32315	0.012205	4.865486	0.779994	1.714469	0.367159	2.011743	4
2.650652	1.224055	2.722871	2.274911	1.37163	1.630707	1.845764	3
1.607415	2.287416	2.580634	1.22177	2.238811	1.518263	0.841124	3
0.407971	0.974984	2.534841	2.228252	3.585527	2.013955	3.485656	5
1.576527	1.697772	2.575915	3.470199	2.282271	1.37511	2.962369	5
1.956178	-0.46028	4.546977	2.448721	1.334782	1.148109	3.918205	5
0.18701	2.273386	4.282304	2.119968	2.185045	2.674903	1.841133	4
0.354561	1.314933	4.056158	2.91016	1.719733	1.791516	-0.16259	4
0.797993	0.857493	3.688851	3.229713	3.474734	2.372434	1.533996	5
1.856804	2.053879	1.920647	2.220341	2.898173	0.918768	1.764507	5
-0.13872	3.299856	3.489781	2.220536	1.711955	1.704413	3.085852	1
0.72802	2.655034	3.106166	2.872185	1.647015	1.176479	0.846061	4
0.225626	1.874406	1.825989	3.058365	2.868861	3.509008	2.042135	1
2.051621	1.818373	4.017949	2.104391	1.201151	0.575975	1.724579	3
0.59504	1.95428	5.204595	1.783968	1.497278	1.731733	1.678559	4
1.584827	0.935282	3.327166	1.94125	2.179968	0.358369	3.245291	5
0.928618	0.658035	3.076131	3.113168	2.172916	1.004145	3.430131	5
2.201803	1.135876	4.001561	1.791912	1.757235	0.255488	2.840382	5
3.807773	3.594538	1.889844	0.931891	1.714179	-0.22761	0.176671	3
0.242025	1.84378	3.468098	2.711658	2.422419	0.129613	1.804384	4
2.001564	1.682021	3.01414	2.000518	1.811704	0.298292	1.451765	3
1.563126	0.95651	2.505286	2.57955	1.915208	0.43884	3.595415	5
0.166357	2.392899	3.069375	2.770552	1.708797	3.004771	0.534774	1
0.537015	2.481759	5.567584	0.735376	1.212872	0.596699	1.804847	4
1.419943	3.311596	2.146657	1.1977	1.445532	1.588575	0.49374	3
1.6282	2.717846	3.449848	2.08389	0.548107	3.320778	3.109258	2
0.74564	4.329717	3.465316	2.586558	0.874382	2.331343	0.952736	2

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

-0.53777	2.184301	1.465823	2.443865	3.215783	3.614718	3.522195	1
0.517961	4.639776	1.693983	2.760274	1.535191	2.33917	2.777603	1
3.464622	3.305747	3.148404	1.874921	1.356197	0.483571	0.587682	3
1.831054	3.21794	1.980434	1.148194	2.693122	0.351515	2.311651	3
1.334201	2.45268	3.196957	1.766991	1.617076	0.218062	2.178214	4
1.925363	1.20103	1.434322	1.670427	2.831532	1.924301	2.443715	5
2.379776	1.265335	2.872741	2.090623	3.297923	2.679207	2.677931	5
-0.50069	3.784005	2.725673	3.553338	0.042037	2.158042	2.048815	2
0.315685	2.035559	1.810852	3.164387	0.491681	3.110445	2.98571	1
1.791176	1.005473	2.139767	2.53269	1.78994	2.214137	2.723798	5
1.979567	1.748545	1.776153	2.846214	2.002051	1.003302	2.429969	5
1.853418	3.53585	3.835734	0.856978	1.400599	3.712702	2.91704	1
1.63315	1.316722	2.619318	2.937318	1.916679	1.496701	3.180816	5
1.884768	1.551881	2.123122	4.401792	3.459827	1.945	2.269949	5
3.020426	2.411129	2.633178	2.075542	1.667037	2.194526	2.91346	3
1.449371	3.431235	3.018328	1.125531	3.259058	1.10168	1.764484	3
0.84953	1.932868	3.02034	1.862252	3.688928	2.444511	1.698493	1
2.228413	1.91244	2.305406	2.513044	2.202764	1.670849	3.270545	5
1.208468	2.707595	4.269007	2.566786	2.451727	1.520423	1.423032	4
2.061931	1.903822	2.856964	2.327123	1.620568	0.117391	1.840711	3
0.262233	3.43046	3.196516	2.788729	2.266742	1.759309	-0.00986	1
1.357973	0.780838	2.722596	2.246043	2.321431	1.691787	2.072079	5
0.114807	2.509803	2.692398	3.128366	1.181392	2.545597	1.148067	1
1.28309	0.90347	3.001318	4.109714	0.083325	2.33898	1.950549	2
0.506534	1.782591	2.399148	2.907124	2.313644	1.898565	1.305203	1
1.213072	0.529087	4.048949	2.688219	1.612988	2.403943	1.783422	5
1.313982	1.203218	2.354178	3.867624	1.752954	2.803632	0.720678	2
1.872386	0.357258	3.278948	2.103521	0.673257	2.418421	2.767138	5
0.721409	1.36012	2.099485	2.777914	1.511871	1.263105	3.078166	5
1.803057	1.579713	2.093822	2.916097	2.61537	2.381333	1.975054	5
1.511414	2.714801	2.477878	2.356489	1.608225	2.422306	1.576296	1
3.784065	1.862054	1.713389	0.213838	2.933285	1.556042	1.609158	3
1.205779	3.309772	2.478432	0.880979	1.048996	1.852513	1.572679	1
3.810057	2.116697	2.3975	-0.04406	3.077084	1.416204	1.145462	3
2.507306	2.291566	2.189901	3.038778	1.571151	1.557165	1.056906	3
0.103926	2.725501	3.826067	2.194335	1.86495	2.26395	1.177269	4
0.809178	1.040189	1.730576	2.894496	3.211068	2.478951	1.698509	5
0.838928	1.784799	2.841608	0.794042	1.844635	1.75334	1.732254	4
2.569555	0.4746	3.345086	1.136888	2.120048	1.299826	1.999741	5
1.322061	-0.11907	2.775271	1.95979	2.899401	1.783886	3.379287	5
-0.76506	4.724631	2.893808	2.774245	2.50157	3.237441	2.484975	1
2.804131	1.719649	1.570869	1.93659	2.742195	1.139427	2.036416	3
1.205436	1.512286	3.53046	1.379409	2.993918	0.657272	2.418126	5
0.051672	0.879804	2.650317	2.384895	3.283675	1.39516	3.257062	5
-0.39607	1.190186	2.649046	2.575062	2.076664	2.576419	3.426286	5
-0.40315	0.425886	3.815744	3.942569	2.3952	1.989152	2.833274	5
-0.07924	2.622817	4.052617	1.266456	1.17043	1.867025	1.448149	4
-0.13567	2.362155	4.004661	2.462405	1.297833	2.140488	0.681625	4
0.477195	1.17295	2.913251	2.483704	2.848027	2.056686	1.758322	5
0.56271	1.616479	1.830526	2.923669	3.684984	0.849889	3.423473	5
1.579464	2.173769	2.527411	3.219991	1.767273	2.623521	2.888911	5
2.700568	1.320227	1.239929	2.207632	2.038575	1.646896	1.555653	3
2.151782	1.974439	4.213681	2.612496	2.459162	0.91177	1.399608	3
1.576249	1.452704	4.058938	2.575511	2.394314	1.063594	2.603736	5
3.780426	1.734454	3.849178	2.897637	2.083926	1.825276	1.092608	3
1.390327	2.075764	4.243	3.125061	1.273445	2.840671	1.859468	4
1.607157	2.968483	3.24849	2.076404	2.62992	2.696016	2.195731	1
2.569179	2.272447	4.441177	2.249513	1.372362	2.432124	0.511077	3
3.757162	1.90669	4.023394	2.056548	2.092316	0.702579	2.357687	3

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

3.200396	1.822515	4.443242	2.109396	2.22672	1.391675	1.539029	3
2.250052	3.01667	3.066849	1.523405	2.086696	1.93857	1.362553	3
3.564286	1.622048	4.393762	2.323449	1.023309	0.742946	1.799375	3
1.820917	1.750117	4.53634	2.28264	1.228009	2.070476	1.366165	4
3.837824	3.469015	3.399461	1.508111	2.106133	0.646965	1.877185	3
3.086287	3.311494	3.384577	1.007094	2.34214	0.704304	1.716368	3
0.735348	2.431545	4.265286	3.135617	1.18764	1.246144	1.800427	4
1.061379	3.511977	3.233219	1.598488	1.538965	1.701663	1.133595	4
1.481552	3.995962	3.090677	1.705871	2.747919	0.002467	1.188856	3
-0.00182	3.260239	3.669034	1.489115	1.660088	3.071547	1.895616	1
2.364332	3.423769	3.730801	0.464028	1.449773	0.034636	0.491184	3
1.790911	3.020807	2.397504	2.504064	3.159573	2.110374	2.839354	1
1.845525	2.336941	3.108308	2.925869	1.398286	1.004538	1.277946	3
3.774452	3.283662	2.601613	1.319941	3.095036	0.246845	0.737773	3
1.505742	3.82593	3.401152	2.344606	1.070413	1.189597	1.387092	4
1.612573	2.40045	3.297188	2.902049	2.074842	2.284885	2.024605	1
1.088512	2.784298	3.62959	2.500349	2.343832	3.113105	2.404938	1
1.42413	2.253803	3.343379	2.051898	2.425804	0.579324	1.473222	3
0.905829	3.986124	2.764364	2.658993	1.428778	2.003098	0.431219	2
1.778831	2.523333	3.375314	2.030899	0.692378	2.061231	0.704335	2
1.765234	2.818131	2.887796	3.433211	1.183735	2.435894	2.171128	2
1.960731	4.06999	4.008457	3.39411	0.026767	1.542573	1.270132	2
0.764445	3.897983	3.379027	3.055913	0.426009	3.234069	0.929019	2
3.687367	1.522458	4.258232	2.500019	0.945134	1.624383	0.883844	3
2.64934	2.323337	3.874644	2.744603	1.575332	0.305109	0.525865	3
1.789778	3.038155	3.024023	3.769444	0.323103	2.528426	1.142301	2
4.672162	3.069382	3.688413	2.440952	1.405466	0.020889	1.708298	3
2.340334	2.50208	3.653272	2.672299	1.360596	1.219283	1.643292	3
1.89812	3.145009	2.649546	3.571723	1.739567	2.162005	2.432012	1
2.405691	2.557828	2.234228	3.77717	0.918691	2.055871	1.870516	2
1.991084	3.045781	3.097603	3.246524	0.560414	3.354772	2.362809	2
2.652284	2.692073	2.782371	1.637233	2.017997	0.278823	1.12878	3
2.078746	2.558682	3.375823	2.666212	0.672835	2.323415	1.714464	2
2.272887	3.299781	2.934946	3.415632	1.601629	2.553767	1.538921	2
2.174742	2.020834	3.200357	3.304615	1.962247	1.781806	1.57773	5
1.554845	3.411567	3.696475	1.814908	2.144365	0.424043	1.026569	3
2.601653	2.277123	4.083702	3.772831	-0.42827	1.541241	1.480311	2
1.853866	4.368635	2.087155	1.677374	1.142678	1.287609	1.80835	3
2.681699	3.558978	3.406055	1.417839	1.343321	0.426572	0.474613	3
2.24989	0.822324	3.131529	2.802165	1.135157	0.648374	2.308554	5
2.111609	1.90889	2.584371	2.77702	1.595925	0.485008	2.907262	5
0.173858	1.347144	2.399445	2.292993	2.871639	2.099188	3.231836	5
1.546568	2.585044	3.272659	0.477661	1.807298	0.726058	1.899376	3
1.156342	1.765744	2.866667	1.718082	2.954764	1.113488	2.110821	5
1.494649	1.806517	2.856774	1.354115	2.009178	1.117367	2.192055	5
1.364551	1.615682	2.777178	1.997047	1.850187	1.154867	1.975221	5
1.412895	1.93883	2.560225	1.571869	1.177979	1.037155	1.555193	3
2.205521	1.692739	2.633795	2.812203	1.770763	1.12824	3.014037	5
0.745193	1.490097	3.379798	2.22975	2.245205	1.51202	1.55745	4
1.378298	2.662703	1.85831	1.981788	1.283554	1.282433	1.512774	1
1.884125	2.075508	2.16487	1.55485	2.294037	1.421776	2.021908	3
0.985738	2.323031	3.344249	2.186234	1.046613	1.139703	2.08681	4
1.339493	2.1716	2.640416	1.643363	1.890265	0.862075	2.452216	5
1.411204	1.768375	2.509155	2.071366	1.069819	1.270294	2.138543	5
1.603957	2.393124	4.600104	1.479665	0.3686	1.257599	1.671143	4
1.593894	1.808995	1.276598	2.542793	2.668689	1.234447	3.011351	5
0.437205	2.05325	2.233585	2.342777	2.863301	0.989024	3.132892	5
1.796248	1.921808	4.253712	0.987076	2.703099	0.264328	0.99685	3
1.637491	2.60536	2.78299	3.176663	3.185908	0.945942	1.681183	1

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024



2.397302	1.887024	1.91816	2.197268	2.581808	1.771002	2.369984	5
2.328269	2.27798	2.125474	3.005204	0.099046	1.713398	1.026657	2
0.11416	2.396599	2.853036	3.178833	1.031306	1.899937	0.55292	4
0.646272	2.409414	3.949841	1.627033	1.13211	1.385222	1.246331	4
1.819873	2.572002	1.843449	1.60919	3.013846	0.301808	1.919204	3
2.893933	1.199162	2.164442	2.545358	2.839459	1.856562	2.979892	5
1.657387	-0.04104	2.817115	2.885721	2.252117	2.258384	3.244889	5
3.223918	1.104266	2.818893	1.829432	1.385741	2.348728	3.350843	5
1.567883	1.69097	2.678636	3.576635	1.69927	2.373808	1.665361	5
1.444466	2.164448	3.129106	2.105301	1.025459	3.286115	2.679373	5
0.789237	2.751414	4.503448	2.279741	0.594937	1.47052	1.258745	4
1.32103	1.739759	2.91269	1.970637	1.670966	2.325363	1.734543	5
1.417863	1.565313	2.942052	2.716931	2.031696	2.665588	1.504992	5
0.105744	2.701506	3.935611	3.081274	0.140042	2.612532	1.21387	4
0.093926	1.328851	3.657152	2.021215	2.748042	1.799659	2.503177	5
2.058253	1.409092	3.385514	1.720862	1.359984	2.940476	2.368557	5
0.610951	2.617612	2.618744	2.959006	1.079474	1.703607	0.602328	2
1.620419	1.452286	3.220025	2.04852	1.620619	2.70717	2.011157	5
1.26425	2.492492	2.254208	3.149003	0.20461	2.680442	0.963521	2
0.931603	0.778784	3.816232	2.411449	1.588901	1.749691	2.903384	5
1.883671	1.958262	2.662179	2.06722	1.593241	2.260557	1.932458	5
1.616866	1.148898	3.165864	2.700711	2.133769	2.779107	2.060409	5
1.96896	1.173538	3.408077	1.916709	1.627131	2.562472	2.227437	5
0.775019	3.539821	1.948109	1.474039	1.512137	2.192336	0.356982	1
-0.48434	2.801792	3.341801	1.253899	2.23096	2.792869	3.211511	1
1.735924	3.692729	4.176931	0.871424	2.20432	-0.09871	1.803309	3
2.436967	2.242692	2.95653	2.42781	1.861757	1.764807	2.614867	5
1.658166	2.250213	2.272366	3.709927	2.741535	2.928559	1.376769	1
1.333809	3.28714	1.923658	2.704404	1.874826	2.942094	1.95615	1
0.304445	2.431619	3.242846	1.164343	2.616041	2.179615	2.512263	1
1.093769	2.70846	3.188444	1.452049	2.704276	2.837869	3.558715	1
0.979075	2.932777	2.236762	1.834613	3.024493	1.92344	3.156133	1
1.504879	2.118966	1.74156	1.487179	3.392883	2.680421	2.117358	1
0.235742	1.514871	2.640203	4.244476	1.9561	1.274938	3.144923	5
0.721346	2.624908	2.503404	1.783081	2.070988	2.354757	2.050832	1
1.511873	1.611845	2.686757	2.24819	2.398428	0.857729	2.340673	5
1.483817	1.742122	2.38017	2.115277	2.46686	0.885315	2.411145	5
1.412824	2.023799	2.394205	2.244071	2.566338	1.066282	1.957895	5
0.96656	1.956889	2.503954	1.889427	2.584678	0.635303	2.486109	5
1.445583	1.659629	2.820313	2.291001	1.995405	1.615854	2.326673	5
1.264227	1.559251	2.530892	2.351941	2.005204	1.908408	2.08316	5
1.300572	1.506208	2.456656	2.476265	1.930084	1.826288	2.238183	5
1.395494	2.681821	2.399638	1.861954	1.670527	2.336857	1.348026	1
1.071372	1.64587	2.335144	2.049403	2.134302	1.103433	2.192995	5
0.972549	2.213103	2.453235	1.965736	1.820293	1.210596	1.269824	1
1.492335	1.795098	2.306659	1.928596	2.03471	1.206811	2.336041	5
0.290952	2.170553	2.27139	3.121171	1.858355	1.795948	1.144805	1
1.575429	2.032213	2.465815	3.19347	1.550548	2.006904	0.837601	2
-0.28365	2.768528	2.892846	2.010788	3.199715	1.111858	1.784	1
1.699107	1.726334	2.98967	2.659644	1.172693	1.45147	1.176434	4
2.310326	1.084356	3.212852	0.991361	2.383933	1.0178	3.223335	5
0.538985	0.684544	2.87213	3.319863	0.471048	1.146485	3.037455	5
1.320483	0.370392	2.959414	2.893502	3.208969	0.487022	2.159851	5
0.632746	0.962392	3.786251	3.674781	1.636723	0.976119	0.43589	4
1.260572	1.114517	3.471529	3.147704	2.509499	0.784426	0.739571	4
1.81431	0.908937	3.437827	3.115334	1.089183	0.8543	1.536967	5
0.480491	1.603937	3.497161	3.171849	2.858567	1.045461	0.796103	4
2.448276	0.9507	3.11357	2.242604	2.513886	1.092078	1.001218	3
1.667621	0.720564	3.065787	2.789554	2.601914	1.00463	1.646084	5

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

1.36549	0.471031	3.670106	2.32908	2.812428	0.692981	2.377931	5
1.782831	0.668699	4.303075	2.950578	1.196954	1.473613	2.410163	5
1.779422	1.804898	2.372978	2.236031	1.796164	1.101095	2.408556	5
0.752197	1.221928	3.601867	1.913002	2.917384	0.485048	2.184378	5
1.090207	0.371767	3.657906	3.103313	2.695586	1.088557	2.130409	5
1.449626	1.446819	4.565353	2.201232	1.589811	1.28579	1.45593	4
1.538993	0.432944	3.880188	2.973588	2.369882	1.22025	3.079243	5
1.267368	0.956728	3.771335	2.573059	2.060642	1.354038	2.111837	5
0.812903	2.100727	2.003404	2.841437	1.176845	4.042103	2.308406	1
-0.12421	2.607063	2.9329	2.202843	1.640928	2.10373	2.387402	1
0.542068	2.551937	3.744826	2.376175	0.753738	3.505419	2.13489	4
0.372456	3.354352	3.712648	1.479283	0.715589	1.445332	0.635211	4
0.305215	2.289783	4.46517	2.340381	1.999469	2.164077	1.869376	4
2.755486	3.573517	3.853695	1.941299	2.051228	1.450862	2.118203	3
1.626729	2.778755	1.826495	3.451388	1.873129	3.158793	0.826211	2
0.076946	1.646119	2.222775	2.737351	1.203729	2.5871	4.468302	5
1.013232	2.162299	3.088201	2.495127	1.321445	0.938687	1.910282	4
1.20519	-0.07545	2.885382	1.956822	2.266986	2.416183	3.019212	5
1.39817	1.852987	3.197305	2.136321	1.394049	0.442642	2.051922	4
0.873249	2.555248	2.54208	2.041056	2.167741	0.808359	1.213751	1
0.806786	1.256641	3.512638	2.772089	1.439192	2.428634	3.160887	5
0.026556	1.299047	2.254734	2.758667	2.102032	2.059072	2.925602	5
-0.37456	1.577272	2.356102	3.532591	1.521418	2.161338	1.712706	1
0.294225	1.883966	2.915752	2.171537	1.986679	0.595522	1.150333	4
1.332085	0.698822	2.722347	3.810148	1.240012	1.953593	2.289551	5
1.531207	1.639334	2.208954	2.580159	1.424991	1.388167	2.864206	5
0.649526	1.983378	3.004372	2.763197	0.644957	1.465754	1.641154	4
1.062165	1.703427	4.137153	3.523577	-0.25471	0.274785	2.414101	4
1.613615	1.567968	2.01006	2.909649	1.084012	1.64672	3.082602	5
2.611317	1.360381	2.572052	3.842697	2.318571	1.267588	1.442266	5
0.244814	0.983054	2.619721	3.328562	3.670014	1.220171	3.959349	5
0.212633	1.470245	3.736618	2.26854	3.534922	1.163535	2.752749	5
0.210494	2.000189	3.356024	2.1878	2.134824	1.09907	3.104368	5
1.926494	2.720868	1.743791	1.398287	2.173038	3.352568	2.561924	1
1.072198	3.31218	4.423606	0.480775	1.247225	1.562622	3.173473	4
1.357499	2.189561	2.255633	3.35382	1.874947	3.258765	3.437023	5
1.497423	1.962183	2.210324	1.454927	2.617754	2.249815	2.748368	5
1.704547	1.358564	2.589937	2.18018	2.343222	1.467078	3.609101	5
1.339563	2.526236	2.490679	1.016699	2.780961	2.661584	2.361953	1
2.328581	2.394616	2.552002	1.14282	2.842293	0.484683	4.308226	5
1.85317	1.934251	3.869415	0.499016	2.363052	1.674276	1.029997	3
1.45469	2.190708	3.760847	1.722148	1.768372	3.116628	3.478788	5
3.470967	3.439438	3.360445	0.721942	-0.20575	-0.06164	0.009922	3
1.296298	2.090994	1.963986	3.324418	1.359161	1.950194	4.18974	5
0.814951	2.698575	2.986318	0.932067	2.782515	1.42676	0.998865	1
0.701812	2.816236	4.503632	3.118434	1.809571	2.136325	1.220668	4
-0.10962	4.748057	1.311358	3.02705	1.085849	3.705541	2.662043	1
1.458165	3.619007	2.461477	1.602822	1.411744	2.264779	2.547659	1
0.800917	4.262438	2.544643	2.894222	0.613533	3.956862	1.671726	2
0.717591	4.02109	1.879332	2.441721	1.49057	2.877834	0.429284	2
0.643691	3.855714	1.005858	3.175629	0.103246	3.558945	0.795806	2
0.460533	3.698006	2.572437	2.387381	2.850441	2.808884	3.094858	1
4.04329	2.578201	0.799226	1.244423	1.632081	1.311067	1.735986	3
1.774165	4.058947	4.405546	1.785724	2.283782	0.758058	0.79129	3
2.724334	4.789961	1.917886	3.663023	0.860011	2.905804	-0.22034	2
1.890045	3.070056	2.121002	2.630324	1.471761	1.45338	1.399154	2
1.179053	2.241616	2.464325	1.743874	2.39835	0.483349	2.739105	5
0.910327	1.109921	3.392557	1.840023	3.649984	0.230089	2.727363	5
-0.76467	2.630535	4.08284	1.372603	1.512798	2.614801	1.87896	4

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

0.018361	2.910309	2.608297	1.602254	2.228515	-0.1038	2.327382	4
2.31223	2.140411	3.730239	2.46278	1.824992	1.428426	2.476548	3
2.000375	2.189982	3.724534	2.161509	1.635054	1.57342	0.200782	3
3.566437	0.913912	4.240227	1.9238	2.017575	2.399885	0.391107	3
1.62852	1.018615	3.425307	2.069394	2.752738	2.893608	1.471069	5
2.456128	1.924375	4.611679	1.543373	2.675139	1.215867	0.819487	3
2.955322	1.138264	3.747873	1.707216	2.573102	0.483788	0.805569	3
2.62885	1.755127	3.044607	2.3257	3.162495	2.415337	1.155672	3
2.310367	1.524535	3.543808	2.150572	2.369389	2.057397	0.899822	3
2.827557	1.951977	3.069947	1.919696	2.682531	1.73087	1.301477	3
2.354338	1.852527	4.186875	2.762147	2.727398	1.526546	1.348267	3
3.133866	1.126868	3.578091	2.250377	2.22218	0.989612	2.052883	3
3.902417	1.344091	2.9635	2.392058	2.238225	1.139263	1.925944	3
4.044799	2.560889	2.663006	2.169593	0.901192	1.77012	1.96679	3
4.155056	3.609037	2.424906	2.437343	0.670008	2.751403	1.023351	2
3.229569	3.060956	1.07279	2.674057	0.661189	2.715768	2.115442	2
2.921269	3.279488	2.066332	2.23657	1.842327	2.123827	1.809801	3
3.044779	4.07456	3.89887	1.460329	1.288036	0.384507	1.178261	3
2.740083	1.644629	2.55435	3.62446	1.955832	2.066756	0.815177	2
3.672096	3.42332	1.365735	3.932623	0.190274	3.855517	0.758265	2
3.179953	3.568001	2.620359	2.696917	-0.87467	3.369777	0.541363	2
2.519518	3.268074	3.607177	2.930387	1.07823	3.237732	2.437606	2
2.225039	3.775535	1.123748	3.689868	1.819697	3.939923	2.586388	2
3.709609	3.536046	2.146801	3.13129	1.525033	3.051844	1.077151	2
3.922836	3.537094	2.352621	3.817752	0.344085	3.99746	1.601192	2
2.559641	4.363924	3.081225	3.940225	1.04974	4.147581	1.955423	2
2.506535	3.511332	2.686218	2.671171	0.351229	3.135231	1.534423	2
3.611068	4.140873	2.759899	3.567679	0.327898	3.496142	1.915584	2
5.041109	4.030347	2.811553	1.898102	0.623562	2.481326	0.318056	3
3.987555	3.862457	2.73161	2.815862	0.253199	2.530565	0.116675	2
3.206587	3.376827	1.547706	3.04708	0.941526	3.026795	1.442369	2
2.687183	3.33638	2.737193	3.16023	0.407868	1.803257	1.018576	2
4.22479	4.024705	2.715407	2.974781	0.622469	2.100873	0.07855	2
3.485571	4.124516	1.799485	1.550554	0.865302	2.835845	0.512219	2
3.689093	2.992012	2.750544	2.126705	0.951029	1.841686	1.154485	3
1.507022	1.700048	3.643006	1.920586	1.721019	1.670477	0.88364	4
2.276998	1.872161	3.071937	1.551547	1.758093	1.456656	3.036033	5
1.722543	1.742988	3.195897	1.77644	1.623838	1.707611	1.691541	3
2.065441	1.855082	2.560649	1.429018	1.677676	1.63554	1.462513	3
1.74568	2.356083	3.455882	1.940336	1.498636	1.462326	1.919923	3
0.158772	2.513544	4.247838	2.551583	1.045512	1.299605	1.587535	4
1.80119	2.071641	4.041234	1.902576	1.296598	1.057213	0.731661	4
2.215429	2.553712	3.092798	1.870086	2.016486	1.713556	1.211197	3
2.561767	1.359762	3.215666	1.723347	2.649111	1.506876	1.212116	3
2.008407	2.326931	2.699744	1.797094	2.059043	1.621615	1.595778	3
2.063938	2.29876	3.576087	1.683763	1.536197	1.5092	1.604547	3
1.870314	3.05033	2.832324	1.120539	1.534361	0.937647	1.53327	3
1.545386	2.699153	2.90158	1.987278	1.572393	0.979358	2.326712	3
1.459833	2.793298	2.536495	1.525111	1.671519	1.382715	1.130589	3
2.883239	1.229672	3.978406	2.649253	1.311891	0.28695	1.875801	3
3.555512	0.756289	4.859439	2.591224	-0.00136	1.007842	1.233879	3
0.508175	3.178791	4.788698	1.290105	-0.27008	1.16648	1.256636	4
-0.43375	2.490532	4.749263	2.352686	-0.37615	2.187117	0.105813	4
3.964904	4.089137	4.415442	3.244999	-1.16908	1.236213	-0.05455	2
2.359152	2.995853	2.391476	2.378635	0.185879	0.813561	0.190325	2
1.015333	3.244709	3.91884	1.170988	-0.83935	0.70902	1.389022	4
-0.1317	3.371376	2.410057	3.437201	0.297436	2.487018	0.199548	2
1.47955	1.064245	4.922544	1.301369	0.974274	2.158269	1.332632	4
1.137828	1.970334	4.54537	1.77048	0.962424	1.676055	0.879076	4

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

1.978596	2.050605	4.222893	1.545038	2.620691	1.180971	2.380491	3
1.621695	1.681869	2.94142	2.467838	-0.34802	1.869441	0.368981	2
1.218523	1.811689	4.994002	2.11	-0.69899	2.880036	1.550563	4
2.064395	1.173791	3.932134	2.708803	1.250605	1.115845	0.557882	4
0.532071	1.356335	3.948873	2.254287	2.468433	1.466865	1.992075	4
1.429912	3.253482	2.093267	3.097008	2.026439	2.325492	1.059837	1
1.462999	2.915668	2.516664	3.674496	3.004662	1.589824	0.748062	1
0.733537	2.892451	2.643295	3.09355	3.151582	1.65196	1.337782	1
0.791875	2.884693	2.779237	3.413417	2.44907	2.601256	1.424172	1
-0.10517	3.040316	3.360112	2.855718	2.873678	1.188593	0.322964	1
0.875719	2.924053	3.610616	2.741726	2.132826	1.585964	0.493479	4
2.176518	4.067647	1.934115	2.559868	2.254118	2.083677	1.380008	1
-0.17358	3.503438	2.423085	3.051185	2.147663	1.953754	2.706169	1
1.679471	2.53749	2.705387	2.011349	3.219434	1.704823	2.592947	5
-0.62134	3.307752	3.073545	2.275577	1.186566	2.329074	1.121935	1
-0.58953	4.10793	2.459029	3.07827	1.627415	1.960017	0.474559	1
-0.4566	3.748106	2.48163	1.703436	2.031344	2.439934	2.085523	1
-0.40305	4.629888	1.803605	2.719529	0.109098	2.449213	0.376085	2
-0.13362	3.298538	2.094871	2.657361	2.068097	2.119957	1.46328	1
1.051681	3.044125	1.860595	2.414682	1.750706	2.127842	0.624443	1
-0.46756	3.672684	2.609306	2.798242	2.727397	2.08414	1.927971	1
-0.22257	3.403974	3.992026	1.594233	0.951226	1.79945	1.564202	4
0.879599	2.559537	2.682985	2.436528	1.732751	1.685048	0.478358	1
2.068797	4.083433	2.641366	3.421411	2.299622	2.077696	0.331541	2
3.216228	3.0991	2.141928	3.095791	1.858518	2.550298	0.088065	2
3.29187	3.301854	1.867055	2.807832	2.601268	1.726811	0.402809	3
3.144054	3.6932	1.424622	1.494059	2.486708	2.370872	0.574533	3
2.457114	2.686718	2.077536	2.537355	2.735416	1.764817	0.329161	3
1.390182	3.449505	1.922259	2.738923	2.591671	0.9854	1.00846	1
2.120156	2.579095	2.882224	2.725341	2.006488	1.055209	0.117931	3
1.970891	3.700663	1.468186	1.396667	1.40279	2.8171	2.009906	1
2.336216	3.764322	2.473572	2.329863	2.576363	1.084098	1.365232	3
-0.10381	3.389959	2.547536	3.543453	2.283116	2.61914	1.589867	1
1.530012	3.427078	3.194501	2.701941	1.67882	0.968439	1.025129	4
0.857718	3.392356	0.472536	3.279675	2.230862	2.233642	1.218844	1
1.505968	2.621823	1.743091	2.215408	1.95822	2.639966	2.912557	1
0.725015	3.984839	1.182635	3.701695	1.594431	2.084002	1.741048	1
1.473229	3.459439	1.638031	3.406329	1.333691	1.702277	0.560334	2
1.060838	4.181436	2.247993	3.323963	1.172574	1.898132	0.339313	2
2.990401	2.281804	3.070215	3.687298	-0.31184	1.27937	0.285347	2
0.769166	3.840194	2.731756	3.841705	1.747542	2.137993	1.252245	1
0.75415	3.558579	3.263125	2.647108	1.429326	2.333785	1.492619	1
1.303379	3.795161	1.530871	3.377136	2.072449	1.99248	1.083788	1
0.524407	3.859915	0.853766	3.074975	2.435645	3.317072	2.826819	1
0.12645	3.785307	2.629406	3.674972	1.265829	3.524083	1.271341	2
0.343963	3.983414	2.502811	1.906588	1.645706	0.417935	0.845107	1
1.710316	3.076969	2.060937	1.610017	1.059669	2.128205	0.703361	2
0.417446	3.648473	1.424328	3.711073	2.197958	3.114104	3.181453	1
2.04927	3.750571	1.462268	2.262071	2.189925	2.108657	0.792803	1
0.69803	2.205002	2.111445	2.568238	1.649992	2.488567	2.237445	1
0.951935	2.583197	3.095091	1.735256	2.707042	2.199157	0.645377	1
1.068594	2.818606	1.152625	2.573538	1.774493	3.034217	1.334008	1
1.308397	2.569901	3.080408	2.525086	2.007064	1.700561	0.976378	1
1.712708	2.433669	2.691373	2.580652	1.52399	1.378826	1.194658	3
0.91916	2.37196	2.775352	2.330603	1.599222	2.702074	0.89072	1
0.817149	3.12306	2.784622	2.661203	1.768797	1.560057	1.036902	1
0.791967	2.595179	1.847499	3.263682	2.414274	2.375985	1.818882	1
0.849967	2.071186	2.320527	2.101878	1.589166	3.016033	2.319835	1
1.60647	1.993996	2.891402	2.562998	2.438122	2.625546	1.083263	1

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

0.942826	2.975032	2.008094	2.730432	1.613834	2.493358	0.169133	2
1.07511	2.919006	2.379194	3.328983	1.773508	2.139629	0.766729	2
1.325045	2.690406	2.595724	1.726559	2.106144	2.474342	0.974182	1
1.411178	2.448139	2.713626	1.825376	2.091093	2.512333	0.987373	1
1.433908	3.131516	2.788815	2.250392	0.990708	2.570261	0.605752	2
0.880346	2.425598	2.678058	1.88785	2.024216	2.640519	1.366953	1
0.260364	2.906487	2.683074	2.969851	2.87145	1.602331	0.491496	1
0.423654	3.974504	2.400218	2.156817	1.89691	1.267873	0.473422	1
0.427651	3.447316	3.1171	2.700789	0.708482	1.333679	0.149171	4
0.579635	3.585689	2.21721	2.667774	2.940801	2.46273	0.537045	1
-0.02029	3.840243	2.522009	2.530284	1.500204	2.86294	0.081363	1
-0.06372	4.230166	3.597157	1.843047	0.983072	1.515249	-0.07676	4
-0.26029	3.873231	3.083164	2.437457	1.954143	1.404252	0.414916	1
-0.09942	2.776442	2.750918	2.707537	3.145203	1.570567	0.377695	1
0.275255	2.768954	4.02854	3.181462	2.991128	2.109993	1.402953	1
0.113402	2.605435	3.763227	2.119889	2.826393	0.865589	0.907433	4
0.149213	2.508363	3.846134	2.298856	2.899768	0.618085	1.543748	4
0.340557	2.541882	3.976928	2.681444	2.89268	1.145417	2.776941	5
-0.22202	2.844312	3.663467	3.049983	2.78542	0.617824	1.919961	4
-0.42178	2.192275	3.690923	2.891726	2.728776	1.202586	1.759638	4
0.457553	2.492178	3.576297	2.309842	2.744103	1.488316	0.765272	4
-0.07661	2.609934	2.688168	3.119072	3.314492	1.011728	2.009197	1
-0.30624	2.770384	3.647785	2.925661	2.651414	1.323014	1.751405	4
0.140752	2.594201	3.258795	3.069871	3.47017	0.903461	0.651931	1
1.494952	2.999964	2.300849	1.995311	1.425531	2.775196	1.773108	1
1.41039	2.949323	2.387595	1.69254	2.185164	2.487053	1.731274	1
1.118924	2.488969	3.415318	2.801899	2.178712	2.20894	1.709332	1
0.680572	3.258869	2.936039	1.918446	2.464094	2.07186	1.309618	1
1.141929	3.06936	2.624611	2.402971	2.363638	2.640456	1.426466	1
0.746483	3.534708	3.054122	2.286824	2.79205	2.205442	1.267024	1
1.011091	3.031657	2.571288	2.223547	2.575557	2.478644	1.656454	1
1.40917	2.33553	2.061849	1.689985	1.99935	1.701782	1.404149	1
0.768691	3.058953	2.917657	1.717871	2.803346	1.933463	1.826406	1
0.623259	3.10424	3.355942	1.998985	2.639103	2.307023	1.329493	1
1.357966	3.236041	1.628006	1.779124	2.009948	2.126546	2.923375	1
2.07341	2.95349	2.752977	0.969581	1.431418	1.74605	0.802422	3
0.792031	2.649246	3.21402	2.835091	2.391127	1.799076	1.483771	1
0.858457	3.130532	3.015193	2.654074	2.640759	1.527418	0.322885	1
0.80738	2.732501	1.65259	2.665072	1.627335	2.728416	2.013305	1
2.121461	3.110723	1.16904	2.698361	2.430201	1.879455	2.229385	1
1.359222	3.174655	1.435069	2.530789	2.244504	2.450394	2.122023	1
0.801118	3.074178	2.997585	3.838252	1.685823	1.335476	0.356832	2
0.080879	2.361793	4.274073	3.686526	2.221517	1.268115	0.479096	4
-0.17235	2.88178	4.48302	3.728202	1.719875	1.135475	0.350021	4
1.761006	2.297744	2.459649	3.053792	1.618949	1.878463	0.104232	2
0.216599	2.173008	3.770535	2.930397	2.304761	1.358994	0.372433	4
0.269085	2.048156	4.424645	2.43455	2.333657	0.970885	0.469465	4
0.065369	2.640117	2.597345	2.581476	2.209659	2.753815	1.558239	1
0.345163	2.569093	3.249664	3.07534	2.493951	1.078831	0.499263	4
0.052513	2.518404	3.110811	3.134081	3.319594	0.871954	0.68042	1
0.30771	3.104776	3.560694	3.132041	2.383767	0.800719	0.482138	4
1.154284	3.557102	1.593781	2.129454	2.591031	2.608611	1.732789	1
3.548581	3.065902	3.364989	2.870269	-0.19792	0.576981	0.807048	3
1.265666	2.865337	3.30641	1.610438	0.737536	0.923749	1.090937	4
1.399631	3.450565	3.602698	2.993068	1.321121	3.436824	2.859307	2
2.071889	4.124985	2.273219	3.721401	1.332661	2.351524	0.687626	2
0.876012	3.10726	5.157052	2.502289	1.431415	0.674595	1.330972	4
2.349308	2.583863	1.776008	3.662912	2.041628	1.749898	2.531925	5
2.636519	2.334488	2.925445	2.995422	2.243155	2.308253	1.318905	3

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024



2.987487	2.852596	2.434173	2.467237	1.838249	2.755136	1.358205	2
0.81905	1.825397	3.348165	4.522798	1.350309	1.59561	1.848665	5
1.774038	2.862877	2.685874	2.435596	2.107649	1.280506	0.910797	3
2.471096	2.604342	2.691034	2.817636	1.91936	2.006992	1.160133	3
3.060003	2.389687	3.987338	3.677606	1.309749	0.365417	0.614433	3
3.262966	3.396536	4.41932	0.726091	2.244941	0.726714	0.128801	3
2.494411	3.012345	4.550361	1.22457	1.950454	1.090167	0.322092	3
2.079433	2.14239	3.469334	1.070271	2.489137	1.932302	0.438562	3
2.268403	1.873654	4.282994	1.313821	1.418581	2.464574	0.276199	3
3.08802	1.748826	4.565023	-0.33519	2.055988	2.092309	0.217988	3
2.777448	1.078595	4.10723	2.455113	1.397793	2.134951	0.741937	3
3.102757	1.592921	3.055213	1.054164	2.005069	1.878598	0.214148	3
3.479759	1.33687	3.174094	1.2196	2.175686	2.51985	-0.06827	3
0.623457	2.841408	1.295385	3.855206	2.838636	3.356909	2.354045	1
1.847572	3.354191	3.861348	3.103105	0.405502	2.467452	1.557334	2
2.32006	2.266582	2.220428	2.264085	0.940936	1.327739	1.041959	3
2.959903	2.952272	3.331057	3.012319	0.19202	1.653348	0.098445	2
1.703666	4.825642	2.81377	-0.18771	1.279538	0.122421	0.405711	3
0.475181	2.03538	3.124756	3.793217	2.522743	3.14862	3.03574	5
2.204704	4.680761	3.398592	-0.06387	1.459862	0.056371	0.729264	3
2.002607	2.755353	3.376209	0.036351	1.407113	0.555023	2.247859	3
0.907119	1.708706	4.912416	2.140988	1.922985	2.28953	1.116472	4
1.825809	2.128214	4.741464	0.159796	1.636236	2.063124	0.352333	3
0.153648	2.889437	2.800667	0.352795	2.08095	2.082555	1.234468	1
0.587994	3.861874	2.269366	1.68284	1.605637	1.89417	0.802835	1
1.024508	3.664618	2.874202	0.661802	1.556209	1.204374	0.130695	3
0.283041	3.817617	2.288075	1.913851	1.877978	1.808863	1.815715	1
0.311823	3.273917	2.51415	3.816218	1.458316	2.762033	2.043699	1
0.718942	4.25634	4.459668	2.072599	1.638075	0.100716	1.716839	4
0.008545	2.195237	3.234108	2.99666	2.548574	1.681762	2.171549	1
-0.471133	4.246083	1.528641	2.336485	0.732913	3.646783	-0.41321	2
1.077048	4.530622	3.141172	1.851634	0.845131	1.322201	-0.08585	2
1.705065	3.239689	4.050878	1.401745	0.04819	0.238856	0.758254	4
2.025447	3.033307	2.675933	2.113983	1.52901	0.942658	2.129124	3
0.244751	4.092002	3.424906	1.330836	2.236125	0.876376	0.474374	4
0.151119	2.98758	3.568751	1.451563	1.656526	1.805595	1.468168	4
-0.24368	2.750309	3.5265	1.860395	1.715834	0.987104	1.895436	4
2.648074	3.621529	3.486606	2.933279	0.373718	2.709986	-0.22809	2
2.066586	3.066316	3.580333	2.246909	1.180946	1.055538	0.656804	3
1.944425	1.998555	3.567294	2.594938	1.536046	2.975502	0.613735	2
1.121274	2.724664	2.638417	2.486761	2.431015	2.384841	1.565011	1
2.850815	1.654452	3.992092	2.263066	2.418238	1.276869	1.221492	3
0.684173	2.59755	4.093945	1.046064	3.083327	0.362483	1.38296	4
0.174206	3.493588	3.316332	1.816635	2.951768	0.969128	0.733653	1
1.860815	1.680196	2.476973	1.941281	1.753742	1.344025	1.426395	3
1.752092	2.024168	2.66644	1.898802	1.6596	1.209577	1.477241	3
1.321311	2.063387	2.163432	2.908879	1.330973	1.88362	2.361532	5
1.647948	2.270076	1.86041	1.867999	1.454386	1.969179	2.568774	5
1.325019	2.361829	1.478412	2.266887	1.764518	2.642484	1.702186	1
1.088055	2.85659	2.246922	2.880238	1.555623	1.051089	1.817443	1
1.062752	2.864692	2.06805	2.854408	1.648133	1.414439	1.940907	1
1.898748	2.937805	2.14582	2.108399	1.533958	0.926171	1.734107	3
1.164505	3.039528	2.132053	2.855484	1.416871	1.0435	2.152127	1
1.217726	2.459069	2.369937	2.894859	1.596448	1.29165	1.294127	1
1.205169	2.99523	2.238958	2.69529	1.1099	1.645469	0.920897	2
2.247636	1.559871	2.359851	2.345988	0.75245	2.326831	2.011774	2
0.515809	3.209018	2.974778	0.088037	0.354395	2.184264	0.377669	4
2.664913	2.258446	2.453266	2.835131	0.94236	1.093029	1.450462	3
2.332702	2.904314	2.102263	3.80914	4.423846	2.545838	2.19781	1

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

0.858277	2.789032	2.675953	3.975471	2.940192	3.199923	1.756495	1
0.135326	3.130819	1.787072	3.322858	3.569177	3.067827	1.901571	1
0.210271	2.715819	3.337833	3.945324	2.118081	3.089931	2.290278	1
-0.10692	3.305084	3.883783	3.738765	2.271649	1.095572	2.372052	4
2.940514	2.045527	1.655645	3.337987	2.325931	1.995342	2.523698	5
0.017031	3.471114	2.781549	3.449273	3.063424	1.982684	2.810396	1
0.217045	3.102494	2.257095	3.712236	3.227408	2.424947	2.706707	1
1.168394	3.158382	2.397039	2.875788	3.195214	1.667232	2.237079	1
2.166365	2.328856	3.406558	3.882285	2.341709	1.610299	1.985158	5
1.207266	3.701287	3.536277	2.471503	2.445392	1.455107	1.94385	1
0.350961	3.216452	3.756608	3.369897	2.633468	1.71541	1.968044	1
2.142924	3.021736	4.265552	2.12064	0.265916	2.962148	1.455148	2
0.33667	1.944071	2.455792	1.119593	2.806737	2.954146	1.19752	1
-0.37456	4.684672	1.857995	2.673432	2.43409	1.675507	0.615034	1
-0.45765	2.951242	3.57413	2.673064	2.310049	1.494068	1.204785	4
2.241543	3.295219	1.761795	-0.46674	2.062207	0.658954	3.085202	3
2.274352	3.904877	0.965383	1.090103	2.177539	1.008027	1.615303	3
0.542086	1.246405	4.771957	2.932708	1.626256	0.35913	2.19558	4
1.405164	4.017422	2.502021	2.645762	2.199201	0.974838	1.105484	1
1.596445	2.820486	2.350912	1.453811	3.042025	1.647329	1.921859	1
-0.10552	2.818759	2.971996	3.080708	1.907297	0.083147	0.823936	4
-0.32487	3.260904	3.534991	2.253789	0.849691	0.516675	1.967281	4
-0.1682	2.358753	3.087227	0.986124	3.435746	2.779199	2.729604	1
2.247645	4.286214	0.019446	3.584856	2.068911	1.866873	0.807345	2
0.47302	1.446077	0.663542	3.750715	1.414859	3.605458	1.93925	1
-0.59701	1.675585	3.925224	1.716529	2.459564	3.219338	0.880136	4
0.861698	3.040857	2.553108	1.336346	1.43595	1.136466	0.604058	4
0.957117	2.787028	3.658154	0.801289	-0.61602	1.330431	0.835537	4
0.124301	2.421105	2.705534	2.460809	1.797187	2.180488	1.753949	1
1.006473	1.997175	1.029746	2.796541	2.776268	0.984417	2.779216	5
0.366053	2.322168	4.060788	1.559525	1.519204	0.253499	2.169938	4
1.583427	3.27796	2.562148	1.507864	2.014645	0.852825	2.43981	3
0.751172	3.492416	4.487172	2.507872	1.848005	0.476099	2.176782	4
0.859564	2.121968	3.57061	2.07186	1.694885	2.381739	1.771004	4
1.150281	2.229375	3.993247	1.538726	1.713609	1.263208	2.984529	4
1.009329	2.523104	3.632711	1.751953	2.49709	0.747835	1.973844	4
0.800092	2.313618	1.947549	2.129778	2.779523	2.736547	1.287074	1
0.507842	2.126182	3.709382	2.025182	2.014483	2.499448	1.949562	4
1.707627	1.784648	3.412401	2.081609	1.543876	1.982379	2.252024	5
1.520279	2.053032	3.102355	2.341057	1.547812	1.045763	2.045449	5
2.051176	1.709775	3.481137	1.391418	1.709236	1.635493	3.759327	5
0.911119	1.734922	3.484695	1.986006	2.121027	3.065789	1.925379	1
1.401215	1.524107	2.979994	1.938822	2.037472	0.806494	2.666591	5
1.082589	1.594227	3.461005	1.861188	2.047426	1.824083	2.205309	5
0.782273	1.504928	3.980124	1.198786	2.167906	1.904642	2.458123	4
1.130089	1.618194	3.558431	1.84232	1.224004	2.513945	1.961609	4
0.777959	2.330444	4.134831	2.302482	1.573921	1.895572	1.789862	4
1.708766	1.298943	2.563442	2.053514	2.096883	1.721538	2.927518	5
1.154063	2.688875	2.425242	2.718147	2.253345	1.159137	1.198447	1
0.809999	1.599301	2.619081	2.243507	1.198234	2.379065	3.111126	5
1.98482	1.356919	3.401547	2.87027	2.888688	0.917695	1.559026	5
2.623055	0.067936	2.551413	1.795425	2.420002	0.685113	3.023309	5
0.104503	0.941991	2.736113	4.900371	2.223849	2.112671	1.511158	5
1.397307	0.341324	2.840602	2.29184	2.505188	0.169115	3.259495	5
1.270621	0.496461	2.746452	2.312243	3.044293	0.303743	3.174375	5
2.274565	0.005369	2.76484	2.662452	2.414838	0.887809	2.310469	5
0.086942	2.180963	2.659627	3.723745	-0.4808	2.794365	2.358254	2
2.554201	2.382038	2.613128	2.197507	2.622773	0.417857	2.937588	5
0.665437	-0.15309	3.013491	3.591409	2.397752	0.910813	3.196063	5

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

0.219131	0.988948	2.949241	2.832939	2.812933	1.931909	2.337423	5
0.08191	1.904748	2.697057	2.395814	2.909281	0.849056	1.816543	1
-0.5757	2.364009	3.812397	1.903619	2.952605	1.246934	2.699965	4
0.281395	2.412998	4.491506	1.717264	1.527465	0.20048	1.743169	4
-0.37792	0.853802	3.500635	4.447944	1.770293	2.376319	2.945239	5
1.43101	1.729342	2.285234	3.594539	2.158406	1.41163	2.35083	5
2.242448	0.452776	2.03011	2.175292	2.960922	0.892266	3.490946	5
0.772287	1.044562	4.099495	2.099755	2.303216	-0.07957	3.408013	5
1.687683	0.705034	3.483106	3.50241	0.084663	1.296573	1.360677	4
0.08152	2.497989	2.633608	2.102286	1.992036	2.405288	2.854927	1
0.564148	0.290457	1.858481	3.457962	2.040157	2.621054	4.093532	5
1.432265	2.214134	2.28557	2.447828	3.114609	1.697488	0.560871	1
1.22986	4.209676	4.152368	1.648818	2.4148	1.380472	3.982964	1
1.798733	2.321707	1.944999	2.484884	2.09713	2.497045	3.945049	5
1.548915	2.98621	2.419907	4.166224	1.884883	3.007174	1.354243	2
1.736698	2.102224	2.781879	2.624937	1.287076	1.154947	2.066471	5
1.841468	2.779364	2.014616	1.952026	1.864021	0.832871	2.831117	5
1.850788	3.557185	1.247119	2.762191	2.367131	2.073187	2.334656	1
1.988117	1.848378	1.617975	3.235807	3.561746	0.849005	3.282251	5
2.963195	1.875433	2.294584	2.090209	1.373802	0.773446	1.733781	3
1.280458	3.577684	3.18186	2.344035	3.374431	2.15427	2.751256	1
0.884161	5.784644	3.534264	1.819497	2.386301	3.77747	0.141682	1
0.074259	3.574523	1.619785	2.533091	0.988846	2.903029	2.823716	1
3.04004	2.314318	2.13163	1.6602	1.868691	0.651936	2.527277	3
2.717961	1.981777	1.938336	2.53088	2.20996	0.227048	1.92194	3
1.469363	2.818761	1.884582	2.648021	2.089939	2.410461	1.996118	1
2.709623	2.493832	1.025723	2.408424	3.062117	3.46406	1.106719	1
2.161146	1.174376	2.314965	2.254531	3.234909	1.291243	2.520153	5
2.287607	1.838934	1.818019	2.927362	2.361122	0.866097	2.034928	5
3.353594	3.559703	2.04658	2.406643	-0.54042	0.195315	0.023831	3
1.392493	2.078828	2.6005	1.897844	2.84124	0.383242	0.947499	3
1.725897	3.336555	1.507295	1.7479	3.54761	2.859758	2.606246	1
1.2252	3.287465	2.245327	2.208732	1.496208	2.975495	2.753529	1
1.518102	2.010543	2.173446	2.299928	2.45509	2.839368	2.859943	5
1.289588	3.386302	4.211413	2.154531	1.303094	0.481756	2.964039	4
1.012439	4.384014	3.35423	2.879892	0.911968	4.236695	1.938896	2
-0.18313	2.332953	2.817455	2.991674	1.413407	2.469997	1.751645	1
-0.50824	2.851968	3.078299	3.017893	1.511157	3.204069	1.452336	1
2.015306	1.892684	3.122085	2.005002	1.28295	1.431305	2.252795	3
1.810405	2.313179	2.719985	2.289299	1.433045	1.995691	2.279748	5
-0.36417	2.441534	4.741204	2.029903	2.179041	1.560313	1.344052	4
1.612228	3.39865	3.771511	2.523235	1.798751	1.338797	1.638589	4
0.498329	2.028352	3.80679	2.242893	1.021459	2.388737	1.175935	4
-0.18434	2.373169	3.690509	2.559589	2.106675	1.890076	2.149593	4
1.521238	2.119707	2.963294	1.800389	1.566119	1.958181	0.758386	3
3.747659	1.227065	2.861703	2.434098	1.443798	2.781314	2.597393	5
-0.4823	1.90793	3.373967	2.878178	2.004723	3.40478	2.332985	1
0.899904	4.377078	2.276759	2.487403	0.184471	1.761139	0.685288	2
1.801516	3.019131	3.060307	2.431625	1.409738	1.490599	0.428911	2
0.524149	2.633798	3.796815	1.644169	0.667038	1.265146	1.836087	4
2.832446	3.170785	1.759903	1.961723	1.444286	1.823112	1.105778	3
-0.07634	2.224685	3.774898	3.031975	-0.1915	1.917331	1.714644	4
-0.00896	3.683818	3.356392	2.308612	1.307789	3.677818	0.323892	2
1.756645	2.94947	3.107809	2.888338	0.822709	3.959166	1.271949	2
2.132132	2.038671	2.938456	2.077305	1.016538	1.692268	1.867374	3
2.027801	2.090666	3.044967	2.391921	1.466157	2.999378	1.451428	2
2.365434	0.881948	2.909211	2.874983	1.970898	2.364969	2.719813	5
1.951106	1.417047	3.499015	3.274452	1.057297	1.360355	2.54604	5
1.155816	1.648827	3.136144	3.231095	1.479935	2.61277	2.369647	5

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024



1.771195	1.978266	2.468392	2.849778	1.952468	2.637186	2.539566	5
2.175577	0.957878	1.749733	4.318935	2.408992	2.347051	3.083741	5
1.730574	1.460436	2.355927	2.801036	2.458172	2.805657	3.037723	5
1.625811	1.123879	2.555173	2.98834	1.932035	2.598875	3.107223	5
1.300338	1.27347	2.863889	2.670251	2.788495	2.009867	4.144211	5
1.058618	1.640886	3.14455	3.155436	1.597802	1.754571	2.858831	5
1.714292	1.198592	2.361832	3.655121	2.911294	2.190251	2.968629	5
1.240011	1.509991	2.984057	1.286569	2.708608	1.855332	3.967645	5
1.152672	1.764461	2.576472	2.889279	2.721701	1.695326	2.606245	5
1.255709	1.355849	2.521385	2.856854	2.597104	1.876426	3.207666	5
0.74156	1.575887	3.573962	3.438606	3.075308	2.406598	2.848083	5
1.487389	2.083264	1.877643	2.610233	2.580977	2.734694	3.221042	5
1.02402	0.666849	3.200515	3.967067	2.679366	2.374665	3.865079	5
0.904672	0.738232	2.490656	2.403095	2.3109	1.981781	2.503543	5
1.97023	1.764496	2.422681	3.936467	1.939548	2.512576	3.901476	5
2.676331	1.08356	3.41355	3.33541	0.698102	2.519931	3.287986	5
2.614462	4.775062	3.793557	-0.19917	-0.981	0.09312	1.252973	3
0.092529	2.213861	1.666891	3.141264	2.591698	3.012315	1.884515	1
0.62021	3.504931	2.630801	1.965301	1.737083	2.335864	1.035281	1
-0.10889	2.970387	2.077207	2.483217	2.67454	2.810844	2.125511	1
-0.28494	2.862408	4.948831	1.475156	1.273039	0.024325	2.188301	4
0.141229	1.826175	2.57906	3.825405	2.331338	2.178282	3.733651	5
-0.27393	1.798164	2.281096	1.096077	3.405163	2.22112	2.368599	1
1.889118	2.197416	2.662556	0.938291	1.45778	1.768633	1.850104	3
2.026809	1.43333	2.852578	2.062381	2.494402	2.510134	1.003418	3
0.4547	1.822873	1.642994	1.648994	2.465097	2.307406	2.260072	1
1.180574	1.979456	2.190599	0.638097	1.822171	1.684538	1.976499	1
-0.15376	2.113963	2.755861	2.31101	2.417009	2.151042	2.155638	1
2.937327	0.559019	3.293035	1.705683	1.755515	1.537882	2.362831	5
0.356661	2.212595	2.084012	1.942391	2.012923	1.77337	1.492639	1
1.257337	1.708001	1.806124	1.843787	2.280795	1.967791	2.486759	5
1.302175	2.292117	3.27532	2.309357	0.828285	1.952833	1.783675	4
1.714566	2.866174	2.614927	1.165569	2.346443	-0.46207	1.580056	3
2.336772	1.820066	2.107818	2.778122	2.028988	1.729201	2.644071	5
-0.531	1.905626	2.663749	4.288357	2.308736	3.089625	4.707173	5
1.955097	2.75595	1.720104	1.485425	2.439215	0.383829	2.150109	3
0.424371	2.775628	2.618747	3.105367	1.291942	1.385739	1.814535	1
2.682818	1.975018	3.091693	2.359624	2.077224	1.058987	2.189526	3
1.640291	2.201269	3.686279	2.493968	3.027828	0.383334	1.950114	5
1.962298	2.543239	1.478078	2.839681	0.880412	1.964117	2.524755	2
1.518659	3.192809	2.697412	1.905137	2.597932	-0.15954	2.23207	3
1.834275	1.687792	3.803747	2.399916	1.433644	0.562578	1.025609	4
1.540272	1.983626	2.956717	3.394021	1.800051	1.677738	0.662117	2
1.509981	2.642669	3.116794	1.549859	1.938711	1.855646	1.954819	3
2.134296	1.907773	2.690553	3.23495	1.495158	0.775124	1.619342	3
0.427512	2.987253	2.561937	2.27099	1.3845	2.114721	0.565118	1
1.466702	2.301835	2.37308	2.599048	2.254712	1.407731	1.813743	1
1.027552	1.923318	3.15668	3.298839	1.721175	1.344687	1.461926	4
2.925279	2.151205	3.252401	2.148987	1.787043	1.139834	1.406604	3
1.803615	0.897055	2.381724	4.027319	0.612286	2.102622	0.497539	2
0.501035	1.594727	3.748318	3.202126	2.717837	1.217422	2.0056	5
1.135913	2.46013	2.699918	2.040346	1.05604	2.40855	1.437545	2
1.47729	1.576555	2.766053	2.486893	3.088382	0.238345	2.288514	5
2.322109	1.8903	1.856853	3.043669	1.448824	1.854425	2.292022	5
0.943979	2.865445	2.334755	2.361299	1.84453	1.57974	1.455633	1
1.09441	2.61972	2.570202	2.266813	0.822919	1.006511	1.137528	4
1.446558	2.894173	3.720822	2.312959	2.573729	1.242164	1.410237	4
0.736881	2.07327	3.906554	3.063998	1.881051	1.369881	0.160261	4
0.665234	2.183043	2.941374	2.995214	1.14126	3.139709	0.670783	2

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

1.431209	2.102447	2.877089	3.272383	1.528063	1.667444	0.597345	2
0.48805	2.199462	2.791748	3.053477	1.218693	3.241743	0.81835	2
1.729035	2.60887	2.382874	2.946179	1.154216	2.539631	0.705188	2
0.923982	2.09841	3.134973	3.049035	1.577602	2.226752	0.562968	2
0.473393	1.823634	2.603832	3.244876	2.472785	2.388323	0.70335	1
0.643718	3.162341	2.628687	3.124583	0.697315	3.489079	0.444281	2
1.231598	1.489925	2.575601	2.956323	1.393692	3.056498	2.419777	5
0.885313	3.604693	2.334157	2.907145	1.783189	2.383189	0.473879	2
1.486663	2.382557	2.521454	3.405304	0.122165	2.458242	1.897779	2
1.305746	2.536706	2.503103	2.726279	1.370371	2.271897	0.760181	2
-0.12128	2.931554	2.985789	3.448854	2.373757	3.0748	0.750214	1
-0.3651	3.29011	2.870149	3.014172	0.790517	3.231845	1.216384	1
1.310901	2.905656	3.206514	2.745517	2.308938	2.328841	1.60868	1
0.8192	2.058696	3.311621	2.910875	2.063997	2.20247	1.529922	1
1.579844	2.31691	1.764519	2.700399	1.475303	3.338388	1.799588	2
1.650651	1.172353	2.25335	2.336537	1.40992	2.091142	1.840565	5
2.400323	0.610945	2.145213	1.814261	2.156261	2.594137	1.989301	5
1.337072	1.787411	2.435036	2.180727	1.476423	1.703351	2.390161	5
1.334314	3.493188	3.203095	0.739232	2.752471	1.577154	1.506409	3
2.395664	1.784892	2.990832	1.597801	3.454405	1.431834	2.221238	5
2.834376	1.372208	2.467716	1.487558	2.422688	2.178153	2.292664	5
1.271013	2.190323	2.02582	1.854061	2.466391	2.423069	2.725961	1
0.129491	1.944993	3.627968	1.689957	1.382203	2.063105	2.376668	4
0.915972	2.036587	2.390177	2.812893	1.865705	1.996444	1.482858	1
-0.29183	2.254987	2.829684	2.300647	0.747438	3.259114	1.744497	1
0.234823	3.984334	2.709338	3.583035	0.06296	3.288988	0.717452	2
-0.03279	1.956234	3.73337	2.42477	1.51287	1.496175	2.24365	4
-0.22374	3.954465	4.147648	3.000342	2.095893	1.375367	0.174058	4
4.446452	3.112146	3.834213	-0.56448	2.322335	0.081094	0.815274	3
0.254195	2.219487	2.347961	1.5985	2.939996	1.619148	2.003347	1
0.722066	1.84351	3.439109	3.028911	0.858413	2.820346	2.055325	4
-0.27786	1.621398	3.810628	3.493549	1.61931	2.388291	1.959439	4
1.95763	2.243665	2.419941	1.550256	2.339185	1.526504	0.87867	3
-0.17712	3.679931	2.027275	3.438949	1.227549	4.346655	0.565953	2
-0.52016	2.644474	4.985067	2.777575	2.129857	1.603163	1.322	4
0.139093	3.077551	3.155317	1.84699	1.544916	0.909727	2.255974	4
-0.29745	3.924371	3.427086	2.814315	-0.34252	2.52275	-0.12371	2
1.197751	1.139765	2.959802	3.724448	2.00368	1.870335	3.248781	5
-0.55263	2.850451	3.603637	2.159742	1.61182	3.131141	2.21753	1
-0.09923	3.147932	3.515215	1.300025	2.023952	0.341102	1.147187	4
1.482171	0.598118	4.524763	2.495524	1.920755	1.016522	1.752847	4
0.435803	0.030049	2.99525	5.212456	3.600696	2.278578	3.051625	5
0.896986	2.123555	1.956048	3.483763	3.273525	1.450855	1.995661	1
1.727307	1.314198	3.995778	4.880579	3.018966	2.337371	2.479633	5
1.007479	1.779471	4.011855	3.485044	1.019926	0.992437	0.427342	4
1.133501	3.612282	3.371249	4.166631	0.783912	2.980189	0.390786	2
0.447813	1.584168	4.595198	4.146647	1.49147	1.118816	2.154007	4
1.36141	0.164857	4.184602	4.615451	0.680796	2.828915	2.215485	5
0.237311	1.661926	4.718851	3.915297	1.538351	2.461316	0.972878	4
1.675214	2.703634	3.664126	1.781546	1.381758	1.584137	2.177306	4
-0.0933	4.003946	3.094488	2.609247	-0.45808	3.497689	1.265117	2
1.115991	1.93992	2.449696	2.209266	1.989389	2.600533	1.638723	1
0.565087	1.267156	1.971504	1.821961	2.941994	2.362466	1.948297	5
0.2899	2.425688	2.527741	1.688038	2.859624	1.102273	1.363903	1
0.012578	2.713523	2.772004	1.695502	2.556442	1.490683	1.172728	1
0.457526	2.242863	2.640553	1.38489	2.9747	1.112302	1.723175	1
0.269487	1.856392	2.378915	2.310383	2.23644	1.466357	2.292227	5
-0.30298	2.039958	2.487779	2.484312	2.889577	1.778061	2.620527	1
-0.059	2.329745	2.661882	1.800231	2.943895	0.849261	2.4205	1

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

3.234036	3.172942	2.152633	1.247851	1.830191	0.741028	1.367281	3
-0.14962	3.212166	2.838131	2.052148	0.76686	2.904901	0.926416	1
1.008297	3.605593	1.552424	2.545575	1.459873	2.458237	1.063863	1
0.069645	3.442147	2.503456	2.854764	2.551114	2.401892	1.840573	1
-0.19621	2.856654	2.546963	3.078251	1.409379	1.312913	2.43579	1
0.922144	3.392091	3.413087	1.786973	0.876997	1.979531	0.815435	4
0.439565	3.695894	3.233887	3.19461	-0.65113	2.981872	0.096498	2
0.463794	3.118323	2.945531	2.132446	0.692042	1.676786	1.832364	4
2.046115	1.860467	4.503206	1.44212	0.944814	0.960159	1.702708	4
0.822082	1.752166	3.96031	3.670542	0.432142	2.094926	1.835506	4
1.384499	1.676338	3.335121	2.344334	1.708029	1.973757	3.015226	5
2.913171	2.251743	3.828942	2.862465	3.506109	2.288636	0.682411	3
2.838667	1.587802	3.139398	2.455651	1.986433	1.559845	2.010168	3
1.984939	1.226032	3.974135	2.871381	1.764569	2.52817	2.269736	5
1.882535	0.965832	3.62802	2.424984	3.088003	2.571588	1.442444	5
2.834767	2.291731	2.914424	1.828595	2.676055	2.190016	0.904297	3
2.406044	2.421871	3.677239	1.100186	2.528083	1.850513	0.909268	3
3.333304	1.738452	3.145411	1.694157	2.436078	0.861111	2.058184	3
2.809199	2.201564	3.268227	2.439596	2.217548	2.20399	0.443276	3
3.232019	2.695417	3.21763	1.39774	1.641224	1.386497	0.029767	3
2.562955	1.649742	4.191257	1.75234	3.416616	0.008248	0.947485	3
2.653311	2.213077	2.654112	1.964367	0.998636	3.271016	3.047206	5
4.088227	3.519633	1.458443	1.578193	0.700923	2.177483	3.025567	3
1.621409	1.437943	3.781382	2.457539	0.583088	1.380606	1.395895	4
2.902669	2.219219	2.532083	1.780608	1.705037	1.497211	1.210752	3
3.005859	2.263617	5.64921	1.245774	-0.42109	0.680305	0.244186	3
2.362506	1.144091	2.361297	2.453162	2.143155	1.79232	2.288028	5
1.667598	2.06235	2.689261	2.022982	2.280881	1.219565	1.887121	5
1.808149	1.78866	4.051322	1.885426	2.158398	0.817292	1.620497	3
0.687603	3.206993	4.011132	3.315963	-0.20797	1.946517	1.362868	4
2.862084	2.377349	2.555443	3.876989	0.702746	2.024126	1.165072	2
0.710643	1.936612	2.900109	3.781125	2.51583	1.740071	2.016443	5
2.057296	3.589327	2.526465	2.853584	-0.28298	1.54849	0.178033	2
1.717724	3.312208	3.219567	3.832021	0.433151	1.332947	0.398813	2
1.784393	3.483958	1.901055	2.434483	0.562683	3.044089	0.828156	2
2.365971	2.201863	3.519977	1.583483	1.150986	1.335765	0.655795	3
4.319165	1.590442	3.087611	1.69606	0.770118	0.599462	1.282893	3
3.346217	1.09885	4.812988	1.455227	0.212139	1.128825	1.865715	3
3.530807	1.567584	4.504891	1.8653	0.940612	0.82131	0.77248	3
2.891285	1.89644	4.433179	2.19465	1.006817	1.09154	0.498398	3
1.928594	2.236547	4.683135	1.988054	0.544993	1.246763	0.558855	4
2.285322	2.125545	4.559235	2.288247	0.666203	1.084367	0.472938	4
1.89005	1.011516	5.266577	2.797959	0.412246	0.880222	0.483154	4
0.418664	1.731204	5.061108	3.2518	0.698308	3.020168	0.715598	4
1.367057	2.925187	4.655244	3.350586	-0.01201	3.470676	0.821254	2
2.309585	1.804595	2.978303	3.676435	0.676995	2.935604	1.066488	2
1.8683	1.609789	3.585674	3.410347	1.090116	2.76966	0.538212	2
1.582343	1.893786	4.194117	3.161633	1.008141	2.783293	0.669849	2
2.150257	2.572329	2.223382	1.867505	2.895349	1.994313	3.149671	5
2.438346	4.148842	2.612882	3.155902	0.171949	1.607915	2.041156	2
2.643976	3.492028	2.734121	3.093574	0.779863	2.711358	1.925412	2
2.855769	2.880836	1.739848	1.828785	2.194659	2.847119	1.926847	3
3.399597	3.245786	2.023543	2.512159	1.595768	2.089901	1.455838	3
2.737046	3.037004	0.67967	3.566229	1.882432	3.613259	1.022656	2
2.989004	3.050118	1.218374	2.338301	1.72523	2.930881	2.004095	2
3.730418	3.135985	1.6401	2.053811	1.028681	2.857294	2.173015	2
2.463663	0.859639	5.162668	0.886539	1.554102	0.509594	2.314751	3
2.946992	0.400476	4.639125	3.18962	1.353431	1.528145	2.900802	5
3.042424	4.105682	3.575925	0.706032	-0.75609	-0.13641	0.230446	3

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

2.253494	0.88575	4.05183	1.474706	3.073917	0.406476	3.763321	5
1.675898	2.724666	4.647242	2.097785	0.23467	0.574127	0.663669	4
2.582725	2.741702	4.9941	1.059533	1.35462	1.077715	1.16564	3
1.050035	2.210001	5.021932	3.464061	1.364692	0.340931	1.686686	4
1.561219	0.545155	4.069079	1.690497	3.179686	0.016492	3.553318	5
1.265462	3.092702	3.594905	2.829159	0.750077	3.152979	1.644279	2
1.074474	3.037171	4.680648	3.823089	0.788346	0.936433	0.868559	4
1.091429	3.677598	3.423406	2.745653	1.001984	2.498806	1.66485	2
2.720772	2.102133	3.405409	2.797069	0.364539	1.46441	1.087318	3
3.226577	1.922205	2.953435	1.647369	0.593546	2.083638	0.851123	3
2.96997	2.214062	3.505646	2.499191	0.846053	0.964966	1.384221	3
3.651752	1.742185	4.164508	2.691835	0.553888	1.162542	1.663439	3
1.774319	2.621301	3.839708	2.941738	1.179815	1.918955	1.74463	4
3.320918	1.48185	3.289602	2.379944	0.653762	1.801415	1.466398	3
2.604631	2.198748	3.566384	3.787496	0.095679	1.115488	1.241199	2
3.833065	2.359699	3.028004	2.96456	0.979526	1.33778	1.312105	3
3.004658	1.994467	3.340586	3.123453	0.168374	1.183954	1.303827	3
3.557233	1.908423	3.907425	3.378859	0.393898	1.68292	1.077381	3
2.411464	2.16817	3.985166	2.790466	1.111273	1.797105	1.584131	3
1.491612	2.692824	3.446391	1.610859	2.136308	1.597012	0.673667	3
1.570925	1.579912	3.93983	2.736112	1.868873	0.511005	2.476103	5
1.74664	1.266399	2.752911	3.290547	2.346396	2.387008	4.022284	5
1.154398	2.149252	1.965355	2.992882	1.978235	3.127639	0.860784	1
0.688774	2.974488	1.694827	3.193321	2.122084	3.338055	1.028929	1
1.131356	2.409504	3.316011	4.297027	-0.46325	1.780486	0.505052	2
2.478426	4.047283	2.050103	4.226233	-0.2782	3.394542	-0.23253	2
2.083689	3.657652	2.921747	3.583169	-0.01864	2.614121	-0.05174	2
0.436883	4.775917	2.633991	3.694657	-0.60229	3.109147	0.170619	2
4.010344	4.141069	2.630313	3.047465	-0.95245	2.075121	-0.17676	2
-0.12992	3.393718	5.397824	0.854292	2.35004	0.100554	2.472098	4
1.590358	2.277793	1.279885	3.553163	2.987285	1.843279	1.926848	1
0.723736	3.291846	0.950193	3.990674	0.001098	3.059685	0.568444	2
2.182197	3.841742	3.585516	1.894945	-0.17265	1.744152	0.364155	2
3.352942	2.882326	3.866515	1.546324	0.773397	0.696639	1.2335	3
2.389582	2.199895	5.216224	1.660491	0.991467	0.364649	1.546675	4
1.212857	3.882324	5.050131	1.263146	-0.44613	1.522973	1.118274	4
0.472468	3.753695	4.995122	2.815492	0.027114	1.436463	0.056062	4
0.938919	3.164955	5.159946	0.67008	1.569086	0.043587	1.313561	4
1.298786	3.083568	1.830169	2.236362	2.000518	3.179449	1.594717	1
0.366913	2.044937	2.617066	3.038203	3.593626	1.970333	0.407605	1
-0.20437	3.531738	2.182952	2.036282	1.892294	2.801329	1.66814	1
0.28563	2.587021	2.643787	2.445734	3.925445	0.792276	0.350427	1
0.996504	3.106436	2.692807	1.902592	3.575833	1.568171	-0.2585	1
2.260508	3.017908	2.137207	1.674803	1.196457	2.873861	1.848838	2
-0.03506	3.609465	2.625299	2.368762	1.671222	3.0121	1.916716	1
0.854331	1.998625	3.000042	3.004479	3.726537	1.246325	0.524352	1
0.262891	2.741493	2.465511	3.593546	2.739738	1.530374	0.298851	1
2.270781	2.561758	2.539467	0.271137	3.602786	0.407443	0.328955	3
1.318672	2.621613	2.430487	2.202098	3.112685	0.926337	0.382588	1
1.473336	3.617204	2.026884	3.569903	3.190754	1.528451	0.754648	1
3.029609	3.419414	0.786625	4.327039	3.598551	1.734834	0.51481	1
1.792849	2.884772	2.081495	3.645535	2.82959	1.953796	0.623779	1
1.334464	2.874837	2.544076	3.153225	2.856396	1.395013	0.581578	1
1.368727	3.383985	2.730762	3.125914	3.853141	1.181855	0.793415	1
1.158614	2.646456	2.146818	2.3928	2.766568	2.142429	1.291993	1
0.880486	3.031536	2.821478	1.423451	0.733423	2.545687	1.142586	2
1.174285	2.721081	2.441791	2.207948	1.827167	2.157325	0.964771	1
0.870188	3.398999	2.271434	2.450359	2.154208	1.686502	0.205592	1
1.653495	3.671909	1.899133	3.211423	3.15191	1.735527	0.69995	1

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

0.682774	4.503063	1.489453	2.222444	1.302957	2.698368	1.259985	1
2.663757	3.054066	3.250958	2.184488	2.114672	1.565751	0.71493	3
-0.03549	2.627792	3.353033	2.490402	1.333189	3.449527	2.01461	1
0.176902	3.363572	1.788922	2.632445	2.046902	1.661218	1.862941	1
1.665005	3.096207	1.841999	2.76653	2.242893	2.006812	0.692106	1
0.434799	3.054804	2.514313	1.468836	0.715913	1.864575	0.778837	4
2.414456	2.360334	2.306623	2.052518	1.905444	2.084339	1.41141	3
1.548719	2.645218	2.647588	3.017119	1.307344	2.603688	1.402963	2
1.043513	2.563992	0.768526	3.563116	1.338746	4.07294	0.737781	2
2.75563	2.346252	3.231356	2.059784	2.305691	0.999648	2.35069	3
1.618229	1.55903	2.663824	2.071062	1.269606	2.184555	2.946364	5
1.927056	2.062933	2.708249	2.422282	0.670938	1.652872	0.78742	2
1.888032	1.739451	3.022219	0.731892	0.901051	1.484288	2.493283	3
1.373058	3.726288	2.173993	1.611522	1.419764	1.355206	1.332446	1
1.587711	4.845681	1.633788	2.276364	0.613327	2.951609	0.774923	2
1.107882	4.1896	0.662106	3.017648	2.54298	3.18947	1.811624	1
0.80748	4.128602	3.05368	0.753182	1.523971	2.218486	1.551826	1
1.792069	5.297029	-1.4584	4.517665	0.420555	3.75568	-0.2235	2
0.29681	2.154562	4.291881	-0.71309	3.192156	4.1492	2.884095	1
2.641933	4.808604	1.697382	3.192166	0.262471	2.395388	1.412021	2
1.862043	3.096722	2.942964	1.87311	2.463407	1.027912	2.61095	3
2.842538	4.881212	0.084864	3.656311	1.139249	2.492176	1.855205	2
-0.56891	4.003578	3.196236	3.384194	0.419863	2.238542	0.05731	2
2.881629	2.605602	4.146121	2.6831	-0.69501	1.296744	1.351407	2
1.066547	2.269026	3.176295	3.933355	0.905649	3.788415	2.012815	2
-0.27702	5.214505	3.964305	-0.42548	3.649732	1.399817	2.064414	1
3.247233	1.250798	1.933796	3.519258	1.290077	3.216229	3.350252	5
5.269156	3.595336	1.57854	4.563517	3.322321	2.0089	2.253221	3
0.402385	3.988677	1.888783	3.045963	2.415748	2.16155	2.283636	1
1.305141	3.669467	2.596833	3.356985	1.244654	1.832795	2.358681	1
1.198453	3.482618	2.315618	2.959246	0.01394	2.162574	0.785387	2
2.34431	4.126819	2.223733	1.390981	1.353677	1.772295	1.929	3
1.125582	2.252314	3.475507	3.005104	1.493761	0.598888	1.6825	4
0.540524	2.337962	4.474714	1.180037	1.137322	1.401177	1.350397	4
0.605022	2.493479	3.007678	3.416692	1.835619	3.153643	1.208213	1
1.70579	2.90063	2.763136	3.22817	2.736035	1.453346	1.065606	1
1.774505	2.964929	4.050098	0.483415	1.620176	2.106961	1.469905	3
0.37949	3.798105	3.253912	2.618223	2.893426	1.931221	1.662662	1
4.088323	4.086708	1.203542	3.401486	1.006494	1.889707	1.626608	2
1.119508	1.699654	3.586956	2.997562	1.258626	1.989826	0.903255	4
0.613604	3.759827	3.856952	2.125737	1.154775	0.907478	1.761888	4
0.907833	2.530289	2.395073	2.958473	0.736132	1.751963	0.549846	2
3.173489	3.591836	4.33018	2.384611	3.189142	3.388148	1.267663	3
0.198984	2.664969	2.869373	4.610011	0.313022	2.824204	0.625394	2
0.630253	2.095562	4.612635	3.10251	0.403171	0.586135	1.524354	4
1.172078	3.404195	2.258	4.688623	0.018005	3.749981	0.113934	2
4.007734	4.416939	3.65958	2.156696	1.668164	2.136666	-0.46751	3
1.868898	3.149336	2.275342	3.520585	0.30994	2.832434	1.386088	2
0.780472	3.074664	2.209664	2.923805	1.234535	3.130313	0.715847	2
4.848926	2.952455	3.823995	0.591641	1.587537	2.18594	-0.83412	3
1.211911	3.276599	1.160352	3.7608	0.172588	3.302692	0.900316	2
1.345695	4.407982	2.247066	3.577123	1.592001	1.564087	2.094433	1
1.224475	3.147634	2.941942	3.798999	1.535248	2.344394	1.478652	2
3.814597	3.334847	3.097241	4.383301	1.594088	3.575003	2.193627	2
2.618453	3.317255	1.941214	3.630248	2.69847	3.52205	2.648051	1
1.294275	1.56371	3.043611	2.412047	2.498057	1.647309	1.693621	5
0.789672	3.383044	3.337881	3.451955	2.680502	1.791768	-0.33461	1
5.565368	3.181652	3.711348	1.365467	3.165442	0.633596	1.577293	3
0.669129	2.118351	2.117884	2.709941	1.785749	2.353919	1.396308	1

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024



2.122874	2.370528	4.039168	0.044906	1.404239	0.054061	1.210217	3
-0.31367	1.429249	3.608487	3.153238	3.435385	2.595252	1.562	1
2.998431	3.071495	3.935008	-0.03663	1.493068	-0.0469	0.969036	3
1.208636	1.198679	3.797957	1.94229	3.154749	1.181498	1.587801	5
1.238483	2.984314	4.102558	1.020331	1.746735	0.210602	0.596202	4
0.721211	2.570974	4.789879	1.510915	0.470652	0.495575	0.773934	4
2.182478	2.318548	4.180739	2.217635	1.400813	1.181345	1.366411	3
4.973196	1.25845	3.181555	1.930606	1.754247	0.502145	0.808431	3
1.299859	3.358898	2.963783	2.996693	1.210242	2.837687	2.661287	1
1.721604	4.747844	2.938984	3.246941	0.280358	1.577821	-0.18553	2
2.151246	2.475189	2.327683	1.99312	0.50071	1.478181	2.367488	3
-0.52803	2.946022	3.74577	3.453622	1.366665	1.530891	2.898386	4
2.520474	2.840891	4.605005	2.492233	1.505935	0.933693	1.547949	3
1.953568	4.710961	2.059415	3.21843	0.404182	2.072298	-0.48158	2
0.67322	2.059827	3.378463	3.263051	1.593942	1.411997	3.478853	5
0.482849	1.669846	5.337114	3.92286	0.857681	2.098765	1.276031	4
1.436908	3.006341	2.111445	3.63576	1.17833	2.696489	-0.03468	2
-0.16469	3.037464	2.593747	2.19126	1.150814	1.183965	2.885273	1
3.098244	2.591925	4.55368	2.771836	0.409717	4.100465	1.1617	2
0.287138	2.638836	3.863141	2.410391	1.952481	0.480413	3.121472	4
0.88184	3.625722	4.892386	0.792852	-0.38779	0.599907	0.319505	4
2.150267	2.531001	1.798742	1.734505	2.569138	1.474977	1.943503	3
0.080232	1.944229	2.89941	3.091852	1.297553	1.130481	1.479588	4
1.307558	3.242025	3.928579	0.550179	0.489302	-0.2167	1.569607	4
-0.23345	2.508582	4.13559	3.019692	1.012514	0.803014	2.163831	4
0.452287	4.095796	2.938024	2.755959	1.197267	1.736364	1.48946	1
0.333146	3.491975	2.998474	2.348185	2.863105	2.005441	1.99996	1
-0.2021	2.38004	4.119341	2.26864	1.40722	0.247862	1.495971	4
1.27648	2.71056	3.416199	3.573639	1.124956	2.475951	1.110492	2
1.071622	0.058392	4.1753	3.035761	3.147516	0.463041	3.434267	5
0.767058	2.902141	2.81539	1.046366	3.481824	2.314722	3.456745	1
3.199205	1.794078	3.094138	0.666184	2.680831	0.969656	3.012809	3
0.381606	1.855712	2.180899	2.28543	2.69681	2.129198	3.061778	5
1.199252	1.771864	3.210781	2.048203	2.117378	1.37389	2.377955	5
0.91132	1.981741	2.199601	2.419341	2.215353	2.0596	2.989397	5
1.465285	2.997421	3.137443	1.03661	2.101259	0.412757	0.556006	3
1.445957	2.331573	1.916218	2.899514	1.818489	2.843057	2.654736	1
2.190434	2.781964	2.697725	2.215768	1.935821	3.086303	2.382583	1
3.060515	2.893715	3.843192	1.274351	2.77693	1.999967	1.625444	3
3.43918	4.685975	2.511207	0.606142	2.48964	0.899216	2.126643	3
2.248858	3.078349	2.536622	1.289691	2.240462	3.084218	2.519339	1
3.37998	3.32946	4.457823	2.144631	1.21309	0.40427	0.75011	3
1.485575	0.653133	3.573337	1.804786	2.614735	1.700206	2.294768	5
-0.11639	1.697496	3.894954	1.163997	2.803677	1.62084	3.170209	5
0.265337	0.794674	3.483188	3.196532	2.270673	0.733305	3.105335	5
0.487467	2.134018	3.509739	2.158815	1.670326	3.086941	1.766996	1
1.785974	2.325783	3.97547	1.09789	1.533602	0.00662	0.661087	3
2.199662	1.043731	3.230455	1.471481	1.594108	0.196087	1.699968	3
0.432774	0.473242	3.749216	2.000787	2.260527	2.0028	2.936089	5
-0.03225	1.823518	3.460935	2.026709	2.073493	1.822957	2.199521	4
2.922641	1.912792	2.869191	1.92473	2.23171	1.463312	1.771086	3
1.95851	2.620691	3.209711	2.40885	2.167502	1.410435	0.780651	3
1.673373	3.1535	3.384783	2.665686	2.386609	3.045046	1.306632	1
2.052142	2.801713	3.616672	2.376778	2.198514	2.571284	2.109671	1
2.398755	2.656117	3.599123	2.113145	1.85368	1.955369	1.029531	3
1.600749	2.772373	2.97559	2.356207	2.179088	2.727056	2.963031	1
2.407436	2.876793	3.588069	2.349736	2.603454	1.472847	1.481762	3
1.477092	2.367975	3.279323	3.706314	2.496294	1.970748	2.027569	5
2.117032	3.129461	3.33882	2.353723	1.303854	3.213898	2.046513	2

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

0.862852	1.787891	4.693773	3.920364	1.536504	1.598562	0.812846	4
2.124976	2.522997	2.142115	2.017715	1.329319	1.353485	2.01721	3
2.053942	1.282666	2.60817	2.173067	1.883355	1.446771	1.932743	5
1.051968	1.351924	2.743535	2.133289	2.15663	1.277404	1.947453	5
1.711215	1.470019	2.419263	1.720749	1.882597	1.273467	2.368535	5
2.929092	1.337477	2.249875	2.137536	0.784348	1.365049	2.001452	3
1.158983	1.4628	2.915975	1.823459	1.509886	0.551248	2.793893	5
2.091268	1.750324	3.37735	1.24898	0.459163	1.414763	2.315137	3
2.076045	1.774582	2.512304	2.256736	1.866886	1.14936	2.611307	5
0.888772	2.398703	2.96251	3.053851	0.409217	0.752585	2.749108	4
1.385868	2.726663	4.786969	1.926702	-0.29151	1.447619	0.300511	4
1.573504	1.385677	2.765509	1.797339	2.803497	0.70662	1.886113	5
1.36709	2.250416	2.120969	3.156059	0.953453	0.834286	0.332707	2
1.83963	1.020248	2.261243	3.005754	1.931713	0.376005	1.855818	5
1.601561	1.25261	2.891928	2.486944	1.195034	1.634183	1.888287	5
-0.02354	3.287441	3.06615	1.477316	0.788567	1.769741	0.388055	4
1.218747	0.968508	2.310128	1.840931	3.599996	2.546517	2.353331	5
2.273433	1.691484	4.048696	2.607554	3.589263	1.255111	0.435131	3
2.088968	1.147388	2.211211	2.663832	2.513624	1.159295	2.510907	5
1.671819	1.377036	3.442522	3.119088	2.535569	0.140997	2.209565	5
0.655599	2.044898	3.029	2.970167	1.316146	2.118602	2.10233	4
1.85728	0.119835	2.531109	2.346743	1.542376	2.049295	3.632266	5
0.810013	0.519835	2.208672	2.690966	1.793883	2.252788	3.340709	5
-0.53672	1.90413	3.751989	2.896342	2.684364	0.736452	2.240227	4
0.912099	0.843401	3.863282	1.466242	1.900905	1.511621	3.068371	5
0.717642	1.816272	2.257425	3.060543	1.17801	1.755652	3.457668	5
-0.58683	3.081178	4.155074	3.340262	-0.52844	2.870146	1.44833	4
0.948814	1.329927	2.309509	2.638619	2.425392	2.050609	2.055008	5
1.405381	2.577678	4.286141	1.980834	2.432689	-0.09613	1.148452	4
1.567328	2.933253	3.513708	2.585126	1.043179	-0.13341	2.420696	4
0.654842	2.497284	3.603089	3.237035	1.70472	1.099211	1.797649	4
1.512999	0.611854	2.683634	2.169291	2.81694	1.732635	3.711279	5
1.750541	0.9083	3.874494	4.076287	-0.0004	3.253308	1.558526	2
3.554138	3.798572	3.92936	3.171349	1.134508	-0.27824	2.674967	3
1.843493	2.035074	1.975868	1.991719	2.417606	0.563503	2.469965	5
1.717436	2.392262	3.051026	2.060343	2.753362	1.495397	3.641729	5
-0.42161	4.174919	2.381554	3.388356	0.438055	3.444924	1.033751	2
1.763247	1.821026	3.455334	0.63166	3.032002	1.410237	2.909767	5
1.676444	2.552671	2.604784	0.875316	1.878914	-0.17302	2.688803	3
2.421358	0.897852	1.757336	1.945325	2.978777	0.589719	2.963783	5
1.091983	1.664438	3.094837	2.810642	2.668531	3.176472	3.365537	5
0.95825	2.322112	2.79394	1.357469	2.849933	1.464401	1.685897	1
1.686879	1.209325	2.357908	1.591704	2.3949	2.815835	3.473977	5
0.679991	0.490045	3.649338	3.121814	3.233997	1.803668	3.433076	5
0.576465	1.683357	3.679851	3.021204	2.972976	2.905107	2.180476	5
0.136986	3.709519	2.895228	2.006352	2.08725	0.559701	0.559701	4
1.992158	1.887124	2.751854	4.05701	2.787676	3.611463	1.616108	1
2.188311	1.67236	3.624552	2.120629	2.385157	-0.40732	2.290743	3
1.103505	3.213246	3.56517	1.335934	2.322979	2.073316	2.533389	1
1.172266	1.179647	3.3055	0.938081	2.639	3.333973	2.398904	5
0.946777	1.12983	3.224024	2.29541	2.958102	2.775739	1.638153	5
1.180773	2.20079	3.909757	0.784649	2.537993	1.654572	2.353767	4
-0.29837	2.708103	4.010237	3.212327	2.782713	2.544077	2.617483	1
0.999984	1.601736	3.175787	1.809006	2.008332	2.584361	2.924514	5
1.191219	1.61463	2.640179	2.097072	2.463071	2.923712	2.126753	5
0.81584	1.766591	1.901241	3.201082	3.089132	1.507481	2.906519	5
-0.52005	-0.21152	3.877069	3.117811	2.445868	1.942376	3.528102	5
0.698561	1.581811	3.206016	2.966686	2.174549	2.628289	3.4346	5
0.294319	1.243359	3.264264	2.504067	2.125595	1.764063	2.399821	5

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

0.552522	1.94189	3.663707	2.656138	1.682984	1.361744	2.218496	4
3.133129	-0.27546	2.912236	2.424335	1.345903	0.670599	2.517861	5
-0.24638	0.480544	3.246561	3.188092	2.920533	2.712854	0.739785	5
1.14412	0.149335	2.163497	1.884293	2.33313	3.013641	3.065498	5
1.106268	1.42373	4.030908	3.058467	1.784729	1.151248	3.145549	5
1.747898	2.289926	3.193032	2.342344	1.836667	2.341647	2.572253	5
1.249783	1.366357	1.891003	3.500575	2.873969	2.428008	3.977269	5
1.369205	1.426718	3.489257	2.725576	2.382661	1.919912	3.088201	5
2.047065	0.823226	2.345861	3.062785	1.533924	2.751118	4.369498	5
1.665568	1.758852	2.102023	2.36764	1.985868	2.164683	2.997736	5
1.235974	1.308576	2.981051	2.429463	1.928441	2.464002	2.952178	5
1.8261	1.512971	3.123711	2.497745	2.373443	2.094497	3.044643	5
2.84051	1.175393	2.586929	3.28986	2.33567	2.090763	3.742619	5
0.279548	1.895825	5.388341	2.120073	2.247174	0.868701	1.081032	4
0.99619	1.012696	1.960564	3.89922	2.166986	3.011827	2.011537	5
0.40928	3.185794	2.623647	1.940549	1.825407	1.698621	1.568015	1
0.215144	2.091797	4.171211	2.320654	3.369494	3.191467	1.64836	1
2.510542	2.017149	2.234838	3.722974	3.594265	1.538423	4.527227	5
2.191789	2.27999	0.75166	3.750002	2.901422	1.686636	2.481703	5
3.326313	2.528328	3.928792	3.121216	1.453615	1.682897	1.617506	3
1.664394	3.09397	1.78878	1.884236	2.924941	1.515557	2.520133	1
3.639972	2.296478	1.151978	4.058536	3.114612	3.240043	1.390437	2
0.449924	1.48284	0.97592	2.929817	3.717695	4.493118	4.460917	5
2.003783	1.617244	1.483172	3.165291	2.814826	1.544825	3.40854	5
1.642709	2.599317	2.743092	2.478182	1.216038	1.569686	2.955092	5
2.020474	3.031131	1.458374	1.963512	2.002057	0.863468	1.791431	3
1.588088	1.83981	1.621011	2.296312	2.576374	1.595488	3.050562	5
-0.03704	2.618573	2.73468	3.523944	1.728803	3.092423	1.011341	1
1.507168	2.289949	2.907394	2.494175	0.342619	2.955806	2.238876	2
0.65722	1.948092	3.384632	3.591149	1.093019	1.948022	2.226399	4
0.906972	2.341611	3.474023	3.766265	1.319244	2.054854	0.849818	2
1.099988	2.333797	3.238913	2.937232	0.493977	1.700426	1.402933	4
1.280015	2.513557	2.225763	1.868445	1.739776	1.374607	1.782267	1
-0.11139	2.095035	2.947376	3.142256	3.032293	1.639643	0.480099	1
1.551912	1.887402	2.344782	3.686308	2.768613	2.681956	1.157552	1
-0.08866	3.745314	2.220336	3.071661	2.849671	1.862011	1.695552	1
-0.14035	2.459132	2.989569	2.991661	2.682929	2.55258	1.272708	1
0.863472	1.802155	2.07836	2.793182	3.686965	2.535373	3.223135	5
1.939982	1.028043	2.661535	3.283031	2.849478	1.791159	2.935827	5
0.202088	2.772472	3.860564	2.418321	1.221271	2.686473	3.045804	4
1.536423	3.963189	3.539271	3.213546	2.934773	0.878772	1.750439	1
0.716654	3.769872	2.337558	3.21909	3.257411	3.09655	1.200753	1
0.002053	2.579149	1.708619	1.826842	2.902119	2.69227	1.846354	1
1.878384	1.367029	2.529927	2.219242	3.170144	1.372932	2.595525	5
1.113165	4.083788	2.197008	2.347144	2.640993	3.571014	1.565829	1
-0.55411	3.677333	2.607452	2.868568	1.895632	1.742989	1.350166	1
0.728818	5.38512	1.999552	1.995521	1.688124	1.794364	1.567654	1
2.000957	2.156025	2.529648	2.916682	2.007876	1.796838	1.507756	3
1.464876	4.794305	2.399407	2.661065	2.77422	2.379961	2.595127	1
1.639087	2.011963	1.930406	2.611254	3.568298	2.516589	2.812242	5
1.446411	3.638014	2.57226	2.162072	2.791145	2.57307	1.488721	1
1.167265	2.626558	2.203502	2.296486	1.842762	2.90644	1.855448	1
2.792874	1.787912	2.792314	2.672087	2.421138	2.292698	1.817582	3
1.661313	1.518343	3.330552	2.900845	1.686547	3.210328	0.977498	2
1.818558	1.962483	3.011182	2.984796	2.464553	2.212576	2.227476	5
2.368946	1.765466	2.807844	3.021599	1.988137	2.766653	1.264226	2
1.519612	1.349884	2.745033	2.585421	1.414565	2.762992	0.696093	2
2.525452	1.940259	3.229155	2.42824	1.51069	1.699371	0.8384	3
1.470027	2.213906	2.174315	2.641719	2.62319	2.124632	1.701656	1

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024



1.40074	1.014476	4.221012	2.082268	2.397258	1.566852	2.246523	5
3.364591	1.251376	3.290845	2.500423	2.222562	2.499598	1.64981	3
2.129269	2.710131	2.313439	3.013249	3.038706	2.468915	1.469671	1
3.640786	2.112478	2.740796	2.354109	1.865754	1.397937	0.737311	3
1.421128	1.717524	3.14217	3.412806	1.643833	2.767619	1.014461	2
3.634259	3.829661	2.455371	1.544377	1.340034	3.256891	2.485461	3
2.697317	2.840325	2.636191	2.10339	1.209549	2.466469	1.862657	3
2.125605	1.718318	2.887255	2.48321	2.397532	1.066204	2.379777	5
3.792892	2.650793	2.764114	1.400925	1.851319	2.681576	2.986922	3
2.072001	3.045846	3.962105	2.177186	2.573999	0.25015	0.832666	3
3.47285	2.593043	2.890262	3.791422	0.974418	0.107865	1.905316	3
3.442853	2.49001	3.917911	2.182262	1.331236	0.624292	0.56678	3
2.219969	2.735774	2.653031	1.323758	1.209602	2.197175	1.866327	3
3.544702	2.323891	2.279193	1.803041	1.570909	2.167078	2.118647	3
3.420414	1.926201	3.185597	0.632802	0.632656	1.50262	1.384866	3
3.209916	2.705199	3.627112	1.981629	2.297275	1.142996	1.049544	3
3.048556	2.6651	3.121058	2.043578	1.409733	1.083988	0.612292	3
2.713898	2.765805	2.622923	3.012792	2.375676	2.068843	1.575362	3
2.443942	2.666966	2.428546	0.891082	0.771637	2.603498	1.684131	3
2.905297	3.397697	2.938849	1.225181	1.163792	1.690736	1.431206	3
3.593219	4.593676	2.85064	2.031216	0.486013	2.463427	1.85159	2
2.102827	2.396113	2.513477	3.23259	0.053848	0.624753	1.872851	2
1.064304	1.898978	2.016754	3.140289	0.964322	2.533744	1.1192	2
2.444071	2.783835	4.013843	2.538264	-0.99133	1.913701	1.514094	2
0.597051	2.841435	3.260321	2.331223	2.770425	1.762876	1.657292	1
1.277791	1.224479	4.027602	2.223094	1.528438	1.553553	1.985067	4
2.544969	1.139785	3.265251	2.26823	-0.46458	2.591822	0.882637	2
1.825547	1.669443	3.223452	3.179786	-0.42529	1.875906	1.452051	2
2.962217	3.600508	5.143498	1.353762	0.671814	0.235175	0.560646	3
1.456116	2.008452	4.33278	2.854759	0.605656	0.405156	2.166573	4
0.626556	3.945301	3.324774	2.371494	-0.03127	1.118954	0.265501	4
-0.31383	2.113856	2.59672	1.908942	1.667484	2.524643	2.408832	1
1.228335	1.387955	5.154633	1.452413	1.155377	0.786883	1.862063	4
1.25387	2.254079	4.47892	1.999785	1.359129	0.771985	2.204713	4
2.077432	1.663845	5.072246	2.79507	-0.51169	0.56814	0.610627	4
0.599443	1.280542	4.815207	2.746904	1.803925	0.649366	2.415114	4
0.598819	1.589002	4.750287	3.058779	1.458149	1.533219	1.688224	4
0.931227	2.847927	4.160636	2.13367	0.982232	1.452196	1.729529	4
0.316014	1.483445	5.063682	1.620782	1.363688	0.744981	2.184789	4
1.805851	0.751263	4.905275	2.126935	0.927103	0.411213	1.870546	4
1.817658	1.874295	3.402797	2.738788	0.632739	3.089684	0.283125	2
2.080507	1.479588	3.698097	2.018675	1.102444	3.123037	0.499457	2
2.155577	1.737956	3.83843	2.286946	1.14978	2.696318	0.43201	2
1.608477	1.801606	3.90294	2.616016	0.307342	3.013917	0.867098	2
2.281242	0.685045	2.986646	2.985925	1.546753	3.087632	0.720522	2
2.214117	0.65798	3.986178	2.320973	1.01724	3.012481	0.405324	2
0.781439	0.915361	4.091384	2.741706	1.203266	2.853794	0.715125	4
1.727043	2.106237	3.150811	3.001749	0.701208	2.788492	0.486409	2
1.728331	1.779813	3.270322	2.618096	0.884794	3.065053	0.971797	2
1.749562	1.403262	3.229064	3.006373	1.472604	2.900566	0.640564	2
0.679291	1.950655	4.747832	2.835375	0.382722	2.499583	0.591783	4
1.147152	1.826271	4.035526	2.320126	-0.02238	3.159645	0.731292	2
1.941818	2.082537	2.989712	2.260192	-0.00818	2.787371	1.151937	2
1.249031	1.527114	4.299129	2.535885	-0.5818	2.879486	0.525447	2
1.19344	1.077144	4.43854	2.214834	1.010501	3.005332	0.498575	4
1.38946	2.086965	3.925157	2.506738	0.61587	2.518739	0.56424	4
1.877671	2.377552	3.591046	2.443115	-0.60871	2.798473	0.648804	2
2.957277	2.94879	2.629078	2.712291	2.437214	2.745738	2.306572	3
2.992108	2.599115	2.293851	3.124804	2.015908	3.133204	2.268303	2

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

3.921003	3.011791	1.363058	2.752717	2.051352	2.988232	2.550854	2
1.728135	3.382881	2.602387	3.073562	1.122538	2.970503	0.769473	2
0.89866	3.708311	3.08077	2.230172	1.323137	1.21315	0.775188	4
0.108157	3.703654	4.751098	2.833147	1.226326	1.494066	0.657168	4
0.949288	3.908633	4.21671	2.584499	1.12431	2.357137	1.324043	4
1.685074	3.335918	4.22883	2.169423	1.972558	2.209607	1.534274	4
2.355394	2.924333	3.329398	1.851904	1.452708	1.768292	1.320825	3
1.392201	2.646019	3.262224	3.078521	1.380314	2.171287	1.551109	2
1.872292	2.807496	3.365211	2.991789	1.430271	1.604211	1.31471	2
4.06007	1.952389	4.366534	2.666384	0.004945	2.058869	1.022499	3
2.515136	3.582175	3.164015	2.511792	0.303662	2.456513	1.106662	2
2.353872	2.84456	3.277328	3.030188	0.686356	1.732787	1.083689	2
3.092874	2.935414	3.090189	3.004494	0.234085	1.989451	0.991129	2
2.985002	3.046288	3.149261	2.913923	0.221522	2.037312	0.911563	2
2.991006	3.1423	3.128822	2.930944	0.71372	1.97819	0.9461	2
2.498692	3.030364	3.712698	3.228355	0.051874	2.453515	0.868749	2
2.932435	3.234334	3.266269	3.874878	1.708321	0.299856	2.488879	3
3.732834	3.443928	4.925664	2.483556	-0.84478	1.269878	-0.24187	2
2.764755	1.765644	4.289369	5.662817	1.16513	2.814028	1.745695	2
3.089919	3.356786	4.52097	0.52877	1.356926	0.340221	0.917349	3
2.476432	2.565019	4.555364	2.821781	-0.36831	1.590714	0.438113	2
2.910139	4.087892	3.980479	1.786325	-0.66089	0.481637	0.032882	3
3.135612	4.630961	3.628399	3.051233	-1.17422	0.352569	0.381981	2
2.872695	3.720954	4.51504	3.199279	-0.98896	1.381106	0.015064	2
2.089671	2.377447	6.417695	0.828802	1.741449	0.852393	0.681979	4
1.288354	2.713286	5.504821	0.619534	1.160781	1.224874	0.05934	4
2.068221	2.422813	6.131995	0.715511	2.167848	1.25567	0.822885	4
1.624061	3.815175	6.237579	2.066145	-1.00305	2.208537	0.277069	4
2.445324	3.714635	5.837543	0.946298	-0.31739	1.034344	0.393447	4
1.445021	2.958948	2.395126	3.098661	2.870223	0.928077	0.090669	1
2.375642	2.68096	2.183977	3.157854	2.235614	1.306861	0.393268	3
1.505374	2.723895	3.330147	2.767737	3.015288	0.696092	0.640706	3
1.567687	2.888448	2.295104	3.176463	3.193394	1.005992	0.495985	1
2.912557	2.523757	1.949625	3.107942	2.987511	1.188252	0.531214	3
1.851181	3.069879	2.227234	3.15	2.626483	1.087311	0.423944	1
2.377584	2.854885	1.961183	2.925096	3.283892	1.388586	1.156093	3
1.467044	2.694963	3.178889	2.979329	2.500077	1.289893	1.388323	1
1.415615	2.35197	2.874528	3.014931	2.432711	1.772328	0.987868	1
2.030281	2.431548	2.221421	3.091684	2.478228	1.352556	0.871416	3
2.553599	4.262361	1.874516	2.474586	2.511507	2.529192	0.508671	2
3.185728	3.696322	1.49651	3.046902	2.934443	2.880074	0.135186	2
2.850695	3.55922	2.511403	2.548477	2.859269	2.493715	0.459517	3
3.577836	3.580969	1.643502	2.802134	2.574489	1.719936	0.253408	3
2.958074	3.415299	2.264899	2.677293	2.42812	2.083265	0.589096	3
3.087259	3.61867	2.115313	3.326557	3.243235	1.954775	0.300382	3
2.751739	3.585996	2.497658	3.382737	2.407784	1.805826	0.848883	2
3.0043	3.158151	2.642835	2.811435	3.556004	2.073591	0.192526	3
2.70127	3.29477	2.061836	3.531687	2.321305	2.139039	0.260408	2
2.866981	3.461092	2.503888	3.076605	2.320136	2.322889	0.164261	2
3.02909	3.796378	1.622972	3.100696	2.428454	2.112373	0.302758	2
1.832561	3.035723	2.92606	3.152572	1.969182	1.66836	2.027277	1
0.391172	3.724756	1.959737	2.563242	2.126821	1.498965	0.513307	1
0.537508	3.205037	1.664459	3.411925	1.951163	2.136093	1.881294	1
-0.03323	3.496502	1.921167	2.296864	2.092613	1.947697	1.894757	1
-0.28869	3.535061	3.032781	1.687279	2.179816	1.986136	3.189025	1
0.043266	3.098997	2.935675	2.583162	0.79795	1.274482	1.279583	4
0.111472	3.729742	3.438625	3.315709	1.270037	1.351169	0.323621	4
1.824843	2.878876	2.439134	3.205687	2.056859	1.26008	0.245724	2
-0.34372	3.260611	1.669527	2.611259	2.802661	1.975953	1.996848	1

Document:

PPD

Author:

PPD

Version Number:

1.0

Version Date:

06MAY2024

0.929042	4.229001	0.958476	1.837791	2.345441	0.85991	0.266006	1
0.835028	4.094564	1.624835	3.745215	0.676649	1.596787	0.633265	2
0.518017	3.482631	0.026971	3.232487	2.585949	1.714216	1.247258	1
2.142077	2.763266	1.717985	2.132657	1.981876	1.682524	1.359786	3
1.163136	2.278781	2.040656	1.66038	2.28934	2.245927	2.48422	1
1.773945	1.815762	2.296841	2.241036	2.003111	2.440107	2.329185	5
0.370864	1.828904	3.135938	1.977168	1.213476	1.233708	2.011518	4
1.286832	2.260544	3.247904	2.244789	1.087078	2.409808	1.666524	4
0.665569	2.919365	2.218953	2.267884	1.69468	1.892542	1.390264	1
0.499638	1.950232	2.077153	2.111414	2.362764	2.243769	2.65479	1
1.813017	3.779611	3.381505	1.889955	2.499938	1.561516	0.468737	3
0.397136	4.680782	2.396155	3.188569	3.35778	3.188256	1.316963	1
1.019573	2.844814	3.271878	1.693419	1.576868	2.980728	1.484369	1
-0.12102	2.640397	1.937596	2.509998	2.081944	2.465172	1.921706	1
0.52094	4.365047	0.079631	3.39627	0.649761	3.180026	0.097283	2
2.731117	3.182713	2.077638	3.00734	2.583772	1.26684	0.103849	3
1.771354	3.13086	2.349316	1.061821	2.445899	2.343069	1.002997	1
2.059941	3.055221	2.663597	1.88279	2.215695	1.325664	0.702866	3
1.303168	2.959174	2.820694	2.397158	2.033969	1.579769	2.122712	1
2.429935	2.785714	1.96915	1.688699	2.165227	2.253247	1.325774	3
0.891107	2.804571	3.191638	2.048713	1.508145	1.19412	1.88979	4
1.907596	2.544843	1.657253	2.422589	1.154796	1.183471	1.661215	3
2.385735	3.027558	1.489701	1.884331	0.99354	1.180347	1.127258	3
1.251581	3.68027	2.711777	2.1435	1.619374	1.509578	0.333364	2
0.798065	3.178204	1.337118	2.323722	1.813707	1.180386	0.886322	1
2.252769	3.452674	2.544877	4.622918	-0.07422	2.354946	0.115854	2
0.583991	1.996347	3.522147	2.550794	2.507082	2.036728	2.388671	5
-0.13509	2.898338	2.444281	2.521597	1.825635	2.888208	1.921385	1
-0.36838	2.995744	3.441612	2.97643	1.572292	2.68975	1.238128	1
-0.30352	3.100945	3.418419	1.915066	2.18415	2.148555	2.157188	1
1.244294	3.111563	2.930995	1.059978	0.847236	1.804209	0.909519	4
-0.14236	1.646401	3.496471	1.485099	1.650087	0.930843	2.037234	4
1.19828	2.207907	2.349218	1.552053	1.722359	1.499779	1.598663	1
0.38149	3.928541	1.372957	2.687336	1.838206	2.154214	0.524778	1
2.481611	3.481827	2.197603	2.130881	1.476809	2.260437	1.234254	2
0.481608	2.39286	2.337152	1.8301	3.06498	1.393734	2.654131	1
2.037414	2.085096	1.496653	2.455538	3.879859	1.623686	2.888888	5
1.550216	3.153218	1.742108	1.904519	1.712383	1.807038	1.351736	1
1.648021	2.673175	1.638725	3.046737	1.692765	2.351428	1.857887	1
1.374126	2.435089	2.234815	2.18588	1.898093	2.19479	0.889646	1
1.019342	2.647679	2.648263	2.498198	1.115062	0.804325	2.647109	4
2.736435	0.551078	3.752571	1.417281	1.549031	0.691697	3.033024	5
1.076616	4.06708	2.069281	1.842046	1.935288	1.900541	2.868004	1
1.33195	2.484582	2.416758	2.379112	1.760003	3.692732	0.736447	2
2.77427	3.355737	2.304729	1.78513	0.741504	2.762615	1.853789	2
1.110734	3.632882	3.21394	1.776796	1.612268	0.850391	0.641557	4
2.389185	2.881695	1.795131	3.20699	0.41942	3.494308	1.27316	2
0.730482	2.662928	2.413819	2.880268	1.47977	2.413753	1.470869	1
1.544426	3.943903	2.727814	1.735903	0.3283	1.153388	0.127138	2
1.279774	1.859157	2.630356	2.828011	0.364033	1.515973	1.979112	4
1.793325	3.012943	1.797364	3.337012	0.706964	2.779247	1.325387	2
2.238936	3.999729	2.426756	1.92557	2.32772	3.174616	1.094697	2
1.328915	2.584895	2.436472	2.695512	0.404388	2.423566	0.966932	2
0.949881	2.271697	2.870003	1.331377	3.139382	1.581926	2.831327	5
1.447089	4.561358	2.758321	1.890039	1.155236	2.090646	-0.24765	2
1.559906	3.743831	2.957692	2.926744	0.70788	3.029807	1.492514	2
0.037952	2.623521	2.977699	2.60586	1.7889	1.516554	1.752384	1
0.544136	2.470642	3.054143	1.796674	2.630448	1.995703	1.006744	1
1.103825	2.393463	3.065722	1.774394	2.428612	1.982995	0.895501	1

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

1.399663	2.370678	3.102827	1.824285	1.496074	2.043118	0.86195	4
0.897121	2.54747	3.141174	1.854219	1.595786	2.011652	0.804589	4
1.201974	2.640957	2.332992	2.627714	2.533396	2.930975	1.314934	1
1.363306	2.722	2.897964	1.712665	1.587274	2.16176	0.545037	2
0.723609	3.782392	3.074652	2.64536	2.840634	1.366008	0.711355	1
0.719305	3.75657	2.379346	3.293745	1.618362	3.079174	0.353328	2
0.328069	3.287281	2.131284	2.691661	1.991577	1.488309	0.506056	1
-0.64046	2.981621	2.625653	2.987986	1.415446	2.682281	2.372283	1
0.787829	3.43195	2.429392	3.333081	1.33786	2.979558	0.795472	2
0.227007	3.521006	2.724771	3.137629	0.03393	2.165901	0.06169	2
-0.40163	3.609939	2.626096	3.870232	-0.36079	2.958831	0.209338	2
1.965187	3.49462	2.311837	3.878262	-0.49392	1.852627	-0.02262	2
1.791554	2.700887	2.96369	2.574842	1.361732	1.22905	0.905313	3
0.592842	2.498902	3.325384	1.998149	2.970382	1.484991	2.433574	1
0.93449	3.04107	3.092865	3.005954	3.044192	1.088331	1.023012	1
0.003281	2.687613	3.929499	2.543304	2.892851	2.191037	3.148313	1
1.068601	3.440496	2.803361	2.06853	2.684096	1.392016	0.972695	1
0.253151	3.366974	3.134181	2.849601	1.98879	1.665742	1.794241	1
0.568625	2.599822	3.489269	2.403426	2.2514	1.457632	1.842686	4
0.00812	2.891183	3.527231	2.837727	2.056235	2.082804	1.521558	1
0.032748	2.470632	2.393383	2.203077	2.552633	2.522461	3.323862	1
0.542252	2.924785	2.188542	1.648248	1.714741	2.188392	2.210163	1
0.489436	2.782794	2.799251	2.348694	2.562243	2.045669	2.597358	1
0.598497	3.537035	2.270759	1.885296	2.640754	1.931446	1.9822	1
2.684479	4.627392	1.323444	2.104489	3.085864	1.524276	4.186668	1
0.655399	2.42486	2.702211	1.692073	2.686051	2.115035	1.992235	1
1.00012	2.63573	1.946578	1.927783	2.474008	2.149825	2.785688	1
0.803679	2.576829	1.90842	2.733659	2.142713	2.062206	2.425543	1
1.362799	2.747179	1.705736	1.951721	2.795911	2.423492	1.966459	1
0.963135	3.36129	1.576244	2.275032	2.391988	1.914535	2.548146	1
0.957478	3.325917	2.675156	2.401962	0.999558	1.423449	0.931414	2
0.847499	2.932603	2.498088	1.810525	2.707284	2.590633	2.0517	1
1.234055	2.177802	2.697905	2.809799	2.466852	1.403281	2.495561	5
2.015017	3.586158	1.209095	0.797506	1.692396	1.815927	1.146375	3
1.555804	2.938869	1.394756	0.825921	2.281687	1.885865	1.503032	1
1.919184	2.652597	2.006072	1.579702	1.47809	1.927411	1.892786	3
1.164025	3.354408	1.683151	2.741454	2.56621	1.453452	2.74602	1
0.86959	2.681597	1.65861	2.77981	2.819379	1.416855	2.724348	1
1.043517	2.337804	1.855299	2.055885	2.697255	1.476669	2.311822	1
2.083676	4.361556	1.724352	2.17223	2.581234	2.50454	1.35888	1
2.615128	3.571862	0.682013	3.528703	2.241834	3.449389	2.821293	1
2.085683	3.602037	1.088369	2.923386	2.205792	2.28507	2.979874	1
1.898764	3.276854	1.77007	2.506758	1.517037	2.607894	1.089812	2
2.5278	2.059308	1.713481	3.124673	1.225085	3.026174	3.025545	5
2.864402	3.013686	1.637174	1.573196	2.441859	1.623372	1.120725	3
2.072019	3.282316	0.870472	2.358488	2.208217	2.802844	1.730093	1
1.63954	3.096221	2.814322	2.561726	2.063223	1.377709	1.451547	1
2.309299	3.454196	1.661915	2.559652	1.830277	1.966368	0.014157	2
0.72982	2.395892	2.585869	2.750007	2.132678	2.026769	1.971763	1
2.549466	3.574283	2.038015	3.583879	1.986217	2.118853	0.140961	2
2.083922	3.433225	1.320953	2.441424	2.589508	2.780382	1.209729	1
1.293829	3.273937	1.462928	2.817106	1.721652	3.104604	2.554968	1
1.195288	3.769418	1.210908	2.98681	1.044027	2.749903	0.60132	2
2.061813	2.704437	2.316068	2.554463	2.553281	3.014762	2.00189	1
2.468648	2.98751	2.060243	3.21991	1.330698	2.781815	2.311667	2
0.936901	2.780699	1.501068	3.119347	1.893182	1.345022	1.445776	1
2.096261	3.729782	2.528279	2.942293	2.272058	1.668373	0.184038	2
-0.06866	2.323305	2.466225	3.008179	2.310103	1.806849	1.758138	1
2.600323	1.57889	2.767321	2.701491	1.678983	0.431804	0.746914	3

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

1.904414	1.941858	2.790823	1.733361	1.862784	0.627279	1.648438	3
1.596553	2.69657	2.367887	2.664833	1.633339	1.978123	0.121749	2
1.07667	1.205244	2.672278	1.959053	2.384767	1.783993	3.279252	5
1.595228	3.077974	2.380944	2.815531	1.774421	1.243553	0.373183	2
3.05165	1.742192	3.165878	2.403648	1.464842	0.801114	0.72373	3
2.207574	2.570317	1.919201	3.671462	-0.20097	2.181307	0.583058	2
1.136287	2.834087	3.186852	2.882391	1.934227	0.932035	1.06899	4
3.138606	1.675005	3.392111	2.846753	0.800305	1.366669	0.36267	3
3.006056	1.788769	2.430313	2.210938	2.343229	0.8086	1.471998	3
3.301842	2.534269	2.727616	1.645315	2.297743	1.398658	0.504945	3
1.045698	3.34271	2.926759	2.671772	-0.54325	3.05828	1.151877	2
1.474318	3.49987	3.358005	2.668088	-0.34163	0.727697	0.198376	2
1.418577	3.540259	1.859501	1.848117	0.758087	1.62029	1.178268	2
1.792042	3.571176	2.781245	2.623082	2.059251	2.687523	0.663873	2
2.246787	3.973687	2.288619	2.616655	0.964431	2.932953	0.383798	2
2.557149	3.009742	3.015698	2.63141	1.263235	2.701192	0.65265	2
2.406639	2.86216	2.747641	2.887785	2.069158	2.148691	0.371257	2
2.144278	3.008093	3.211825	4.019281	0.030605	2.866497	0.860084	2
2.555363	2.579017	3.075949	2.0346	2.256304	2.102979	0.446911	3
2.53739	3.435742	2.628374	3.319847	1.749244	2.053878	1.172975	2
2.645764	3.632515	2.547884	2.116629	2.961363	2.525557	0.751793	3
2.167688	3.177878	2.822987	2.693744	2.104781	2.348668	0.571723	2
1.225418	2.761464	2.284974	2.906629	1.555919	2.234763	1.344509	1
2.549378	1.883245	4.847159	-0.38613	2.328991	0.399031	0.899669	3
0.835491	3.410214	3.238864	2.174315	1.569618	3.313993	1.048845	1
0.197072	3.720005	3.210243	1.462301	1.715089	3.289458	0.349891	1
0.956348	1.634326	4.496375	2.859105	1.713968	2.541391	0.572134	4
2.710831	2.895985	4.542081	1.117162	1.602833	0.638402	1.605333	3
0.468519	2.775847	4.793864	1.572114	2.577669	2.142251	0.374559	4
0.801185	3.856247	4.476053	1.102946	1.665504	2.180561	1.051688	4
1.396774	2.38184	3.159023	2.272422	1.642917	2.218226	0.494604	2
1.029972	1.815946	3.624451	2.805185	1.766394	1.950249	0.557906	4
2.351785	2.454701	1.492669	4.377274	1.452214	3.421769	1.610619	2
2.32405	3.466859	1.816886	2.125494	2.298043	2.802006	1.772149	1
1.22715	2.873227	2.457041	2.742809	1.886899	1.460491	1.371267	1
1.281567	3.046454	2.498313	1.471574	2.914418	2.038731	1.977465	1
0.288136	1.74727	3.931425	2.686452	2.618377	2.564444	2.479821	5
2.522687	2.759939	1.745555	1.6985	2.060347	0.322064	1.304326	3
0.543637	2.544981	3.348045	1.906861	2.258307	1.031273	1.44175	4
1.620347	3.401088	2.574342	-0.41533	2.252736	0.219513	1.438078	3
1.842942	3.37822	2.328411	1.420737	2.466913	0.174455	2.317012	3
0.948361	3.600731	3.023847	2.142095	2.757594	0.861544	1.1149	1
1.868794	3.629237	1.867504	3.675692	1.405051	3.091689	0.902801	2
0.109365	3.572819	2.384525	2.616362	1.429333	1.794456	1.190442	1
2.186493	1.83317	2.188746	1.631281	2.02835	1.133724	2.584236	5
-0.19669	3.080497	2.427698	1.772721	1.871182	2.58294	1.963527	1
1.045365	3.084264	2.502615	1.233211	2.190984	1.398955	2.304011	1
0.498219	3.184056	3.006726	1.873029	1.272331	2.277158	2.527363	1
0.064184	3.279553	2.142248	1.683496	2.028901	1.967967	2.81393	1
1.294706	3.528197	2.401889	2.620905	1.628489	2.505685	1.915161	1
1.237893	4.214992	3.247795	1.255129	1.727378	1.922664	1.535637	1
0.895371	2.295853	2.195042	3.304022	1.494507	2.228977	1.607169	1
-0.15976	2.294287	3.693329	1.853443	2.346265	2.371389	1.889254	4
0.765196	3.619231	3.406026	2.56884	1.039612	2.176356	1.173186	2
0.040116	2.078193	3.350767	1.54803	2.515734	2.492502	1.961021	1
-0.01981	2.391736	2.677275	2.01822	2.822933	2.111246	2.320911	1
2.137868	3.088558	2.695161	1.66284	2.394352	1.829432	2.164855	3
2.081211	1.547291	3.061405	1.85112	1.647561	2.145304	1.606017	3
2.045868	2.033077	4.076113	2.57444	2.231006	2.358381	2.016695	5

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

1.758938	3.006452	2.01326	0.699399	3.04425	1.384979	0.665989	3
1.237003	2.523978	2.330382	2.049435	1.997275	1.271707	0.498445	1
0.667497	2.718609	2.958894	1.611983	2.782766	2.031715	2.059987	1
2.0786	2.254637	2.013767	2.860412	1.253703	2.580455	1.367255	2
1.137981	2.2767	2.173088	2.474196	1.543822	2.78904	1.474368	1
0.83508	2.375671	2.923106	2.319775	1.112637	1.568078	1.782344	4
1.532628	2.452578	4.199479	2.184313	1.28271	1.39555	1.30231	4
2.832667	3.229237	2.248558	5.046877	-0.14981	3.168044	0.514728	2
2.804329	3.544024	3.281753	1.443864	0.979548	1.515588	2.244697	3
4.176895	3.853278	3.442913	3.436163	-0.20598	1.787425	0.697663	2
1.447793	1.661014	4.651958	1.638069	0.705343	1.763816	0.192127	4
0.837814	3.230974	2.320599	3.009408	0.461031	2.905844	1.343623	2
1.802944	1.716569	3.558995	2.552908	0.4513	2.238213	-0.50813	2
0.957177	1.475594	3.511604	2.462799	0.950496	1.55846	1.053852	4
1.767879	2.111048	3.558412	1.886744	-0.32273	1.971333	-0.18521	2
0.567263	0.795808	2.30941	2.196065	2.747347	1.982559	2.3133	5
1.47234	2.608456	2.826792	2.398996	1.022706	2.533647	0.7236	2
1.025226	2.719732	2.423171	2.797212	2.343007	2.681939	1.803731	1
1.665459	0.517428	3.510286	1.925527	2.679155	2.339655	2.32634	5
0.626203	3.278759	4.570286	1.802226	1.454045	0.984405	1.873493	4
0.989795	3.025333	2.064807	1.322011	2.195479	2.639946	1.743527	1
0.748755	2.27195	2.717904	3.103542	2.114782	3.677446	1.694106	1
-0.54808	3.454881	2.794786	0.243503	2.598806	2.136147	2.934898	1
1.73608	2.049779	2.363716	2.801236	2.019415	1.639227	1.9725	5
2.540272	3.227549	3.596597	2.319795	1.413479	2.179313	0.192601	2
4.283287	3.240125	2.663105	2.760057	0.818601	1.64212	1.574151	3
1.391141	2.810916	2.450279	2.953166	2.210613	2.323273	1.154374	1

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024



## APPENDIX 10. MARDER PANSS NEGATIVE SYMPTOMS (MPNS) HETEROGENEITY INDEX METHOD

Subject-level PANSS item scores between two assessments (e.g., Screening and Baseline) are encoded in a variance-covariance difference (VCD) vector. The VCD vector captures the intra-item variance, between-item covariance, and between-item differences of PANSS items between two assessment time points from a single subject.

Briefly, for each subject  $h$ , a variance-covariance matrix of the 30 PANSS items is defined as

$$V = \begin{bmatrix} \sigma_{s_1}^2 & \cdots & \sigma_{s_1,30} \\ \vdots & \ddots & \vdots \\ \sigma_{s_{30},1} & \cdots & \sigma_{s_{30}}^2 \end{bmatrix},$$

where

$$\sigma_{s_j}^2 = \sum_{t=1}^2 (s_t^j - \bar{s}^j)^2,$$

is the unbiased estimator of the variance of  $s^j$  (score of PANSS item  $j$ ),  $j = 1, 2, \dots, 30$ , and

$$\sigma_{s_i,j} = \sum_{t=1}^2 (s_t^i - \bar{s}^i)(s_t^j - \bar{s}^j),$$

is the unbiased estimator of the covariance of  $s^i$  and  $s^j$  (scores of PANSS items  $i$  and  $j$ ), and

$$\bar{s}^j = \frac{\sum_{t=1}^2 s_t^j}{2}; \quad \bar{s}^i = \frac{\sum_{t=1}^2 s_t^i}{2}.$$

Note that the denominators of  $\sigma_{s_j}^2$  and  $\sigma_{s_i,j}$  are  $2 - 1 = 1$ , for two time points.

The unique elements of  $V$  for subject  $h$  are kept in vector  $u_{cov_h}$ , consisting of the elements of  $V$  on and below the main diagonal.

Separately, for each subject  $h$  and each timepoint  $t$ , a different matrix for the 30 PANSS items is defined as

$$D = \begin{bmatrix} d_{s_{1,1}} & \cdots & d_{s_{1,30}} \\ \vdots & \ddots & \vdots \\ d_{s_{30},1} & \cdots & d_{s_{30},30} \end{bmatrix},$$

where  $d_{s_i,j} = s^i - s^j$  for scores of items  $i$  and  $j$ . Note that the diagonal elements of  $D$  are 0.

The unique elements of  $D$  for subject  $h$  at timepoint  $t$  are kept in vector  $d_{t(h)}$ , consisting of elements of  $D$  below the main diagonal.

Together, the VCD vector of subject  $h$  for 2 timepoints (e.g., Screening and Baseline) is defined as

$$VCDV_{h(t=1,t=2)} = [u_{cov_h} \quad d_{1(h)}, d_{2(h)}] \rightarrow \mathbb{R}^{1,1335},$$

and the VCD vector for  $N$  subjects is

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

$$VCDV_{(t=1,t=2)} = \begin{bmatrix} VCDV_{h_1(t=1,t=2)} \\ VCDV_{h_2(t=1,t=2)} \\ \vdots \\ VCDV_{h_N(t=1,t=2)} \end{bmatrix} \rightarrow \mathbb{R}^{N,1335}.$$

Using the PANSS-defined VCD vector, and the 7 items of the Marder PANSS Negative Symptoms factor, a new vector of 84 elements per subject is used to define a Marder Negative Heterogeneity Index (MNHI). Table 7 lists the parameters used to derive the MNHI.

**Table 10: Parameters Used to Derive the Marder Negative Heterogeneity Index (MNHI)**

$\sigma_{s_i}^2$	Variance of PANSS item $i$ between Screening and Baseline for subject $h$
$\Delta\sigma_{s(i,j)_t}^2$	$\sigma_{s_i}^2 - \sigma_{s_j}^2$ at visit $t$ for subject $h$
$\sigma_{s_{i,j}}$	Covariance of PANSS item $i$ and PANSS item $j$ between Screening and Baseline for subject $h$
$d_{s_{i,j}}$	Difference between PANSS item $i$ and PANSS item $j$ at a given timepoint for subject $h$
$P$	Set of combinations of two Marder PANSS Negative Symptoms factor items
$C(x)$	Count of $x$

The 7 items of the Marder PANSS Negative Symptoms factor are congruent based on the Marder factor model. Therefore,  $\sigma_{s_i}^2 - \sigma_{s_j}^2$  is expected to be small for all  $p$  combinations. Similarly,  $\Delta\sigma_{s(i,j)_t}^2$  is expected to be small for all  $p$  combinations, at  $t$  = Screening and  $t$  = Baseline. Furthermore,  $C(\sigma_{s_{i,j}} < 0)$  is expected to be small for all  $p$  combinations. Hence, the raw Marder Negative Heterogeneity Index (rMNHI) of subject  $h$  is defined as the sum of L1 norm of variance differences, count of negative covariance, L1 norm of between item differences at Screening and Baseline. It can be expressed as

$$rMNHI = \|\Delta\sigma_{s_p}^2\|_1 + \sum_{p=1}^{21} C(\sigma_{s_p} < 0) + \|d_{s_p,t=1}\|_1 + \|d_{s_p,t=2}\|_1.$$

The min-max scaling (min = 0, max = 223) is then applied to rMNHI to derive the MNHI for subject  $h$ .

The optimal threshold to classify MPNS enriched subjects is determined by fitting the one-factor Marder Negative model through computing confirmatory factor analysis (CFA) statistics (comparative fit index [CFI], Tucker Lewis index [TLI], and root mean square error of approximation [RMSEA]) iteratively. The first iteration draws samples from the range of MNHI from the lowest to the lowest + 0.01 point. The range expands incrementally by 0.01 point for each iteration until the upper bound of the range is above the observed maximum MNHI. The smallest upper bound MNHI corresponds to the median CFI (>0.95), TFI (>0.95), and/or RMSEA (<0.08) and is identified as 0.113. It is used to classify subjects into MPNS enriched (MNHI ≤ 0.113) or de-enriched (MNHI > 0.113) groups.

Document:	PPD		
Author:	PPD	Version Number:	1.0
		Version Date:	06MAY2024



## APPENDIX 11. SCHEDULE OF EVENTS

**Table 2: Schedule of Assessments**

	Screening Period	Treatment Period									Follow-up Period
	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11
	Screening <sup>a</sup>	Pre-switch Baseline	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7 TC	Week 8 <sup>b</sup> EOI/ET <sup>c</sup>	Week 9 <sup>d</sup> Follow-up
Study Day <sup>e</sup>	Days -21 to -1	Day 1	Day 8	Day 15	Day 22	Day 29	Day 36	Day 43	Day 50	Day 57	7 ± 2 days after last dose
Informed consent	X										
Informed consent for duplicate subject check	X										
<b>CCI</b>											
Review inclusion/exclusion criteria	X	X									
Prior/concomitant medication review	X	X	X	X	X	X	X	X	X	X	X
Dispensation of study drug <sup>g</sup>		X	X	X	X	X	X	X			
Study drug accountability			X	X	X	X	X	X		X	
Demography	X										
Medical history	X										
Psychiatric history	X										
Nicotine use information	X									X	
SCID-5-CT <sup>h</sup>	X										
Physical and neurological examination	X									X	X
Height	X										
Vital signs <sup>i</sup>	X	X	X	X	X	X	X	X		X	X
Weight (including BMI) <sup>j</sup>	X	X				X				X	
Waist circumference		X				X				X	
12-lead Electrocardiogram (ECG)	X	X								X	
Hematology, chemistry, and urinalysis <sup>k</sup>	X	X								X	
Blood sample for hepatitis screening	X										

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

**Table 2: Schedule of Assessments (Continued)**

	Screening Period	Treatment Period									Follow-up Period
	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11
	Screening <sup>a</sup>	Pre-switch Baseline	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7 TC	Week 8 <sup>b</sup> EOT/ET <sup>c</sup>	Week 9 <sup>d</sup> Follow-up
Study Day <sup>e</sup>	Days -21 to -1	Day 1	Day 8	Day 15	Day 22	Day 29	Day 36	Day 43	Day 50	Day 57	7 ± 2 days after last dose
Serum follicle stimulating hormone (FSH) <sup>l</sup>	X										
Serum human chorionic gonadotropin (β-hCG), (females)	X									X	
Urine β-hCG (females) <sup>m</sup>		X				X					X
Rapid urine β-hCG (females) <sup>m</sup>										X	
CCI											
Blood sample for POPPK <sup>o</sup>		X	X			X				X	
Urine drug screen <sup>p</sup>	X	X				X				X	
Rapid urine drug screen <sup>p</sup>										X	
Positive and Negative Syndrome Scale (PANSS)	X	X	X	X		X		X		X	
Clinical Global Impression – Severity (CGI-S)	X	X	X	X		X		X		X	
Clinical Global Impression – Improvement (CGI-I)			X	X		X		X		X	
Brief Negative Symptom Scale (BNSS)		X				X				X	
Pittsburg Sleep Quality Index (PSQI)		X				X				X	
Columbia Suicide Severity Rating Scale (C-SSRS)	X	X	X	X	X	X	X	X	X	X	X
Simpson-Angus Scale (SAS) <sup>q</sup>		X								X	
Barnes Akathisia Rating Scale (BARS) <sup>q</sup>		X								X	

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024

**Table 2: Schedule of Assessments (Continued)**

	Screening Period	Treatment Period									Follow-up Period
	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11
	Screening <sup>a</sup>	Pre-switch Baseline	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7 TC	Week 8 <sup>b</sup> EOT/ET <sup>c</sup>	Week 9 <sup>d</sup> Follow-up
Study Day <sup>e</sup>	Days -21 to -1	Day 1	Day 8	Day 15	Day 22	Day 29	Day 36	Day 43	Day 50	Day 57	7 ± 2 days after last dose
Abnormal Involuntary Movement Scale (AIMS) <sup>a</sup>		X								X	
SF-12		X								X	
Medication Satisfaction Questionnaire (MSQ)		X								X	
Personal and Social Performance Scale (PSP)		X								X	
Healthcare Resource Utilization (HCRU) <sup>f</sup>		X								X	
Pretreatment/Adverse events (AE) monitoring <sup>g</sup>	X	X	X	X	X	X	X	X	X	X	X
Duplicate Subject Check <sup>h</sup>	X									X	
Tokenization consent (optional) <sup>i</sup>	X										

Abbreviations: AE = adverse event; BARS = Barnes Akathisia Rating Scale;  $\beta$  hCG = human chorionic gonadotropin; BMI = Body Mass Index; BNSS = Brief Negative Symptom Scale; C-SSRS = Columbia Suicide Severity Rating Scale; eCRF = electronic case report form; EDC = electronic data capture; DSM-5 = Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition; EOT = end of treatment; ET = early termination; FSH = Follicle stimulating hormone; MSQ = Medication Satisfaction Questionnaire; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; PK = pharmacokinetic; PSQI = Pittsburgh Sleep Quality Index; SAS = Simpson-Angus Scale; SCID-5-CT = Structured Clinical Interview for DSM-5; SF-12 = Short Form Health survey; Clinical Trials Version; TC = telephone contact visit; UDS = urine drug screen.

<sup>a</sup> Subjects who screen fail can be re-screened up to 2 times after consultation with the Medical Monitor. Screening assessments may occur over multiple days. The Screening Period may be extended for up to 7 days after approval from the Medical Monitor.

<sup>b</sup> All procedures and assessments scheduled for Week 8 will be utilized as Baseline procedures and assessments for the open-label extension study (SEP361-309).

<sup>c</sup> If a subject discontinues from the study, all Early Termination (ET) procedures should be performed at the ET visit, within 48 hours of last study dose.

<sup>d</sup> Subjects who discontinue early from the study or complete the study and do not enter the extension study (SEP361-309) will have a safety Follow-up Visit 7 (± 2) days after their last dose of study drug. While every effort should be made to complete the Follow-up Visit in the clinic, administration of C-SSRS, and collection of AEs, and concomitant medications may occur by telephone contact if the subject is unable to come to the clinic for the Follow-up Visit.

<sup>e</sup> Visit window for Day 8 is +2 days, and visit windows post Day 8 are: ± 2 days for every Visit.

<sup>f</sup> Requested, but not required for study participation.

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024



- <sup>g</sup> All study drug will be taken once daily in the evening at bedtime by mouth, without regard to food.
- <sup>h</sup> The SCID-5-CT will be used to support the DSM-5 diagnosis and must be administered by a qualified rater with at least 2 years' experience with the population under study.
- <sup>i</sup> Vital signs will include respiratory rate, oral body temperature and supine and standing measurements of blood pressure and pulse rate.
- <sup>j</sup> BMI will be calculated and recorded in the eCRF by the clinical site at screening. For other visits, BMI will be derived in the EDC system.
- <sup>k</sup> Subjects must be fasted (no food or drink except water at least 8 hours prior to specified blood tests) at Pre-switch Baseline (Visit 2) and Week 8/EOT/ET (Visit 10). Fasting for 8 hours prior to Screening (Visit 1) is also recommended to avoid potential retests. Blood samples should be drawn in the morning followed by a snack or meal. A list of clinical laboratory tests is provided in [Section 23](#).
- <sup>l</sup> Blood samples for follicle stimulating hormone (FSH) will be collected for post-menopausal women or if menopause is suspected.
- <sup>m</sup> Positive urine drug screen (UDS) results should be discussed with the Medical Monitor.
- CCI**
- <sup>n</sup> Blood samples for determination of plasma SEP-363856 concentrations will be collected predose (prior to administration of the first dose) on Day 1; 3 additional samples will be collected on Days 8, 29 and 57/ET. The time and date of the previous dose of study drug and the time and date of blood sampling must be recorded. The remaining plasma samples, after PK measurement is completed, **CCI**
- CCI**
- <sup>p</sup> Any positive urine  $\beta$ -hCG test should be confirmed by a serum  $\beta$ -hCG test.
- <sup>q</sup> Unscheduled SAS, BARS and AIMS scales should be administered if a subject develops extrapyramidal symptoms (EPS) requiring treatment.
- <sup>r</sup> Healthcare resource utilization questions are described in [Section 11.5.8](#). Baseline will have 3-month lookback period. Week 8/ET will be since last assessment.
- <sup>s</sup> Events occurring prior to first dose of study drug are pretreatment events. Events occurring after first dose of study drug are adverse events. Determination done programmatically.
- <sup>t</sup> Where local regulations allow, duplicate subject check will be performed. Following the last contact with a subject, the duplicate enrollment system should be updated, as appropriate.

Document: PPD

Author: PPD

Version Number:

1.0

Version Date:

06MAY2024